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Abstract 
RNA metabolism is of critical importance for normal cellular functions and needs to 
be finely tuned in order to maintain stable conditions within the cell. The exosome 
complex is the most important RNA processing machinery, responsible for the correct 
processing of many different types of RNAs and interacting with different co-factors 
which bind and carry specific subtypes of RNA for degradation to the complex. 
Mutations in exosome complex subunits (EXOSC3, EXOSC8) were reported to 
cause severe childhood onset complex neurological disorders presenting with 
pontocerebellar hypoplasia type 1 (PCH1), spinal muscular atrophy (SMA) and 
central nervous system hypomyelination. We have recently identified a homozygous 
pathogenic mutation in RNA Binding Motif Protein 7 RBM7, a subunit of the nuclear 
exosome targeting (NEXT) complex in a single patient with SMA-like phenotype and 
proved that RBM7 is a novel human disease gene related to the exosome complex. 
In order to understand the disease mechanism in RBM7 deficiency and to explore the 
role of exosome complex in neurodevelopment, we performed gene expression 
studies (RT-PCR, RNA sequencing) in human cells of patients carrying mutations in 
EXOSC8 and RBM7. Furthermore we performed functional studies in zebrafish (D. 
rerio) by morpholino oligonucleotide mediated knock-down of rbm7, exosc8 and 
exosc3 and also by introducing pathogenic mutations in exosomal protein genes in 
zebrafish embryos by the CRISPR/Cas9 system. 
We showed that mutations in RBM7 and EXOSC8 mutant fibroblasts cause 
differential expression of several different transcripts, 62 of them being shared 
between the two cell lines. Altered gene expression of some AU-rich element 
containing genes may potentially contribute to the clinical presentation. 
Knock-down of rbm7, exosc8 and exosc3 caused impaired neurodevelopment in 
zebrafish, illustrated by abnormal growth of motor neuron axons and failure to 
differentiate cerebellar Purkinje cells. RT-PCR analysis in zebrafish showed a 
dramatic increase in expression of atxn1b (an AU-rich element containing homolog of 
the human ATXN1 gene) in rbm7, exosc8 and exosc3 downregulated fish, which may 
be responsible for the cerebellar defects. We have successfully introduced several 
germline mutations with CRISPR/Cas9 technology in rbm7. Phenotype of the F1 
mutants is milder than what observed with the morpholino oligonucleotide injected 
fish. Mutants at a closer look do not show any morphological defect but further 
experiment may indicate similar characteristics to the morphants, although more 
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subtle. Further studies on the CRISPR/Cas9 generated zebrafish models will extend 
our knowledge on the disease mechanisms caused by defective RNA metabolism. 
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Chapter 1: Introduction 
1.1 RNA processing and disease 
Transcriptional and post-transcriptional regulation is of fundamental importance for 
correct cellular functions (Lee and Young, 2013) (Kiebler et al., 2013). 
Fine tuning of coding and non-coding RNA (ncRNA) levels is very important: either 
too much or too little transcript within the cell can give rise to an unbalance of protein 
synthesis and then defects of cellular processes (Moraes, 2010). Such a complex 
task is performed through precise integration of transcription and degradation steps 
of cellular RNAs, in order to achieve correct protein expression levels (Rogowska, 
2005) (Dori-Bachash et al., 2011).  
RNA processing including splicing (Seng et al., 2015), capping and poly-adenylation 
is also very important for correct cellular functions  (Poulos et al., 2011). Furthermore, 
regulatory elements such as ncRNAs also need to be correctly transcribed, 
processed and degraded. Although they do not get translated into proteins, they are 
known to play key roles in epigenetic, transcriptional and post-transcriptional 
regulation (Schmitz et al., 2016). Said that, our knowledge about ncRNAs is still very 
limited (Chi, 2016). 
All this complexity comes at a price: it is not surprising that a faulty machinery within 
the system can give rise to disease. A number of conditions have been linked to 
impaired RNA processing: cancer, neuromuscular diseases, neurological disorders 
(Cooper et al., 2009).  
Among the large number of defects due to impaired RNA metabolism, a novel group 
of neurological disorders caused by defective functionality of the exosome complex 
has begun to be increasingly important in the field. 
Our lab started investigating this subset of neurological disorders soon after the first 
mutation on an exosome complex sub-unit (EXOSC3) was discovered in 2012 by 
Wan and colleagues (Wan et al., 2012).  
We initially focused on some patients of Roma ethnic background with complex 
overlapping symptoms of pontocerebellar hypoplasia type 1 (PCH1), spinal muscular 
atrophy (SMA), central nervous system demyelination and mitochondrial disease 
(Boczonadi et al., 2014) (Pyle et al., 2015) and identified a novel disease gene: 
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EXOSC8. Subsequently, we identified and investigated the role of a new mutation in 
a sub-unit of a co-factor of the exosome complex (RBM7; Giunta et al., 2016) in a 
Palestinian patient with motor neuron disease. Results of some of the experiments I 
performed for the investigation of functions of EXOSC8 and RBM7 are explained in 
this thesis.  
Furthermore, here I show some data (not yet published) about the CRISPR/Cas9 
driven gene inactivation of RBM7 homolog in zebrafish (D. rerio) and identification of 
new patients with mutation on EXOSC3 and TSEN54, which also causes PCH. It is 
worth to say that, as a complementary model, Dr. Juliane Mueller (Newcastle 
University) has created in parallel a mutant line of EXOSC8 in the same organism, 
however, these data are not shown here. 
1.2 The exosome complex  
The exosome complex is the main RNA metabolism machinery within the cell, 
responsible for many functions regarding RNA degradation and  quality control 
(Houseley et al., 2006). The structure and functions of the exosome complex are 
highly conserved through all forms of life. 
The exosome is a large multi-subunit complex formed, in all eukaryotic and archaea 
cells, by 9 proteins (called Exo-9). Six of them (Rrp41/EXOSC4, Rrp42/EXOSC7, 
Rrp43/EXOSC8, Rrp45/EXOSC9, Rrp46/EXOSC5 and Mtr3/EXOSC6) form the 
barrel-like structure, where the RNA filament passes through (in a 3’-5’ direction) in 
order to be degraded. Three proteins (Rrp40/EXOSC3, Csl4/EXOSC1 and 
Rrp4/EXOSC2) form the “cap” of the complex, with RNA binding properties (Oddone 
et al., 2007) (Januszyk and Lima, 2010). 
This barrel-like structure seems to be catalytically active in prokaryotes through three 
active sites situated in the internal side of the channel (Makino et al., 2013). However, 
in eukaryotes the Exo-9 structure seems to be enzymatically inactive due to some 
amino acid changes. The functionality of Exo-9 in the cytoplasm in eukaryotes 
resides in an additional subunit, Rrp44/DIS3/EXOSC11, a hydrolytic exonuclease 
belonging to the RNase R family that, when bound to Exo-9, forms the functional 
structure Exo-10 (Januszyk and Lima, 2010) (Oddone et al., 2007).  
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The cytosol active Exo-10 requires an additional sub-unit to become catalytically 
active in the nucleus: Rrp6/EXOSC10, forming an 11 subunit nuclear exosome called 
Exo-11 (Januszyk and Lima, 2014). A paralog of DIS3 is indispensable for 
exonuclease activity (DIS3L1) and is only present in the cytoplasmic form (Sudo et 
al., 2016). The exosome complex also has endonucleolytic activities (Januszyk and 
Lima, 2014).  
The exosome complex is directly involved in metabolism of almost all types of RNA 
within the cell.  
As mentioned earlier, the exosome carries out a variety of functions related to gene 
expression regulation through mRNA decay (Houseley et al., 2006): other than 
performing 3’-5’ turnover of normal mRNAs (Kilchert et al., 2016), the exosome 
complex in human cells is also responsible for degradation of AU-rich sequence 
elements (AREs). AREs can be found in 3’ UTR of mRNAs that encode for proteins 
for which only a transient expression is required (Chen et al., 2001). AREs can be 
loosely categorized as sequences with the presence of various copies of an AUUUA 
pentanucleotide and a high content of uridylate and sometimes also adenylate 
residues (Chen and Shyu, 1994). Also called AU instability elements, AREs have 
been found to interact directly with the exosome  complex (Mukherjee et al., 2002) 
suggesting this complex has a direct involvement in ARE-containing mRNA turnover. 
Figure 1.1 Structures of Prokaryotic and Eukaryotic exosome complex. The Eukaryotic 
exosome complex has different cytoplasmic, nuclear and nucleolar forms. Modified from 
Januszyk and Lima, 2014. 
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The exosome complex is also responsible for processing non-functional RNAs; 
accumulation of faulty  RNAs can be harmful to the cell as they can compete for the 
good ones for cofactors (Kilchert et al., 2016). The exosome degrades RNAs with a 
premature stop codon  through the non-sense mediated decay pathway (NMD; 
Lejeune et al., 2003); the non-stop decay (NSD) pathway degrades mRNAs that lack 
a termination codon (Frischmeyer et al., 2002) and the no-go decay (NGD) pathway 
targets mRNAs on which translation has stopped (Doma and Parker, 2006). 
Although rare, failure in performing those decay pathways can give rise to disease in 
humans such as PEHO (Nahorski et al., 2016), MNGIE with neuropathy  (Torres-
Torronteras et al., 2011).  
Furthermore, the exosome complex is involved in degradation of non-coding RNAs 
such as tRNAs (Lubas et al., 2015), long-non coding RNAs (lncRNAs; Chlebowski et 
al., 2013), PROMoter uPstream Transcripts (PROMPTs; Norbury, 2011), which are 
transcribed antisense of most protein coding genes and which functions are not 
completely understood, but thought to act as transcriptional regulators (Preker et al., 
2008) (Lloret-Llinares et al., 2016). Finally, the exosome complex is secondarily 
involved in splicing regulation, being primarily responsible of metabolism of splicing 
factors (Zhang et al., 2015). 
The exosome complex itself is highly unspecific (Kilchert et al., 2016). One open 
question is how the exosome can be loaded on so many different substrates, 
performing these tasks so efficiently and specifically (Kilchert et al., 2016). 
High substrate specificity of the exosome complex is guaranteed by the interaction 
with exosome-specificity factors (ESFs) which lead to specific processing or 
degradation pathways. Indeed, experimental evidence shows that different classes of 
RNAs  are recognized by different co-factors which subsequently determines its fate 
(Schmidt and Butler, 2013) (Kilchert et al., 2016). 
1.2.1 Exosome-Specificity Factors 
To date, four complexes have been identified as cofactors of the exosome complex, 
responsible for binding and helping with the degradation/processing of specific 
subtypes of RNAs.  
1.2.2 The TRAMP complex 
The Trf4/5-Air1/2-Mtr4 polyadenylation (TRAMP) complex is involved in two catalytic 
activities: the TRf4-Air2 is a poly(A)polymerase sub-complex, Mtr4 carries out 
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helicase activities (Falk et al., 2014) in yeast. The TRAMP complex  predominantly 
acts promoting exosomal decay by the oligoadenylation and unwinding of RNA 
targets (Lubas et al., 2015). A part from Mtr4, the other proteins have little sequence 
similarity in human. In mammalian cells, a homolog of the TRAMP complex has been 
proposed, formed by PAPD5 (Trf4/5 homolog), ZCCHC7 (Air1/2 homolog) and 
MTR4/DOB1/SKIV2L2. EXOSC10/Rrp6 seems to play an important role in TRAMP 
stable assembly (Sudo et al., 2016). In yeast, the TRAMP complex targets aberrant 
coding and non-coding RNAs. Another MTR4 related protein is WDR74 (Hiraishi et 
al., 2015). MTR4 sub-unit participates in another stable co-factor of the exosome 
complex, the nuclear exosome-targeting (NEXT) complex (Norbury, 2011) (Lubas et 
al., 2011).  
1.2.3 The NEXT complex 
The NEXT complex - which is not found in yeast - consists of a putative RNA binding 
protein (RBM7) and other two proteins: ZCCHC8 and MTR4. Opposite to ZCCHC7 
which is only localized in the nucleolus, ZCCHC8 and RBM7 are localized in the 
nucleus. Therefore it seems that different RNA substrates in different nuclear 
localizations are targeted by the NEXT complex or the TRAMP complex (Sudo et al., 
2016). The NEXT complex facilitates the exosome-driven degradation of RNA 
polymerase II transcripts including non-coding RNAs such as the PROMPTs (Lubas 
et al., 2011) and other ncRNAs (Hrossova et al., 2015) (Sofos et al., 2016). RBM7 
sub-unit binds with high affinity to U-rich stretches in RNA (Hrossova et al., 2015) 
suggesting it may also be involved in ARE genes degradation. RBM7 was also 
previously reported to be involved in splicing (Guo et al., 2003). 
1.2.4 The SKI complex 
The SKI complex as it is found in yeast is a heterotetramer that channels RNAs 
toward the exosome complex, activating the NMD, NGD and NSD (Synowsky and 
Heck, 2007) (Halbach et al., 2013) (Chlebowski et al., 2013). 
It consists of a Ski2 sub-unit, a Ski3 sub-unit and 2 Ski8 sub-units. The human 
homolog of the SKI complex, hSKI, has a hSKI8 sub-unit (Zhu et al., 2005), a 
SKI2W/SKIV2L (Ski2 homolog) sub-unit (Dangel et al., 1995) and a TTC37 (Ski3 
homolog) sub-unit.  
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1.2.5 The CBC complex 
A fourth complex, the human cap-binding complex (CBC) is also functionally 
connected to the exosome (Andersen et al., 2013). It associates with arsenic 
resistance protein 2 (ARS2) forming the CBC-ARS2 complex and then connects 
(together with ZC3H18/ NHN1 protein) to the NEXT complex, therefore forming the 
CBC-NEXT complex. 
 
 
Figure 1.2 Cellular localization of the Exosome Specific Factors. Each factor seems to 
target specific subtypes of RNA in different cellular compartments.  Modified from Januszyk 
and Lima, 2014. TRAMP complex’s functions are mainly oligoadenylation and unwinding of 
RNAs; NEXT binds and facilitates exosome degradation of non-coding RNAs and SKI 
complex is involved in NGD, NSD and NMD pathways.  
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1.3 The exosome complex in health and disease 
Impaired functionality of any of the exosome complex sub-units or Exosome-
Specificity Factors can give rise to a wide variety of diseases. Mutations on EXOSC3, 
EXOSC8, EXOSC2 cause a predominant neurological phenotype with PCH (Wan et 
al., 2012) (Boczonadi et al., 2014) (Di Donato et al., 2016).  
1.3.1 Symptoms caused by EXOSC3 mutations 
The first pathogenic mutations on an exosome complex sub-unit (EXOSC3) were 
identified by Wan and colleagues in 2012. Patients presented with severe 
pontocerebellar hypoplasia and spinal motor neuron degeneration. Six different 
pathogenic mutations (one of them intronic) were described in this study (Fig. 1.3): 
missense, deletions and splice mutations. 
EXOSC3/Rrp40 is part of the exosome “cap”, and is an RNA binding subunit of the 
exosome complex (Luz et al., 2007). Probably the binding activity is performed 
through interaction with other sub-units (Oddone et al., 2007). It has been 
hypothesized that EXOSC3/Rrp40 might also have a hydrolytic activity (Luz et al., 
2007). 
In order to understand functions of EXOSC3 in neurodevelopment, Wan and 
colleagues performed functional studies in zebrafish knocking down functions of 
exosc3, the zebrafish homolog of the human gene. 
Downregulation of exosc3 in zebrafish with morpholino (MO) showed reduction of 
levels of pvalb7 and atoh1a (respectively a Purkinje cells (PCs) marker and a dorsal 
hindbrain progenitor-specific marker) transcripts tested by in situ hybridization. 
Morpholinos act reducing gene expression binding to the mRNA and resulting in a 
non-functional protein, therefore co-injection of a functional mRNA should ideally 
rescue the phenotype caused by the impaired endogenous mRNA.  
Co-injection of human and zebrafish WT mRNA and exosc3-MO in zebrafish largely 
rescued the phenotype, which was not rescued by co-injection of either human or 
zebrafish mutant mRNA and morpholino. 
Subsequently other studies identified more mutations in EXOSC3, which can cause a 
broad spectrum of PCH1 symptoms (Tab. 1), and showed that EXOSC3 mutations 
may account for about half of the total cases of PCH1 worldwide (Eggens et al., 2014) 
(Eggens, 2016).  
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Table 1. Clinical data of 14 patients with EXOSC3 mutation (From Eggens et al., 2014). 
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 Figure 1.3. Schematic representation of the EXOSC3 pathogenic mutations and 
anatomical features of the patients. Mutations identified in EXOSC3 are missense (circle), 
deletions (triangle) or splice site mutations (star). Brain MRI of the patient (a, b) show a clear 
reduction in cerebellum size compared to an age matched control (e, f). For a second patient 
also reduction of cerebellum (c, d) is clear compared to an age matching control (g, h). Brain 
autopsy of the patient who died at age 18 shows cerebellar atrophy (l) compared to control 
(o). At higher magnification patient’s brain show dysmorphic Purkinje cells and loss of 
granule cells (m) compared to control (p). Loss of motor neuorns in the anterior horn of the 
spinal cord is also present in the patient (n) compared to control (q). Images modified from 
Wan et al., 2012. 
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1.3.2 Symptoms caused by EXOSC8 mutations 
Our group subsequently identified 2 pathogenic missense mutations (Fig. 1.4) on 
EXOSC8 – which is one of the six subunits forming the barrel-like structure of the 
exosome complex - in 22 patients from three different families of Roma and 
Palestinian ethnic  origin  with cerebellar and corpus callosum hypoplasia (Fig. 1.4), 
abnormal myelination of the central nervous system (Fig. 1.4), spinal motor neuron 
disease and mitochondrial disease (Table 2; Boczonadi et al., 2014). Mutations were  
c.5C>T, p.Ala2Val in exon 1 and c.815G>C, p.Ser272Thr in exon 11. Extended 
functional studies in human fibroblasts, myoblasts and oligodendroglia cells as well 
as in zebrafish confirmed the pathogenicity of the mutations. 
Patients fibroblasts and myoblasts were used to test gene expression of ARE genes 
such as MBP, MOBP, SMN1 which levels resulted to be higher than in controls cells. 
Non ARE genes levels were not affected. In human oligodendroglia cells EXOSC8 
was downregulated by siRNA, resulting in a similar pattern of gene expression.  
Downregulation of exosc8 in zebrafish also resulted in upregulation of some ARE 
genes. Particularly interesting is the overexpression of MBP, given its known key role 
in the myelination process and correspondent myelination issues in the patients. 
Myelination is a complex process that needs to be tightly regulated, overexpression 
of a fundamental protein such as MBP may indeed have toxic effects. 
Further zebrafish experiments which will be better explained in results chapter 2 
seem to indicate a direct involvement of mbp overexpression in myelination issues. 
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Table 2. Clinical presentation of 9 patients from 2 pedigrees. Abbreviations: P: pedigree; m: 
month; ret.: retardation; BAEP: brainstem auditory evoked potentials, VEP: visual evoked 
potentials, ALT: alanine transaminase, GGT: gamma-glutamyl transferase. Table from Boczonadi 
et al. 2014. 
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Figure 1.4. MRI scan, autopsy staining of patients with EXOSC8 mutation and position of 
the mutations within the gene. The MRI scan highlights reduced cerebellar volume and  thin 
corpus callosum in the Palestinian patient (top). Spinal cord normal control (i, l) and patient 
V:20 of the Roma family. In EXOSC8 deficiency, myelin basic protein is present–apart from the 
longitudinal descending fibre tracts (k, *). Myelin is well preserved within the peripheral nerve 
roots (n, arrowhead) while indicates severe loss of myelin within the spinal cord (n). Images 
modified from Boczonadi et al., 2014. 
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1.3.3 Symptoms caused by EXOSC2 mutations 
Di Donato and colleagues (Di Donato et al., 2016) published a study where they 
reported three patients from two unrelated, non-consanguineous German families 
with a novel syndrome with retinitis pigmentosa, progressive hearing loss, premature 
ageing, intellectual disability and facial dysmorphism caused by mutations in 
EXOSC2. EXOSC2 is located in the ‘cap’ of the exosome complex, similarly to 
EXOSC3. They identified a homozygous missense mutation and a compound 
heterozygous mutation Brain MRI showed also hypomyelination and mild cerebellar 
hypoplasia. Unfortunately, no functional studies on cells or animal models were 
performed. Nevertheless, this study extends the knowledge of clinical symptoms 
caused by impaired RNA metabolism due to exosome complex deficiencies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.5. Domain organisation of the EXOSC2 protein (RRP4) with the localisation of 
the discovered mutations is shown (from Di Donato et al., 2016). 
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   Figure1.6. Morphological features of patients with mutations on EXOSC2 (top) and brain 
MRIs (bottom; from Di Donato et al., 2016). Patient 1 Top figure A1, A3 (3 y/o) and A2 (6y/o). 
Brain MRI (A-C) shows mildly enlarged extra-axial spaces and borderline cerebellar hypoplasia. 
Patient 2, who is patient’s 1 paternal aunt, is in top figure B1 (1 y/o) and B2,B3 (41 y/o). Her brain 
MRI at age 39 shows mild cortical and cerebellar atrophy with unremarkable white matter (H,I). 
Patient 3 at age of 1 year (top figure C1), 13 years (C2) and 28 years (C3, C4). His brain MRI was 
abnormal with diffuse dysmyelination, bilateral calcifications in the basal ganglia and thalamus and 
mild cortical and cerebellar atrophy (D-F). 
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 Table 3. Clinical data of EXOSC2 patients (from DiDonato et al., 2016) 
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To complete the  overview of diseases caused by dysfunction of the exosome 
complex, it’s worth to mention that not only neurological syndromes are caused by 
reduced functionality of the exosome complex, other types of diseases have been 
linked to exosome complex defective functions:  
Polymyositis/Scleroderma overlapping syndrome (PM/Scl) is an autoimmune disease 
which affects antigens  PM/Scl75 and PM/Scl100 which are actually part of the 
human exosome complex (the antibodies target mainly hRrp4, hRrp40, hRrp41, 
hRrp42, hRrp46p, hCsl4) (Rick Brouwer et al., 2002). 
Autoimmune diseases targeting aminoacyl-tRNA synthetases show a remarkable 
similarity to PM/Scl syndrome, representing again a similarity between exosome-
driven pathologies and tRNAs driven pathologies (as explained better in the next 
paragraph) causing dermatomyositis, polymyositis, skin hyperkeratosis and other 
symptoms (Hamaguchi et al., 2013) (Mirrakhimov, 2015) having such a narrow 
spectrum of symptoms and such a specific etiology it is in fact referred to as “anti-
synthetase syndrome”. 
Another disease caused by defective exosome complex functions is the thrico-
hepato-enteric syndrome (THES), also called syndromic diarrhea (SD) which is 
caused by mutations on Ski2/SKIV2L/SKI2W and Ski3/TTC37, sub-units of the SKI 
complex (Monies et al., 2015).  
 
1.4 RNA processing and pontocerebellar hypoplasias 
Given the typical PCH features of the EXOSC3, EXOSC8 and EXOSC2 patients, 
Fabre and Badens  hypothesized that the main RNA class which may be affected by 
mutations in these 3 sub-units may be tRNAs (Fabre and Badens, 2014).  
A striking number of mutations on tRNA splicing endonuclease (TSEN) complex are 
often responsible for development of PCH. Mutations on TSEN54, TSEN2, TSEN15, 
TSEN34 (Simonati et al., 2011) (Bierhals et al., 2013) (Breuss et al., 2016) 
(Cassandrini et al., 2010) are responsible for this condition. 
Other genes involved in tRNAs processing and which mutations are causative of 
PCH are CLP1 (Weitzer et al., 2015), RARS2 (mitochondrial argynil-tRNA synthetase 
2; Edvardson et al., 2007). 
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This hypothesis of a defective tRNA-driven neural degeneration was subsequently 
backed by Weitzer and colleagues (Weitzer et al., 2015); it is worth mentioning that a 
direct interaction between tRNAs and EXOSC2 has been demonstrated in 
mammalian cells (Goodarzi et al., 2016), although in this study it is thought to be 
linked to cancer progression. 
Many other aminoacyl-RNA synthetase mutations are known to cause neurological 
disorders and cerebellar degeneration: DARS (Taft et al., 2013); QARS (Zhang et al., 
2014); EARS2 (Güngör et al., 2016); VARS2 (Baertling et al., 2016); GARS (Del Bo 
et al., 2006); HARS (Safka Brozkova et al., 2015); IARS (Kopajtich et al., 2016); 
KARS (McLaughlin et al., 2010); RARS (Wolf et al., 2014); YARS (Thomas et al., 
2016). 
In my thesis I describe the identification of a new mutation on RBM7 in a single 
patient with motor neuron disease and functional experiments we performed in 
zebrafish (Giunta et al., 2016). Notably, RBM7 is likely to be involved in tRNAs 
processing and degradation of surplus of tRNAs (as well as other ncRNAs), as a high 
level of cross-linking between RBM7 protein and these RNA species has been 
observed (Lubas et al., 2015).  
1.4.1 Subtypes of pontocerebellar hypoplasias 
Pontocerebellar hypoplasia is a heterogeneous group of very rare developmental 
disorders with prenatal onset, characterized by abnormally small cerebellum and 
ventral pons. Most affected areas are cerebellar cortex, dentate nuclei, inferior olivary 
and ventral pontine nuclei (D’Arrigo et al., 2014). Estimated incidence is lower than 
1:200,000 (Namavar et al., 2011a). Main symptom is severe psychomotor retardation. 
PCH often results in early death of the patient (Ekert et al., 2016). 
Initially PCHs were classified in only 2 subtypes: with spinal motor neuron 
involvement (type 1) or without spinal motor neuron involvement (type 2). To date, 10 
different subtypes of PCH have been clinically and genetically described (Eggens, 
2016). 
As mentioned before, PCH1  (OMIM 607596) includes symptoms of pontocerebellar 
degeneration plus degeneration of anterior spinal horn, morphologically similar to 
spinal muscular atrophy (Eggens et al., 2014). Phenotype is actually very broad, 
cerebellar involvement can be very severe or milder and patient’s survival can also 
be very different (from few days up to 18 years). PCH1 can be caused by mutations 
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in EXOSC3 (estimated 50% of the cases), , TSEN54, EXOSC8 (Eggens, 2016) and 
Vaccinia-related kinase 1 (VRK1), a nuclear serine/threonine protein kinase known to 
play multiple roles in cellular proliferation, cell cycle regulation, carcinogenesis, 
neuronal migration and neural stem cell differentiation (Vinograd-Byk et al., 2015). 
PCH2 (OMIM 277470; 612389; 612390) is the most common subtype of 
pontocerebellar hypoplasia, mostly caused by mutations in tRNA splicing 
endonuclease subunit 54 (TSEN54). Other mutations in TSEN2 and TSEN34 have 
been identified. Clinically patients have a dragonfly-like pattern of the cerebellar 
hemispheres on coronal brain MRI, where the vermis is relatively intact, delayed 
myelination can occur as well as cortical atrophy (in 40% of the cases). Life 
expectancy can range from infancy to early puberty.  (Namavar et al., 2011a) 
(Eggens, 2016) 
PCH3 (OMIM 608027) is an extremely rare subtype of PCH. Patients suffer of 
hypotonia, microcephaly, optic atrophy and short stature (Namavar et al., 2011b). A 
pathogenic mutation was identified in PCLO, a gene only present in vertebrates 
which product is a large protein component of the presynaptic active zone, a 
specialized area mediating neurotransmitter release (Ahmed et al., 2015). It interacts 
with and controls the assembly of presynaptic F-actin. All the other cases of PCH3  
remain unresolved. 
Patients with PCH4 (OMIM 225753) and PCH5 (OMIM 610204) have the same 
characteristics of PCH2 but with an earlier and more severe onset (Eggens, 2016)  
PCH6 (OMIM 611523) is a rare form and combines features of PCH with 
mitochondrial disease shown as elevated lactate levels. Mutations of mitochondrial 
Arginyl tRNA synthetase (RARS2) have been reported to cause this subtype (Eggens, 
2016). 
PCH7 (OMIM 614969) patients have brain and gonadal abnormalities, developmental 
delay. XY patients have impalpable testicles and micropenis; XX patients have 
atrophic ovaries. Brain MRI showed a hypoplastic pons and cerebellum, large 
ventricles and thin white matter. Mutations in TOE1, a putative splicing factor, have 
been associated with this subtype (Eggens, 2016). 
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PCH8 (OMIM 614961) was reported in six patients from 3 families. Patients showed 
severe psychomotor retardation, abnormal movements, hypotonia, spasticity, and 
variable visual defects. Brain MRI shows pontocerebellar hypoplasia, decreased 
cerebral white matter, and a thin corpus callosum (Mochida et al., 2012). It is caused 
by recessive mutation in Charged Multivesicular Body Protein 1A (CHMP1A) a 
member of the endosomal-sorting-complex-required-for-transport-III (ESCRT-III). 
CHMP1A also localizes in the nuclear matrix and is thought to regulate chromatin 
structure. 
PCH9 (OMIM 615809) is characterized by severely delayed psychomotor 
development, progressive microcephaly, spasticity, seizures, and brain abnormalities, 
including brain atrophy, thin corpus callosum, and delayed myelination. PCH9 has 
been described in five families and linked to mutations in adenosine monophosphate 
deaminase 2 (AMPD2). AMPD2 encodes one of three known AMP deaminase 
homologues, which converts AMP to IMP (Akizu et al., 2013). 
PCH10 (OMIM 615803) Patients suffer from both central and peripheral nervous 
system abnormalities. Brain MRI shows small pons, cerebellum and brainstem, as 
well as cortical involvement. Mutations in Cleavage And Polyadenylation Factor I 
Subunit 1(CLP1) has been associated with this subtype (Eggens, 2016). CLP1 is 
also a component of the tRNA splicing endonuclease and involved in tRNA 
metabolism (Weitzer et al., 2015). 
1.5 Zebrafish as a model system 
Zebrafish has become a widely used model for studying neurodevelopment and 
neurodegeneration. Most anatomical structures, developmental processes and 
protein structures are largely conserved between zebrafish and other vertebrates 
(Scalise et al., 2016) (Lyons and Talbot, 2015) (Babin et al., 2014).  
Zebrafish has been largely used as a model to study developmental biology  (Weis, 
1968) and   soon it gained its role as a new powerful tool to study human disease 
(Zon, 1999). Nowadays high quality zebrafish genome assembly have been 
generated (Howe et al., 2013) showing that 71.4% of human genes have at least one 
zebrafish orthologue with  an average of 2.28 zebrafish genes for each human gene. 
This is due to a whole-genome duplication called the teleost-specific genome 
duplication (Meyer and Schartl, 1999). Zebrafish possess 26,206 protein-coding 
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genes (Howe et al., 2013). Continue genetic screening and phenotyping through 
mutagenesis, gene knock-down or gene overexpression has led to a great 
understand of molecular mechanisms which can be translated to human biology. 
Zebrafish have been used for modelling human muscle disease (Guyon et al., 2007) 
(Sztal et al., 2015) and neurological diseases  (Stewart et al., 2014) 
1.6 Zebrafish development 
Zebrafish (Danio rerio) is a freshwater teleost which is found in nature in the 
Himalayan region. It has firstly become an important model to study developmental 
biology thanks to some of its features such as external fecundation and development, 
transparency of the body during the early stages of development (pigmentation starts 
developing at ~48 hpf)  which allows direct observation, high number of eggs per lay 
(in the range of hundreds), short embryo development time (within 5 days all organs 
are completely developed), and of course developmental, anatomical, genetic 
similarity to human (Detrich et al., 1999), bridging the gap between D. melanogaster 
and C. elegans and mouse.  
Zebrafish development cycle has been finely staged (Kimmel et al., 1995): since the 
16 cells stage the fate of each cell has been established and it is now known which 
cells will form each of the three germ layers (ectoderm, mesoderm and endoderm) 
and therefore the tissues and organs which will develop from the respective layer 
(Fig. 1.1) (Strehlow et al., 1994) (Kimmel et al., 1990) (Gilbert and Raunio 1997).  
Spatial gene expression analysis through in situ hybridization have shown that 
embryonic territories are very early defined through secretion of factors (such as 
BMP2B and CHD) with opposite roles from different cell populations (Schier and 
Talbot, 1998), therefore defining the polarization of the gastrula (Fig. 1.1). Therefore 
a left-right and a dorsal-ventral axis are established (Gilbert, 2000). 
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The neural tube formation is then induced by specific factors secreted by the 
underlying mesoderm, which turns part of  the ectoderm into neuro ectoderm, neural  
 
plate and then neural tube (Schmidt et al., 2013). Neural tube formation starts after 
somitogenesis. Antero-posterior patterning of the neural tube is once again induced 
by secreted signals which establish a gradient of expression throughout the neural 
tube, polarizing it. Different anatomical areas act as organizers for the antero-
posterior patterning. The anterior neural boundary organizes the definition of the 
anterior neural plate, secreting some antagonists of Wnt factors (Schmidt et al., 
2013). Subsequently, other organizers that pattern the AP development of the neural 
system are intra-brain boundaries such as, for example,  the intrathalamic boundary, 
characterised by shh expression which orchestrates the development of the 
thalamic complex in the diencephalon in zebrafish. The midbrain-hindbrain boundary 
is also a well established organizer, characterised by the secretion of FGF8 (Schmidt 
et al., 2013). 
The somites start developing at about 10.5 hpf at the sides of the notochord. The 
notochord itself exerts an important role in inducing the specification of surrounding  
tissues. Secreting factors such as shh toward the adjacent paraxial mesoderm, the 
first somite forms from the most rostral area of the presomitic mesoderm and 
somitogenesis continues caudally with the formation of a new pair of somites every 
~30 minutes (Stickney et al., 2000). The somites then give rise to the development of 
the axial skeleton and skeletal muscle of the trunk. 
A B 
Figure 1.6. Axis definition and fate map in zebrafish. Experimental evidence (Kimmel et al;., 
1990) has allowed to draw a fate map of the zebrafish blastula (A). Secreted factors (like CHD) 
from the embryonic shield in the dorsal side of the gastrula will inhibit the ventralizing factors 
such as BMP2B, defining the dorso-ventral axis (B). Images modified from Schier and Talbot, 
1998 (B) and Gilbert and Raunio, 1997 (A). 
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1.6.1 Spinal cord and Spinal Motor Neuron development in zebrafish 
The antero-posterior patterning of the spinal cord is defined by gradient of expression 
of genes such as FGF, Wnt, Retinoic Acid (RA). The polarization of the spinal cord 
seems to occur via a caudalization of an otherwise (by default) all-rostral structure. 
FGF and Wnt proteins initially suppress anterior gene expression in the posterior 
neural plate in an RA-independent manner. Then the same signals activate 
posterior genes, in an RA-dependant manner (Lewis and Eisen, 2003). 
The neural tube has obviously a dorso-ventral patterning as well (Fig. 1.2). Dorsal 
sensory neurons and ventral motor neuron (MNs) are connected by a number of inter 
neurons. Identification of molecular markers in the last years has allowed to further 
categorize more neuronal sub groups within the neural tube. Dorsal neurons are 
divided into 6 subgroups in mouse; ventral neurons are divided into 5 groups (Lai et 
al., 2016). Each domain is characterized by the expression of specific markers 
(Wilson and Maden, 2005) (Lai et al., 2016). In addition to these there are 2 
additional  late-onset dorsal domains, which can be further divided into subgroups 
depending on axonal projections or neuropeptide secretion (Lai et al., 2016). 
Motor neurons (and other neuronal types) in the ventral region are specified by 
repression of alternative cell fates  through expression of transcriptional repressor 
factors (Davis-Dusenbery et al., 2014) such as olig2 (Lee, 2005), nkx6 (Hutchinson et 
al., 2007) (Sander, 2000) and pax6 (Wilson and Maden, 2005). RA is important for 
activating expression of olig2 and pax6  (Paschaki et al., 2012).  
MNs have distinct identities throughout the length of the spinal cord. Major 
differences in the antero-posterior identities of spinal motor neurons have been linked 
to actions of some members of the Hox gene family (Fig. 1.2) as their expression and 
functional profiles correlate with the AP positional identity of MNs (Wilson and Maden, 
2005) (Bonanomi and Pfaff, 2010) (Lai et al., 2016). RA is a known regulator of hox 
genes expression in vertebrates (Cunningham and Duester, 2015). 
The spinal cord in zebrafish (as for other anamniotes vertebrates) has both primary  
neurons and secondary  neurons. These two neuronal cell types have anatomical 
and functional distinctions: primary neurons are larger in size, develop earlier and 
have sensory  , motor and inter-neuronal functions (Higashijima, 2004)while 
secondary neurons have smaller size, develop later during embryo development and 
consist of only interneurons and motor neurons (Lewis and Eisen, 2003).  
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When positional identity of motor neurons is defined, they start extending processes: 
either axons or dendrites to connect each other with upstream and downstream 
neurons or tissues. MNs pathfinding seems to be driven by (but not only) 
semaphorins, a large class of secreted or transmembrane proteins, in vertebrates 
(Svensson et al., 2008). It may be that muscle-secreted semaphorins inhibit growth 
of axons, preventing them from reaching the wrong target (Lewis and Eisen, 2003). 
Mutant fish for plexin A3, a semaphorin receptor, show defects in exit position from 
the spinal cord (Palaisa and Granato, 2007), sema3a1 is also important for MNs 
growth (Sato-Maeda, 2006).   
 
1.6.2 Myelination process in zebrafish 
Zebrafish is considered a good model for studies of the myelination process and 
related human diseases (Buckley et al., 2010) (Sager et al., 2010) (Raphael and 
Talbot, 2011).  
Myelin is an insulating membrane that surrounds nerves permitting a better signal 
transduction along the nerve fibres. In humans, the importance of myelin for correct 
neuronal functions is highlighted by the severity of diseases with an impairment of 
myelin. Such disorders are characterized by abortive impulse conduction and the 
Figure 1.7 Definition of dorso-ventral and antero-posterior neuronal identities in the 
vertebrates’ spinal cord. Many different subtypes of sensory, motor and interneuron are 
present in the vertebrate spinal cord, each of them characterised by the expression of 
specific markers (left). Hox genes play a key role in antero-posterior patterning of the 
spinal cord through gradients of expression, defining different subset of neurons which 
will innervate the limbs or the internal walls (right). Images modified from Wilson and 
Maden, 2005 (left) and  Bonanomi and Pfaff, 2010 (right). 
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resulting loss of sensory, motor, and cognitive functions. Myelinating cells and the 
myelination process have been intensely studied and we now have knowledge of its 
structure, its formation and factors that might affect its functions.  
Composed of about 70% lipid and 30% proteins (Buckley et al., 2008), myelin takes 
the form of overlapping sheaths around axons and is produced by oligodendrocytes 
in the central nervous system (CNS) and by Schwann cells in the peripheral nervous 
system (PNS). Myelination process in zebrafish starts at about 3 dpf, beginning from 
lateral line neurons and ventral motor neurons in the neural tube (Buckley et al., 
2010). In all vertebrates Schwann cells originates from neural crest-derived 
precursors which associate with and proliferate along axonal tracts that grow out 
from the neural tube and peripheral ganglia (Jessen and Mirsky, 2005). Schwann cell 
precursors extend processes that envelop axon bundles and progressively segregate 
and subdivide them. Ultimately, each myelinating Schwann cell ensheaths a single 
axonal segment, then elaborates a multi-layered myelin sheath that gradually 
becomes compacted (Kazakova et al., 2006). Oligodendrocyte progenitors are 
generated by neuroepithelial precursors. They proliferate and migrate from their sites 
of origin before associating with axons and differentiating into oligodendrocytes, 
which elaborate myelin sheaths round single or multiple axons (Richardson et al., 
2006). Myelination process requires the highly co-ordinated expression of specific 
structural and regulatory proteins (Brösamle and Halpern, 2002). Myelin basic protein 
(MBP), referred as the “executive molecule of myelin” is of fundamental importance 
for this process (Boggs, 2006). In mammals MBP accounts for about 8% of the total 
myelin proteins in CNS and PNS being the second most abundant after proteolipid 
protein (PLP) (Müller et al., 2013). MBP is a fundamental protein for the myelination 
process in the CNS, as highlighted by severe hypomyelination observed in different 
mutant mice, while almost a normal myelination is possible in mice lacking PLP. MBP 
is essential to provide adhesion of the myelin sheaths at the cytoplasmic interface, 
interacting electrostatically with the lipid layer (Min et al., 2009). Apparently in mice it 
is not indispensable for myelination of the PNS which can be explained by 
compensatory roles of P0 (Müller et al., 2013). Notably P0 in zebrafish PNS is less 
expressed than in mammals and does not work as a myelin adhesion protein 
(Buckley et al., 2008) therefore mbp in zebrafish is essential also for myelination of 
the PNS (Pogoda et al., 2006). Two mbp paralogs are present in zebrafish: mbpa (on 
chromosome 19) and mbpb (on chr 16), which have very similar but not identical 
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expression pattern (Nawaz et al., 2013) the second one being more closely related to 
the MBP present in tetrapods, both are abundant in zebrafish myelin. mbpb but not 
mbpa is expressed as early as 11 hpf in the polster, the hatching gland precursor 
underlying the developing forebrain (Nawaz et al., 2013). Both paralogs were found 
in association with the plasma membrane suggesting a structural function like MBP in 
mouse. Both paralogs have a complex splice structure and mbpb exists in a 
transcription unit from which two protein products emerge: MBPb and the unrelated 
GOLLI. The function of the second one is not completely understood, although mice 
lacking for the golli product of the mbp gene have a phenotype suggesting an 
involvement in the myelination process (Nawaz et al., 2013). Although MBP is mainly 
known to have structural function in myelin, it seems also to have other roles. There 
is evidence that one classic MBP isoform alone is capable of fulfilling this function in 
the absence of the other isoforms, making the roles of the other isoforms unclear 
(Campagnoni and Skoff, 2001). The complex splicing variants of MBP, its post-
translational modifications and its tertiary structure that might be compatible with 
multiple protein associations, seem to indicate it has different functions within the cell 
(Müller et al., 2013).  
Some studies in mouse showed different MBP isoforms play different roles at 
different developmental stages in different cell compartments. These non-myelin-
related functions are various: some isoforms appear to be in the cytoplasm and 
nucleus but not in the plasma membrane (Smith et al., 2013), it interacts with 
cytoskeletal proteins influencing their polymerization (Hill et al., 2005), it has been 
connected to signalling pathways which are important for differentiation and 
myelination (Smith et al., 2012) (Kräm er-Albers and White, 2011), modulates 
voltage-operated Ca2+  channels (Smith et al., 2011) and also, a role of MBP as a 
transcription factor has been speculated (Staugaitis et al., 1996). 
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The presence of the GOLLI product within the same transcription unit makes the 
situation even more complicated as the golli-mbp gene seems to have other different 
neural and non-neural roles in mouse (Müller et al., 2013) (Fulton et al., 2010). 
GOLLI-MBP isoforms are expressed throughout the immune system in thymocytes 
and T-cells and also in the entire haemopoietic system (Feng, 2007) (Marty et al., 
2002). Overall, it seems classic forms of mbp have many other roles with functions 
beyond that of serving as myelin structural proteins, playing a role also in 
oligodendrocyte and Schwann cells differentiation as well as regulating the 
myelination program. 
1.6.3 Cerebellar development in zebrafish 
Cerebellar functions are also highly conserved in vertebrates, integrating sensory 
and motor information. In mammals cerebellum is thought to perform also some 
higher cognitive and emotional tasks (Buckner, 2013).  
Zebrafish cerebellum is formed by three layers of cells just like in mammals, from 
external to internal: a molecular layer, a PCs layer and a granule layer (Kani et al., 
2010). The three layers are first detectable at 5 dpf (Bae et al., 2009). Zebrafish 
cerebellum can be divided in lobular structures from rostral to caudal, each of them 
containing all three cell layers: valvula cerebelli (Va), the corpus cerebelli (CCe), and 
the vestibulolateral lobe, which consists of the eminentia granularis (EG) and the 
Figure 1.8 All three cerebellar layers are easily recognizable upon 
immunostaining. From external to internal: Molecular Layer (ML); Purkinje Cell Layer 
(PCL), Granule Cell Layer (GCL; left). Schematic representation of different cell types 
and their connections within zebrafish cerebellum (right). Images from Bae et al., 2009. 
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lobus caudalis cerebelli (LCa). The eminentia granularis contains only the granule 
cell layer (Bae et al., 2009; Fig. 1.3).  
The different types of neurons in the zebrafish cerebellum, like in mammals, can be 
divided in GABAergic/glycinergic neurons (inhibitory) and glutamatergic neurons 
(excitatory), according to the main neurotransmitter they secrete. This differentiation 
begins 3 days post fecundation (Bae et al., 2009). Granule cells, eurydendroid cells 
(which are absent in mammals, substituted by the deep cerebellar nuclei) are 
glutamatergic; Purkinje cells and interneuron such as Golgi cells and stellate cells are 
inhibitory. PCs layer in all vertebrates receives information from the climbing fibres 
from the inferior olives, and the mossy fibres principally from the pontine nuclei (via 
granule cell parallel fibres). The pons (and pontine nuclei) are highly affected in PCH 
(D’Arrigo et al., 2014). The PCs in mammals send their inhibitory signals outside the 
cerebellar cortex thorugh the Deep Cerebellar Nuclei (DCN). The DCN in teleosts is 
substituted by the eurydendroid cells (Bae et al., 2009) (Heap et al., 2013). 
Purkinje cells can be stained with pvalb7 antibody, granule cells express instead 
vglut1. Either vglut1 and pvalb7  are initially expressed at 3 dpf (Bae et al., 2009). 
pvalb7 may be expressed even earlier in PCs (2.8 dpf; Hamling et al., 2015). The 
signal of the 2 antibodies merges in the more external layer at 5 dpf, indicating that 
the molecular layer is completely formed by 5 dpf (Bae et al., 2009; Fig. 1.6). 
Purkinje cells start differentiating at 2.8 dpf in dorsomedial clusters and ventrolateral 
clusters, symmetrically (Fig. 1.4; Hamling et al., 2015) from progenitor cells 
expressing ptf1a (Kani et al., 2010). By 4 dpf the PCs layer have acquired the 
distinctive “wing-shaped” pattern. 
Mutations affecting cerebellar development compromise the formation of the PCs 
layer which can result scattered or with an inverted wing-shape (Fig. 1.5; Bae et al., 
2009).  
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Figure 1.10 Dorsal view of Purkinje cell layer in WT and mutant zebrafish. Wild type 
(A); Mutations in genes affecting cerebellar development can cause the formation of 
scattered structures (B, C) or inverted structure (D), although the fish may not show any 
clear morphological phenotype. Images modified from Bae et al., 2009.  
 
Figure 1.9 Dorsal view of Purkinje cell layer development in zebrafish. Clusters  of PCs 
can be seen as early as 2.8 dpf in the dorsomedial region (red) and ventrolateral region 
(yellow). They progressively expand until they reach confluence (3.3 dpf) and form the 
classical wing-shaped structure. Images from Hamling et al., 2015. 
A B 
C D 
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Figure1.11 Purkinje cells and Granule cells in zebrafish.  Co-immunostaining of pvalb7 
and vglut1 show merged signal in the most dorsal part (Ka, top; Kb, right) at 5 dpf 
indicating that the ML is formed. K dorsal view; Ka and Kb show transverse sections 
obtained by manipulation of Z-stack from image K Image from Bae et al., 2009. 
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1.7 Zebrafish models of PCH 
Zebrafish have been used as a model for a countless number of studies about 
neurodevelopment and neurodegeneration. It is a versatile and cost efficient model 
thanks to external fecundation and body transparency, which allows direct 
observation of anatomical defects caused either by gene knock down or mutagenesis 
(Schmidt et al., 2013) (Babin et al., 2014) (Martín-Jiménez et al., 2015). Here I will 
analyze the state of the art for the use of zebrafish as a model to specifically study 
pontocerebellar hypoplasias and motor neuron diseases. 
Other than the previously mentioned studies about the investigation of functions of 
EXOSC3 and EXOSC8, several other publications took advantage of this model 
system to study cerebellar development. Zebrafish cerebellum development has 
been well staged and studied (Hamling et al., 2015) (Kani et al., 2010). 
1.7.1 TSEN54 
Kasher and colleagues created knock-down and mutant zebrafish models of PCH 
targeting tRNA-splicing endonuclease subunit 54 (tsen54) and mitochondrial arginyl-
tRNA synthetase (rars2; Kasher et al., 2011). 
In the article, they show expression of tsen54 in 24 hpf zebrafish through in situ 
hybridization. tsen54  is expressed systemically, but a stronger signal is present 
within the midbrain-hindbrain boundary (mhb), in the telencephalon and hindbrain 
(Fig. 1.7).  
Gene knock down with an antisense morpholino shows a defective development of 
the head region, which they state, it is not reflected in the general body morphology.  
To study if there could be any analogy between the roles of tsen54 and rars2 in 
neurodevelopment, the authors performed gene knock-down of rars2 as well, 
showing similar morphological defects in the brain. Specifically, the mhb is missing in 
both morphant fish. Defects were partially rescued through co-injection of WT 
(human or zebrafish) mRNA in both models. Notably, the mhb seems to partially 
develop in the rescued fish.  
In situ hybridization was performed in both models to study brain development using 
fgf8 and otx2  as markers of brain development. Again similar defective expression 
patterns of the markers could be shown in both models, which was partially rescued 
by WT mRNA injection. 
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Acridine orange staining highlighted a higher cell death rate in the brain of both 
tsen54 and rars2 morphant models, resembling the patient phenotype that also show 
cell death in the pons. 
Although the phenotypes were rescued through co-injection of mRNA (Fig. 1.7), 
therefore demonstrating the specificity of the phenotype, to avoid any doubt about 
the causes of brain cell death, a p53-MO co-injection could have been performed.  
Finally, in the paper Kasher and colleagues report the creation of a tsen54 mutant 
line but they only say the homozygous mutant fish die within 9 dpf. No phenotype 
could be seen and the causes of the sudden death are unknown. Hopefully this 
mutant line will be investigated further with a modern, comprehensive technique (e.g. 
RNA-seq) to study what patho-mechanisms lead to death of the mutant fish. 
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H G F 
Figure 1.12 tsen54 expression and tsen54 and rars2 knock down. tsen54 is ubiquitously 
expressed but signal is stronger in mhb and telencephalon (A). Knock-down of tsen54 (D) 
and rars2 (G) cause defective development of brain and mhb compared to control (C, F). 
Co-injection of respective mRNAs and morpholinos rescued the brain phenotype, mhb is 
partially formed in both models (E, H). Graphs representing the percentage of defects in 
knock-down fish and rescued fish for tsen54 experiments (B, left) and rars2 experiments (B, 
right). Scale bar = 200 µm. Figures modified from  Kasher et al., 2011 
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1.7.2 CLP1 
Schaffer and colleagues show in their paper functional analysis of clp1 in a zebrafish 
mutant strain (Schaffer et al., 2014). 
They generated a clp1 R44X mutant line by ENU mutagenesis which showed 
defective body morphology and clp1 expression - tested by in situ hybridization. 
Mutant fish did not survive after 5 dpf, demonstrating an essential role of clp1 during 
embryo development.  
Expression of otx2 as a marker of midbrain development was normal up to 24 hpf 
even in mutant fish. At 48 hpf mutants started displaying lower otx2 expression (Fig. 
1.8). Because of the sudden decrease in expression suggest neurodegeneration 
instead of defective differentiation, they tested for cell death with TUNEL, showing 
indeed an increased cell death rate in the brain of mutant fish. Injection of p53-MO 
partially rescued otx2 expression in mutants suggesting that the neural apoptosis is 
p53 dependent. Immunostaining of motor neuron with SV2 showed defects of these 
structures too (Fig. 1.8). 
Injection of human WT CLP1 mRNA showed body morphology phenotype as well as 
otx2 expression rescue while injection of mutant CLP1 mRNA did not, therefore 
suggesting that the human mutation lacks activity in vivo (Fig. 1.8). 
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Figure 1.13 clp1 is important for CNS and PNS development. Mutant clp1-/- fish develop 
normally up to 48 hpf when they start showing a curved tail (A). They curvature of the tail was 
used to calculate the severity of the phenotype and to quantify the rescue by WT mRNA and 
mutant mRNA, demonstrating a lack of activity of the human mutant gene (B). Analysis of 
otx2 expression as a marker of brain development show normal signal even in mutants at 24 
hpf. Signal decreases at 48 hpf in mutants compared to controls (C). Injection of the WT 
mRNA rescues expression of otx2 in brain of mutant fish. Injection of mutant mRNA does not 
rescue the expression (D). The graph shows the percentage of different phenotypes in 
mutant and rescued fish (E). Injection of p53 morpholino rescues expression of otx2 in the 
brain, indicating that brain degeneration is p53 dependent (F). clp1 inactivation affects also 
primary motor neurons (G). Images modified from Schaffer et al., 2014. 
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1.7.3 CHMP1A 
CHMP1A was originally identified as binding to polycomb proteins (Plc) and to recruit 
in the cytoplasm the transcriptional repressor BMI1 which in turn inhibits expression 
of INK4A, a repressor of stem cell proliferation. Mochida and colleagues show that 
morpholino based gene knock-down of chmp1a causes reduced cerebellum size 
compared to control fish (Mochida et al., 2012; Fig. 1.9), similar to what caused by 
knock-down of zebrafish orthologs of BMI1: bmi1a and bmi1b. Cerebellar phenotype 
was partially rescued by injection of human WT mRNA (Fig. 1.9). 
The authors then tested for interactions between chmp1a and the zebrafish ortholog 
of INK4A: cdkn2a. Double knock-down of chmp1a and cdkn2a  resulted in partial 
rescue of the phenotype, accordingly to the molecular function of these 2 proteins. 
   
 
  
 
  
 
  
Figure 1.14 chmp1a morpholino affects brain development. Cerebellar morphology of 5 
dpf morphnat fish is defective (B) compared to controls (A). Midbrain-hindbrain boundary is 
disrupted in morphant fish(a, b) compared to controls (c). Hindbrain structures are rescue 
through injection of WT mRNA (d, e). The graph shows percentage of phenotypes in 
moprhant and rescued fish (f). Image modified from Mochida et al., 2012. 
 
A B 
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1.7.4 QARS 
QARS encodes for glutaminyl-tRNA synthetase, variants in this gene cause 
neurological symptoms and pontocerebellar hypoplasia. Zhang and colleagues took 
advantage of a previously published mutant qars zebrafish line and phenotyped it 
(Zhang et al., 2014). In their study they demonstrate that the onset of 
neurodegeneration starts at 3 dpf, presumably for compensation through maternal 
effect. Mutant qars-/- fish do not show any defect until that age, subsequently they 
develop smaller eyes and head. Eyes and head size is significantly smaller (Fig. 
1.10). To test if neurogenesis was normal up to 2 dpf in mutant fish the authors 
performed immunostaining of fish head sections with anti-Pax6 (a marker of neural 
progenitors), anti-PH3 (a marker for mitotic cells) and anti-HuC/D (a marker for post-
mitotic neurons), showing that mitosis was normal both in the eyes and brain in 
mutant fish compared to controls (Fig. 1.11). 
Cell death tested by TUNEL staining was instead much higher in 6 dpf mutant fish 
compared to controls and comparable to WT in 2 dpf mutants indicating that the brain 
phenotype was indeed caused by neurodegeneration rather than defective 
neurodevelopment (Fig. 1.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15 Head and eyes have smaller size in qars mutant 
zebrafish. Image from Zhang et al., 2014. 
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Figure 1.16 Neurogenesis and cell death in control and qars mutant fish. 
Neurogenesis is normal in mutant fish compared to control at 2 dpf (A-C). Neural 
progenitors stained with anti-Pax6, mitotic cells (anti-PH3) and postmitotic cells (anti-
HuC/D) show a similar pattern (A). TUNEL staining shows a much stronger signal in 
mutants brain’s section at 6 dpf compared to control. At 2 dpf TUNEL staining is 
comparable in mutants and controls (E-F). Image modified from Zhang et al., 2014. 
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2 Chapter 2: Materials & Methods 
 
2.1 Next Generation sequencing (NGS) 
2.1.1 Whole exome sequencing 
Whole-exome sequencing was performed on one or several individuals from each 
pedigree depending on the mode of inheritance of the disease. Whole-exome 
sequencing was outsourced to AROS (AROS Applied Biotechnology A/S, Aarhus, 
Denmark). Genomic DNA was subjected to a library preparation using TruSeqTM 
DNA Sample Preparation Kit (Illumina Inc., San Diego, USA) and the targeted 
regions were captured using the Illumina Nextera Rapid Capture Exome Kit (37Mb) 
(Illumina Inc., San Diego, USA). The captured fragments were sequenced on an 
Illumina HiSeq 2500 platform (Illumina Inc., San Diego, USA) producing 100 bp 
paired-end reads. 
2.1.2 Bioinformatic analysis 
Bioinformatic analysis was performed using an in-house algorithm incorporating the 
published tools. The following was performed by Dr. Helen Griffin (Newcastle 
University): the reads were aligned to the human reference genome (UCSChg19) 
using Burrows-Wheeler Aligner (Li and Durbin, 2010), PCR duplicates were removed 
with Picard v1.85 (available at http://broadinstitute.github.io/picard/), single base 
variants (SBV) and insertions/deletions (indels) were identified with Varscan v2.2 
(Koboldt et al., 2009) and Dindel v1.01 (Albers et al., 2011) respectively. 
2.1.3 RNA-seq 
For RNA sequencing experiments, total RNA was extracted from fibroblasts or 
muscle tissue using the mirVana™ miRNA Isolation Kit (Ambion) and DNAse treated 
with the DNA-free™ DNA Removal Kit (Ambion). RNA quality was tested with an 
Agilent 2100 Bioanalyzer and only samples with an RNA Integrity Number (RIN) >7 
were sent for sequencing. RNAseq libraries were prepared using Illumina (Illumina, 
Inc. California, U.S.) TruSeq Stranded Total RNA with Ribo-Zero Human kit and were 
sequenced on an Illumina HiSeq 2500 platform using paired-end protocol. 
2.1.4 Bioinformatic analysis 
Bioinformatic analysis of EXOSC8 and RBM7 mutant fibroblasts was performed by 
Dr. Yaobo Xu (Newcastle University). The quality of sequencing reads was firstly 
checked with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
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The 12 bp on the left ends and 4 bp of the right ends of all reads were clipped off with 
Seqtk (https://github.com/lh3/seqtk) to remove GC-content biased bases. The 
programme (https://github.com/optimuscoprime/autoadapt) was then used to remove 
low quality bases (Q < 20) and contaminations from standard Illumina paired-end 
sequencing adaptors on 3’ ends of reads. Autoadapt uses FastQC to identify the 
exact sources of contaminations and uses cutadapt (Martin, 2011) to remove them 
automatically. Poly-N tails were trimmed off from reads with an in house Perl script. 
Only reads that were at least 20bp in length after trimming were kept. These high 
quality reads were then mapped to the human reference genome hg38 with Tophat2 
(Kim et al., 2013). Number of reads mapped to genes were counted using HTSeq-
count (Anders et al., 2014). Differentially expressed genes were then identified with 
Bionconductor (Gentleman et al., 2004) package DESeq2 (Love, et al., 2014). P-
values of detected expression changes were corrected with Benjamini & Hochberg 
algorithm. Genes differentially expressed with P-values ≤ 0.05 and fold change ≥ 2 
were considered as differentially expressed genes. 
2.2 Sanger sequencing 
2.2.1 Polymerase Chain Reaction 
Primer oligonucleotide sequences specific for the genes of interest were designed 
using Primer 3 (v.0.4.0) software. Primer 3 specifies product size as well as melting 
temperature of the designed primers and their GC content (%). Target DNA 
sequences were uploaded into the online software and primer sequences selected to 
span the region of interest. The generated primer sequences were checked for 
specificity using the online program Basic Local Alignment Search Tool (BLAST) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). A list of the primers used is provided below. 
 
Gene Exon Fw primer Rv primer Ta (°C)            Size (bp) 
EXOSC3 1 acggccatcaagcttcataaac ctcttcttttgggaggtcttct myTaq 63 539 
EXOSC3 2 ggggtgcctaagagataatggag gatagccttctggatatgtgagtgttc myTaq 63 441 
EXOSC3 3 tccccaagactcaactccaaag atcagcccaccagaaactacacag myTaq 63 539 
40 
 
EXOSC3 4 tggaagaaaggaggcagcaaatg cacaaaagcgtgggtgaaaac myTaq 63 515 
EXOSC8 1 gtctgggcaggggaaagt aggaaatggcaccccaac myTaq 55 300 
EXOSC8 11 tcacttggaggtcttgtgaa ttggtttgcctaagtcattgc myTaq 59 460 
RBM7 1 gtttgtgacgccagggag cgtcactttcggcctaaacg myTaq 61 400 
RBM7 2 ggaaatccgtgcatcattttca ccatgtgtcaatgttacccgt myTaq 61 475 
RBM7 3 cccggccagtagtttgagat acaacaaccccaaaaggcaa myTaq 55 
+ Betaine 
360 
RBM7 4 tattctggctgcatgagagc cagcccagtgaaaactaaaatga myTaq 57 451 
RBM7 5 tgctttagttgtggatccatct tgtgacaacttgtaaagctgct myTaq 59 600 
      
Table 4. List of primers used for PCR reactions 
 
PCR reaction was prepared using the following mix: 
MyTaq™ DNA Polymerase (Bioline) ………………….. 0.2 µl 
MyTaq™ reaction buffer (Bioline) ……………………….. 5 µl 
Fw primer (10 µM) ………………………………………… 1 µl 
Rv primer (10 µM) …………………………………………. 1 µl 
H2O ……………………………………………………….16.8 µl 
DNA…………………………………………………………...1 µl 
 
Reaction times and T° were as following: 
Step 1 – denaturation at 95 °C for 1 minute } 1 cycle 
 
Step 2 –  denaturation at 95 °C for 15 seconds 
               annealing T° user determined (see above), 10 secs per Kb 
               extension 72 ° for 10 seconds 
  
2.2.2 Electrophoresis on agarose gel 
 
40 μl/100ml of ethidium bromide was mixed into the molten 1-2 % agarose gel in 
1xTAE buffer pH8.0 (Tris base, acetic acid and Ethylenediaminetetraacetic acid – 
EDTA). 5μl of PCR product was mixed with 1μl of loading dye (dH2O, 15% glycerol, 
1% orange dye) and subjected to electrophoresis for a minimum of 30minutes at 75V 
} 25-35 cycles 
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before being visualised under UV light. Gel images were captured on a GelDoc-It 310 
Imaging system (UVP). 
2.2.3 ExoFAP PCR clean up 
 
Purification of PCR products was performed using 2 hydrolytic enzymes added to 3 
or 5 µl of PCR product as following: 
 
Exonuclease I (20 U/µL, Thermo Fisher)…………………………………………… 0.5 µl 
FastAP Thermosensitive Alkaline Phosphatase (1 U/µL, Thermo Fisher)……...… 1 µl 
 
Reaction times and T° were as following: 
1. Enzyme incubation 37 °C for 15 minutes 
2. Enzyme inactivation 80 °C for 15 minutes 
3. Hold at 4 °C indefinitely 
 
2.2.4 BigDye Terminator cycle 
 BigDye® Terminator v3.1 (Applied Biosystems)……………………………….….. 1 µl 
 BigDye® Terminator v1.1 & v3.1 5X Sequencing Buffer…………………………. 2 µl 
 Fw or Rv primer (10 µM).………………………………………………………..….…1 µl  
H2O………………………………………………………………………………..….…11 µl 
Reaction times and T° were as following: 
 
96 °C 1 min 
96 °C 10 secs 
50 °C   5 secs 
60 °C  4 mins 
4 °C   
2.2.5 Ethanol precipitation 
20 µl of sequencing reaction were precipitated according to the following protocol: 
1. Briefly spin the 96 well plate; 
2. Add 2 µl of 125 mM EDTA to each well; 
3. Add 2 µl of Sodium acetate  solution (3M) to each well; 
4. Add 70 µl of 100 ethanol to each well; 
5. Seal the plate with a plate sealer and mix inverting several times; 
6. Incubate at RT for 15 minutes; 
7. Spin plate at 2,000 g for 30 mins; 
8. Invert the plate on tissue paper and spin briefly at 100 g; 
} 25 cycles 
∞ 
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9. Add 70 µl of 70% ethanol to each well; 
10. Spin the plate at 1,650 g for 15 minutes; 
11. Invert the plate on tissue paper and spin briefly at 100 g; 
12. Allow the plate to air dry in the dark (without lid) for 10 minutes; 
13. Resuspend in 10 µl Hi-Di™ Formamide (Applied Biosystems) 
 
2.2.6 Sanger Sequencing 
DNA resuspended in Hi-Di™ was heated for 2 mins at 95 °C and then sequenced with 
a 3130xl Genetic Analyzer. Raw data were suddenly analysed with Seqscape® v2.6 
(ThermoFisher) or Mutation Surveyor® v4.0.5 (Softgenetics). 
2.3 RNA isolation 
RNA was isolated using different methods depending on the downstream 
applications. 
2.3.1 RNA isolation for miRNA qRT-PCR analysis and RNAseq from cells and 
tissues 
Total RNA was isolated from cells or muscle tissue using the mirVana™ miRNA 
Isolation Kit (Ambion) following manufacturer instructions.  
2.3.2 RNA isolation for qRT-PCR 
Total RNA isolation for qRT-PCR application was performed through a customized 
protocol with the RNAeasy mini kit (Qiagen). 
A first step to prevent RNA degradation due to RNAse action was done with 
β−mercaptoethanol in RLT Buffer (1:100, Qiagen). Lysate was then passed through 
QIAshredder columns to increase RNA yield. Subsequent steps were performed as 
indicated on RNAeasy mini kit protocol and RNA eluted in 30-50 µl of nuclease free 
water in order to have a minimum concentration of 200 ng/µl. 
2.3.3 RNA isolation for RT-PCR 
Samples were homogenized using 1 ml Trizol® (Ambion) and incubated 5 mins at RT. 
Following incubation, 200 µl of chloroform were added for each ml of Trizol®. Tubes 
were then shaken vigorously for 15 secs, incubated for 2-3 mins at RT and 
centrifuged at 12,000 g for 15 mins at 4°C. Once the top aqueous phase is removed 
and placed in a new tube, 500 µl of 100% isopropanol per ml of Trizol® were added, 
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incubated at RT for 10 minutes and then span at 12,000 g for 20 mins at 4°C. 
Optionally, 1 µl of linear polyacrylamide can be added to increase RNA precipitation 
during this step. 
After centrifugation supernatant is removed and the RNA pellet washed with 1 ml of 
75% of ethanol per ml of Trizol used. Sample is vortexed, span at 7,500 g for 5 mins, 
ethanol is removed and the pellet is left to air dry for 5-10 mins. The pellet is 
resuspended in 30 µl of water incubating for 10-15 minutes at 55-60 °C. 
Human WARS primers: 
Primers pair          Temp. 
1F3R                      61    
8F11R                    59 
11F13R                  61  
 
2.4 cDNA reverse transcription 
Total RNA extracted from cells or zebrafish was reverse transcribed with High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). A minimum of 2 µg 
of RNA were used for a single reverse transcription reaction. 
2.5 qRT-PCR 
qRT-PCR reaction was prepared using the following mix: 
iTaq™ Universal SYBR® Green Supermix (BioRad)…………..……………. 12.5 µl 
Fw primer (10 mM)………………………………………………………..…….. 1.25 µl 
Rv primer (10 mM)……………………………………………………..……….. 1.25 µl 
H2O…………………………………………………….……………………………….9µl 
cDNA…………………………………………………………………………….…… 1 µl 
 
Reactions were performed in a 96-well plate using a Bio-Rad iCycler Thermal Cycler 
equipped with a MyiQ™ Single-Color Real-Time PCR Detection System. 
 
The following primers were used: 
 
 
Gene Species Fw primer Rv primer  
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atxn1a  D.r. GGGTGGAAGACCTGAAAACA GCCGAACACAAAGAAAGGAT  
atxn1b D.r. TACAGACATCGCCCACAGAG CAGCGGCACTCCTAATGCT  
hoxc6b D.r. CTGCGTCTTGTCAAATAGCGA GCTTCAGACCAAGGCAAGAC  
hoxc8 D.r. CTCTCCGAGCCTCATGTTCC ACCAGATCTTCACCTGTCGT  
hoxc9 D.r. GGGAAGCACAAAGACGACAA CCTTGCTACCTCATATCGCC  
hoxc10 D.r. GGAGGGAATACGCAGGAAGA ACGGACACCTCTTCTTTCGA  
hoxc11a D.r. CCAGAGGATGAGGAGGAACA CGCTCCAGTTCACGAATCTG  
hoxc11b D.r. TGGACATCGCTTCTTCCTCA TGTCTTCAGTTCTCCGCAGT  
hoxd10 D.r. GTTAACCAGTTGCTCGTCGG CGCTGGAGGAGAAGAATTGC  
hoxd11 D.r. ACCAAATCTTCACTTGTCGGTC CCGTTTCAACCTGCGATGAA  
hoxd13 D.r. CTGACAGAATGAAGCCGCTG GGTTCAGAGAGCAATGATGGG  
hoxa13a D.r. ACTGCCGATGGAGAGTTACC AACACGTTTCTTCCTTCCGC  
hoxa13b D.r. ACTAACGGGTGGAGCAGTC TTGTGGCATATTCTCGTTCTAGT  
β-act D.r. CGAGCTGTCTTCCCATCCA TCACCAACGTAGCTGTCTTTCTG  
ef1α D.r. CTGGAGGCCAGCTCAAACAT ATCAAGAAGAGTAGTAGTACCG
CTAGCATTAC 
 
HOXC6 H.s. AAAAGAGGAAAAGCGGGAAG CGAGGGAGAAAGGGAGAGAG  
HOXC8 H.s. GGGAGACGGAGAAACAGTGA AGGTGGGAGTGTGGTGAGAG  
HOXC9 H.s. AGACGCTGGAACTGGAGAAG AGGCTGGGTAGGGTTTAGGA  
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HOXC11 H.s. TGACTCTCGCTGTGGGACA GAGGATTGTTCGGCTCAGG  
HOTAIR H.s. GGAGTGGGGAGTGGAGAGA CGTGGCATTTCTGGTCTTGT  
TUBB H.s. GCTGGTGGAAAACACAGATG 
 
GTTGAGGTCCCCGTAGGTG 
 
 
Table 5. List of primers used for qRT-PCR reactions. 
 
2.6 Animal Models  
2.6.1 Fish strains and maintenance 
Zebrafish (Danio rerio) of the wild type golden strain and Tg(Isl1:GFP) strain 
expressing GFP in the cranial motor neurons under control of the islet1 promoter 
were used for experiments. 
Adult fish were kept in fresh water at 28.5 °C. Males and females were paired and 
kept separated by a net the night before the embryos were required. The following 
day the net was removed. Embryos were collected and raised in E3 medium ((5mM 
NaCl,0.17mM KCl, 0.33mM CaCl2, 0.33mM MgS04, 0.1PPM methylene blue) and 
staged in hours or days post fertilization according to Kimmel’s criteria (Kimmel et al.). 
After 24 hours embryos were dechorionated manually or using pronase (0.5-2 mg/ml, 
Roche). Embryos and larvae were then euthanized in 4mg/ml tricaine 
methanesulfonate E3 medium mix (1:2; Westerfield, 2000) and fixed in 4% 
Paraformaldehyde (PFA) or frozen in dry ice depending on the needs. 
2.6.2 Antisense oligonucleotide morpholino preparation 
Antisense morpholino oligonucleotide (MO, Gene Tools LLC) against rbm7 were 
designed to target an intron-exon or an exon-intron boundary in order to cause 
defective splicing. The following morpholinos against rbm7  were used: 
SPL rbm7_In1-Ex2 MO: 5’-ATGGCCCAGCCTAGTGGAAAAAGAA-3’; 
SPL rbm7_Ex2-In2 MO: 5’-ACGCAATAAGGAAAGTCCTACCGGT-3’  
Two previously published morpholino against exosc3 (Wan et al., 2012) and exosc8 
(Boczonadi et al., 2014) both these morpholinos target the translation start site (AUG) 
AUG exosc3 MO: 5’- TCCATGATGGAGGAGCGGAAAACAC-3’;  
AUG exosc8 MO: 5′-TTTAAAACCAGCCGCCATGATGTTT-3′;  
AUG mbpa MO: 5’-GGCCATTCTAGGTGTTGATCTGTTC-3’ 
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Gene tools’ standard control morpholino which does not have a target in zebrafish 
was used as negative control oligo: 
CTRL MO: 5′-CCTCTTACCTCAGTTACAATTTATA-3’.  
The MOs were re-suspended in 1x Danieau solution (0.4mM MgSO4, 58 mM 
NaCl,0.7mM KCl, 5mM HEPES, 0.6 mM Ca(NO3)2; pH 7.6; Westerfield, 2000). 
2.6.3 Micro-needle preparation and microinjection 
Borosilicate glass capillaries (Article # 1403550, Hilgenberg GmbH, Malsfeld, 
Germany) were pulled with a P97 Flaming Brown Micropipette Puller with a heat of 
695, a pull of 70 and velocity of 60. Needles were filled using Microloader Tips 
(Eppendorf) with a mix of Danieau Buffer, Morpholino and Phenol red. Embryos were 
injected up to 2 cells stage with an Eppendorf Femtojet microinjector. The following 
quantities were injected for each morpholino: 
SPL rbm7_In1-Ex2 MO: 2.2 ng 
SPL rbm7_Ex2-In2 MO: 1.1 ng 
AUG exosc3 MO: 1.5 ng 
AUG exosc8 MO: 10 ng 
AUG mbpa MO: 1 ng 
CTRL MO: 5 ng 
Morphant embryos were then visualized with an epifluorescence stereomicroscope 
(Leica MZ16F). 
2.6.4 RT-PCR 
 
RNA was extracted from ~20-40 fish at different developmental stages using the 
RNAeasy kit (Qiagen) as described above and reverse transcribed using the High 
Capacity Reverse Transcription kit (ThermoFisher). 
rbm7 primers and conditions were used as published before in Giunta et al., 2016 
exosc8 primers and conditions were used as published in Boczonadi et al., 2014 
mbpb primers and conditions were used as published in (Nawaz et al., 2013) 
β-actin primers and conditions were used as published in (Argenton et al., 2004) 
 
2.7 CRISPR/Cas9 mutagenesis 
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2.7.1 Design of gRNAs 
Guide RNAs were designed using CRISPRscan (http://www.crisprscan.org/). 
 
2 gRNAs (Oligo1) were chosen  
rbm7_Exon2_gRNA: taatacgactcactataGGGATTTTAACCTTGATCAAgttttagagctagaa 
rbm7_Exon4_gRNA: 
taatacgactcactataGGCCTCTGCATGTGCTGTGGgttttagagctagaa 
the BLUE part being the actual guide RNA, the RED part the T7 promoter, the 
GREEN the overlapping crRNA-TracrRNA sequence (Oligo2) which will anneal to the 
generic oligo2: 5’-AAA AGC ACC GAC TCG GTG CCA CTT TTT CAA GTT GAT 
AAC GGA CTA GCC TTA TTT TAA CTT GCT ATT TCT AGC TCT AAA AC-3’ 
 
 
2.7.2 Annealing: 
Annealing mix of oligo 1 to oligo 2 was as following: 
MyTaq™ DNA Polymerase (Bioline) ……………………………...……….. 0.2 µl 
MyTaq™ reaction buffer (Bioline) …………………….………………..…….. 5 µl 
Oligo1 (100 µM) ………………………………………………………………… 2 µl 
Oligo2 (100 µM) …………………………………………………………...……. 2 µl 
H2O …………………………………………………………………...………….16 µl 
Annealing conditions were as following: 
Denaturation 95 °C……………………………………………..……….5 mins 
89°C……………………………………………………………….…….15 secs 
83°C…………………………………………………………….……….15 secs 
77°C…………………………………………………………….……….15 secs 
71°C…………………………………………………………….……….15 secs 
65°C…………………………….……………………..……….……….15 secs 
59°C………………………….…………………………………...…….15 secs 
53°C……………………….…………………………………………….15 secs 
Annealing 50°C……………………………………………..………….10 mins 
Extension 72°C……………………………………………….……….10 mins 
4°C………………………………………………………………..……….  
 
∞ 
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The size of product was verified on an agarose gel and the annealed product was 
purified with the QIAquick PCR Purification Kit (Qiagen). 
 
2.7.3 In vitro transcription 
Guide RNAs were transcribed in vitro using 8 µl of annealed DNA product (60-120 
ng/µl) using the MEGAshortscript Kit (ThermoFisher) as follows: 
T7 10x reaction buffer……………………………………………….……… 2 µl 
T7 ATP solution (75 µM)…………………………………………….……… 2 µl 
T7 CTP solution (75 µM)…………………………………………….……… 2 µl 
T7 GTP solution (75 µM)…………………………………………….……… 2 µl 
T7 UTP solution (75 µM)……………………………………………….…… 2 µl 
DNA template…………………………………………………………..……. 8 µl 
T7 enzyme mix……………………………………………………….……… 2 µl 
The mix was incubated at 37 °C overnight then DNAse treated with TURBO DNAse 
(Thermo Fisher). 
The RNA was then eluted to 300 µl and purified with the miRvana kit (Ambion) 
adding 1.25 volumes of ethanol, spin through the column, add 700 µl of solution 1, 
spin, add 500 µl of solution 2/3, spin, add 500 µl, spin, elute in nuclease free water. 
Cas9 RNA was transcribed from pCS2-nCas9n plasmid (Plasmid #47929, Addgene). 
Size and quality of RNA was then checked on a 2.5% agarose gel. 
2.7.4 Microinjection 
Fish at 1 cell stage were injected into the cell or just below it using the following mix: 
1 µl gRNA 
1 µl Cas9 RNA 
2.5 µl Danieau buffer 
0.5 µl Phenol Red 
2.7.5 Screening for mutations 
 Fish of min 10-15 fish were collected, genomic DNA was extracted with DNeasy 
Blood & Tissue Kit (Qiagen) following manufacturer instructions. 
PCR was performed with zebrafish genomic DNA using the following intronic primers 
(Ta 59 °C): 
Exon2: Fw 5’-TTGCAGGCAATTTATAGTTCACAGAAA-3’ 
            Rv 5’-GGCATGAGGGTATGCTGAAA-3’ 
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Exon4: Fw 5’-TGAGAGTGATCACATTTACACCTG-3’ 
            Rv 5’- AAATCGTGACAGGCCTATGTTT-3’ 
PCR product was run on a 2% gel and purified with QIAquick PCR Purification Kit 
(Qiagen). 
The PCR product was suddenly ligated into pGEM-T Easy Vector (Promega) using 
the following mix. 
Rapid Ligation Buffer (2X)………………………………… 5 µl 
pGEM-T Easy Vector……………………………………….1 µl 
PCR product…………………………………………………3 µl 
T4 DNA Ligase………………………………………………1 µl 
Ligation conditions: 
16°C………………………………………..….………...10 hours 
65°C…………………………………………..……....20 minutes  
4°C…………………………………………………….. 
Ligation was performed using JM109 High Efficiency Competent Cells (Promega) 
adding 2 µl of ligation product to 10 µl of competent cells and following the protocol 
provided with the kit (Heat-shocking for 45-50 seconds). 
150 µl of transformed cells were plated on LB/ampicillin plates. 
Each colony was then amplified by PCR. PCR product was then run on 2% agarose 
gel to check the presence of the fragment. 
If positive, 3 µl of PCR were transferred to a new 96 well plate and an ExoFAP 
reaction was performed on this product to remove unwanted deoxynucleotides and 
primers. The subsequent sequencing steps were performed as previously described. 
2.7.6 High throughput gDNA extraction 
For gDNA isolation from F1 single embryos (at least 48 hpf; with or without chorion) 
we used a lysis buffer containing 500 µl of NaOH (2.5 M) 20 µl of EDTA (0.5 M) in 50 
ml of deionized H2O. Each embryo was placed in a well in a 96 well plate and 15 µl of 
the mix were added. The plate was placed at 95°C for 30 mins and rapidly cooled 
down on ice. The alkaline solution was neutralized adding 1 volume of neutralizing 
buffer (40 mM of Tris-HCl; 325 mg in 50 ml of deionized H2O). 
Samples were let on ice for 10 minutes and then 5 µl of supernatant were used as 
template for PCR (Wilkinson et al., 2013). 
2.8 Immunostaining and confocal imaging 
∞ 
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Embryos at 48 hpf or 4.5 dpf were collected and fixed in 4% PFA in PBS at 4°C  
overnight. The following day the PFA was removed and fish were washed three times 
in PBS and once in dH2O and partially permeabilised in cold acetone (-20°C). 
Acetone was removed after 7 minutes at -20°C and fish washed in dH2O.  
Water is removed and fish are washed three times with PBS-Tween20 (0.1%) 
(PBST). Samples older than 48 hpf are treated with Collagenase A in PBST (1mg/ml) 
to further permeabilize the tissues. Depending on the age of the embryos, samples 
were incubated at RT in Collagenase A for: 
- 30 minutes if 3 days old 
- 1 hour if 4 days old 
- 1.5 hours if 5 days old 
Collagenase A was removed and samples washed three times with PBST. 
Samples were suddenly blocked with 5% horse serum for at least 1 hour. 
Primary antibody was added at the correct concentration in 5% horse serum and 
samples incubated overnight at 4°C. Purkinje cells were stained with Parvalbumin7 
antibody (a kind gift of Prof. Masahiko Hibi, Nagoya University, Japan; 1:1000, 
mouse ascites); Synaptic vesicles were stained with SV2 antibody (1:200, 
Developmental Studies Hybridoma Bank, Iowa).  
The following day samples were washed thoroughly with PBST and the secondary 
antibody was added at the correct dilution in 5% horse serum (Alexa Fluor 488, 
Invitrogen, 1:500). Acetylcholine receptors were visualized by using Alexa Fluor 594 
conjugated α-bungarotoxin (1 μg/ml, Invitrogen). 
Samples were incubated at RT for at least 2 hours and eventually imaged in 
methylcellulose 3% using a Nikon A1R confocal. Z-stack images were generated by 
scanning through the whole body with a 10x objective and then images manipulated 
to have the best resolution with NIS-element AR 3.2 64 bit software. 
2.9 Western blot  
2.9.1     Bradford assay 
Serial dilutions of bovine serum albumin (BSA) were previously prepared at 
concentrations of 0 mg/ml; 0.05 mg/ml; 0.1 mg/ml; 0.2 mg/ml; 0.3 mg/ml; 0.4 mg/ml; 
0.5 mg/ml. 
Protein assay dye reagent concentrate (Bio-Rad) was diluted 1:5 in H2O. 
Cells were lysed with 50 µl of PathScan® Sandwich ELISA Lysis Buffer (1X; Cell 
Signaling technology) or RIPA buffer. 
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10 µl of cell lysate/standard (cell lysate eventually diluted 1:10) were added to 190 µl 
of diluted Protein assay dye reagent concentrate and the concentration was 
measured with an Infinite® F50 (Tecan) plate reader. 
Absorbance readings and concentrations of the standards were plotted in a graph 
and then concentration of the samples was calculated. 
2.9.2 Gel electrophoresis 
A maximum volume of 20 µl of cell lysate was mixed with 7.5 µl NuPAGE® LDS 
Sample Buffer (4X; Life technologies) and 3 µl of reducing agent. Samples were then 
boiled at 70°C for 10 mins and then a maximum volume of 30 µl of cell lysate was 
loaded into a 4-12% SDS–polyacrylamide gel. Molecular weight of the bands was 
compared to SeeBlue® Plus2 Pre-stained Protein Standard (ThermoFisher). 
500 µl of NuPAGE® Antioxidant (ThermoFisher) was added to the internal chamber 
of the tank using NuPAGE® MES SDS Running Buffer (20X) (ThermoFisher) 
previously diluted 20 times as running buffer. 
2.9.3 Protein transfer 
Proteins were transferred to a PVDF membrane with an iBlot®2 PVDF Mini transfer 
stack (ThermoFisher). Efficiency of protein transfer was checked by red Ponceau 
staining. Membrane was washed thoroughly with TTBS (20 ml Tris-HCl pH 7.5, 29.2 
g NaCl, 1 ml Tween20, Top up to 1 litre with dH2O) and then blocked with 5% milk 
powder in TTBS for at least 30 minutes at RT. Primary antibodies were added at the 
correct concentration (RBM7, Abcam ab84116, 1:600; SNX15, Abcam ab172534, 
1:500; β-actin, Sigma A1978, 1:2000;) in 5% milk in TTBS and incubated overnight at 
4°C. 
The following day the antibody was removed and the membrane was washed 3 X 
10/15 mins in TTBS and then the secondary antibody was added in 5% milk in TTBS 
and incubate at RT for at least 1 hour (polyclonal swine anti-rabbit 
immunoglobulins/HRP or Polyclonal Rabbit Anti-mouse immunoglobulins/HRP; Dako, 
Denmark) and washed 3 X 10/15 mins. 
2.9.4 Blot development 
The membrane was incubated for 5 min in a dark place with Clarity™ Western ECL 
Blotting Substrate peroxide solution:luminol/enhancer solution 1:1 (Bio-rad) and then 
imaged with an Amersham Imager 600 (GE Healthcare Life Science). 
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2.10 Tissue culture 
Human primary fibroblasts and immortalized myoblasts were grown in plastic flasks 
(CELLSTAR®, Greiner Bio-One International, Item No: 690175 - 25 cm2 and 658175 
– 75 cm2). Fibroblasts were grown in 1X Dulbecco Modified Eagle Medium (Gibco®), 
10% FBS (F7524, Sigma), 1% Pen/Strep (10,000 U/mL, Gibco®) unless otherwise 
specified.  
2.11 Electron microscopy 
Zebrafish at 4 dpf were fixed in 2% glutaraldehyde in sodium cacodylate buffer at 
4 °C overnight and suddenly washed three times (15 min each) in cacodylate buffer, 
and then stained with 1% osmium tetroxide (Agar Scientific) in dH2O for 1 h. Fish 
were dehydrated using  graded acetone (25, 50 and 75% and twice in 100%). Fish 
were impregnated through increasing concentration of resin in acetone (25, 50, 75 
and 100%) and then embedded in 100% resin at 60 °C for 24 h (TAAB Lab. Equip). 
Ultra-thin transverse sections of ~70 nm were cut using a diamond knife on a 
Reichert Ultracut E ultramicrotome. The sections were stretched with chloroform to 
eliminate compression and mounted on pioloform-filmed copper grids. The grids 
were then stained with 2% aqueous uranyl acetate lead citrate and subsequently 
examined using a Philips CM 100 Compustage (FEI) Transmission Electron 
Microscope and digital images were collected using an AMT CCD camera (Deben) at 
the Electron Microscopy Research Services, Newcastle University. 
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3 Chapter 3: Results – Exome Sequencing and RNA sequencing 
 
3.1 Diseases caused by impaired functionality of the exosome complex 
The first identified condition caused by defects in the exosome complex’s functions 
was the polymyositis/scleroderma syndrome (Wolfe et al., 1977), an autoimmune 
syndrome caused by the presence of auto-antibodies against antigen PM1/Scl in 
these patients  (which was subsequently recognized to be the human exosome 
complex). Symptoms caused by PM/Scl syndrome are not neurological like most of 
the other exosome complex related diseases known so far. Symptoms can include 
chronic muscle inflammation, weakening/loss of muscle mass, hardening of the skin 
and disposition of calcium under the skin (scleroderma) (Staals and Pruijn, 2011). 
More recently, Wan and colleagues (Wan et al., 2012) identified the first mutations on 
an exosome complex sub-unit (EXOSC3) which causes a dysfunction of the 
exosome causing pontocerebellar hypoplasia type 1 (PCH1). 
Subsequently, our group identified mutations on subunit EXOSC8 with overlapping 
symptoms of PCH1 and hypomyelination of the central nervous system in 22 children 
from three independent pedigrees (Boczonadi et al., 2014). 
Mutations on EXOSC2 sub-unit were identified as cause of neurological disorders in 
two unrelated German families in 2016 (Di Donato et al., 2016) with symptoms of 
hypomyelination, retinitis pigmentosa, hearing loss, premature ageing and others. 
Soon after, our group published a new study were we describe a patient with a 
mutation on RBM7 (a component of an exosome complex co-factor) with an SMA-like 
phenotype (Giunta et al., 2016). 
In an attempt to discover new exosome complex related pathologies, we searched 
for mutations on exosome complex subunits and/or co-factors in an unresolved 
cohort of neurological patients and in databases, based on the symptoms of the 
subjects. Transcriptome analysis of primary fibroblasts from 2 subjects was also 
performed, in order to understand which genes were differentially expressed or 
differentially spliced due to impaired exosome complex functions. 
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3.2 Overview of the techniques 
3.2.1 Next Generation Sequencing for identifying new mutations involved in 
pontocerebellar hypoplasia. 
In the last few years, the development of new technologies for genome and 
transcriptome sequencing known as “Next Generation Sequencing platforms” have 
reduced the cost of DNA and RNA sequencing by many orders of magnitude 
compared to Sanger sequencing  or standard gene expression analysis techniques  
(Reon and Dutta, 2016). These technologies allow to have a high throughput 
screening potentially for all mutations in the coding sequences of a given genome as 
well as transcript levels by Whole Exome Sequencing (WES; Bamshad et al., 2011) 
and RNA-sequencing (RNA-seq; Reon and Dutta, 2016). The use of these 
technologies releases a huge amount of data (Hrdlickova et al., 2016). On average, 
exome sequencing identifies ~20,000 single nucleotide variants (SNV) in a European 
American genome (Bamshad et al., 2011). If we need to analyse or compare several 
different samples, there is a need to reduce the number of potentially interesting 
variants to an acceptable number through filtering of potentially interesting 
genes/transcripts. 
3.2.2 Variants filtering of exome sequencing data 
Out of all the SNV identified by exome sequencing, on average 95% are already 
known as polymorphisms and non-pathogenic (Bamshad et al., 2011). Techniques to 
screen this massive amount of data from the background of common non-pathogenic 
variants vary. One of the most used approaches is the comparison of exome 
sequencing of closely or not related individuals, sharing a common phenotype, with 
control subjects DNAs, available in public databases such as dbSNP93, 1000 
Genomes Project (1000 Genomes Project Consortium et al., 2010) and Exome 
Variant Server (Johnston and Biesecker, 2013), screening for rare or novel alleles. 
The disease-causing variant might be present in the database as well, although with 
a very low frequency (usually less than 2%). Then a variant filtering methodology has 
to be designed, in order to further reduce the number of variants that will be analysed 
for segregation analysis in the families.  
There is no optimal statistical test or filtering strategy, given the variability of the gene 
functions and functional mutations, it depends on the type of analysis that needs to 
be performed (Do et al., 2012). 
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3.2.3 Select variants based on gene functions 
Some studies have shown data filtering is very useful when applied to searching for 
specific gene functions, noticeably increasing power. Most of the annotation tools 
commonly used such as ANNOVAR (Wang et al., 2010), PolyPhen2 (Adzhubei et al., 
2013), SIFT (Kumar et al., 2009) also provide annotation on putative gene functions. 
Other databases such as KEGG (Kanehisa and Goto, 2000) and WikiPathways 
(Kutmon et al., 2016) provide functional annotations about metabolic pathways and 
enzymes. Including functional filtering in the exome sequencing analysis can greatly 
reduce the number of candidate variants (Friedrichs et al., 2016). 
3.2.4 Select variants based on mode of inheritance 
Mode of inheritance can be thought as filtering strategy for some diseases. For 
recessive models only homozygous (for consanguineous families) or compound 
heterozygous (for non-consanguineous families) variants should be considered (Fig. 
3.1; Ku et al., 2011). The combination of more of the filtering strategies is usually 
applied and improves the detection rate. 
3.2.5 Segregation analysis within families 
In order to confirm the pathogenicity of a mutation identified by exome sequencing, it 
is important to analyse ancestors and/or progeny - preferably with a similar disease 
phenotype - to confirm the segregation within the family and to investigate the 
inheritance pattern of the disease. Study of the family tree can give much information 
about the pathology and the type of inheritance (Fig. 3.1; Becker et al., 2011). If no 
family member with the same symptoms is present, analysis of the parents (so called 
trio analysis) can be helpful to highlight genes which are heterozygous in non-
affected subjects (if it is an autosomal recessive disease model) and therefore 
narrow down the number of total candidate genes (Zhu et al., 2015). 
3.2.6 Ethnic and population differences 
Special attention needs to be paid when analysing exome sequencing from small 
ethnic groups which are not frequently studied, even more if it is about 
consanguineous families (Foo et al., 2012) as some variants may be more frequent 
in some populations but absent in others. Alternatively, if a control database from an 
ethnically matched group is not available, it would be good to sequence at least a 
sufficient number of non-affected individuals from the same population.  
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3.2.7 RNA-sequencing 
RNA-seq technology aims to provide a complete profile of the whole transcript of a 
cell or tissue. Transcriptomic analysis is very important in some cases, in order to 
understand what pathogenic or compensatory mechanisms have been triggered 
within the cell at a specific developmental stage. The trigger may be a mutation 
(Bova et al., 2016) or an exogenous factor such as a drug or an infection (Benson et 
al., 2016) (Rolfe et al., 2016). RNA-seq allows to identify differences in expression of 
mRNA as well as non-coding RNAs. Differences in RNA splicing can also be 
recognised (Griffith et al., 2015). 
Something which is very important to consider when doing RNA-seq analysis is 
tissue specificity of gene expression, which becomes particularly relevant when it 
comes to tissue specific diseases, especially because obtaining biopsies from 
specifically affected tissues may be impossible. Brain and nerves can only be 
collected post-mortem and, unlike animal tissues which can be collected and 
conserved in a controlled environment, post-mortem tissues can only be collected 
naturally, which often causes degradation of RNA (Sidova et al., 2015). High RNA 
A 
Figure 3.1 Studying large consanguineous families genotype/phenotype correlation it is 
possible to easily identify recessive inheritance of a given mutation. Here the example of 
EXOSC8 mutation (A). For non-consanguineous families, trio analysis can help to identify either 
homozygous (B) or compound heterozygous mutations as for EXOSC2 mutation (C). Images 
modified from Boczonadi et al., 2014 and Di Donato et al., 2016. 
B C 
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quality is fundamental for RNA-seq analysis.  
Therefore in some cases transcriptomic analysis has to rely on primary fibroblasts, 
which are easily accessible, although gene expression may be undoubtedly different 
than in neurons. Gene expression analysis in fibroblast can be still useful to give 
indications of a potential molecular pathomechanism.  
3.3 Results 
3.3.1 PCH patients cohort – Identification of known mutations 
In an attempt to discover new patients with exosomal deficiencies, Sanger 
sequencing was performed on 17 patients of Roma ethnic origin with pontocerebellar 
hypoplasia type 1, looking for two founder mutations on EXOSC8 and EXOSC3 
which were previously reported to be disease causing (Wan et al., 2012) (Boczonadi 
et al., 2014). 
A known homozygous c.92G>C; p.31G>A mutation on EXOSC3 was identified in 
three patients (308/3, 792/3 and T.M.) with a predominant PCH1 phenotype. 
All the other subjects were negative for mutations in EXOSC8 and EXOSC3. 
Whole Exome Sequencing (WES) was then performed on some of the remaining 
samples in order to identify the causes of the pathology. 
Bioinformatic analysis and filtering was performed by Dr. Helen Griffin and Dr. Angela 
Pyle (Newcastle University), respectively. Another known c.919G>T; p.307A>S 
mutation in TSEN54 was identified in another patient (K.E.), which is a common 
cause for pontocerebellar hypoplasia type 1, 2, 4 and 5 (Simonati et al., 2011) 
(Namavar et al., 2011c). The variant was found to be heterozygous in both parents. 
In other 2 patients, non-reported mutations on another gene (LAMP2) have been 
identified (c.1114_1116del and 1171G>A; p.391V>I).  
LAMP2 (Lysosomal Associated Membrane Protein 2) is situated on Chr:X, the 
mutation is X-linked recessive in both male patients. The mother of one of the 
patients is a heterozygous healthy carrier. Reported mutations on LAMP2 so far have 
been linked to Danon disease (Di Mauro et al., 2007) with symptoms of 
cardiomyopathy, myopathy, mental retardation and cardiac failure. 
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Very recently our collaborators contacted our group upon identification of a patient 
who presented with cerebellar hypoplasia and spinal motor neuropathywith a 
homozygous mutation in another gene related to exosome complex functions. The 
mutation is heterozygous in both consanguineous parents of Hispanic origin and 
never been reported in human. We will perform further analysis of this mutation upon 
receipt of primary fibroblasts.  
 
 
 
 
 
 
Patient code Mutation Clinical 
presentation 
WES 
308/3 EXOSC3        
c.92G>C; 
p.31G>A 
PCH1 NO  
792/3 EXOSC3        
c.92G>C; 
p.31G>A 
PCH1 NO 
T.M. EXOSC3         
c.92G>C; 
p.31G>A 
PCH1 YES 
K.E. TSEN54       
c.919G>T; 
p.307A>S 
PCH1 YES 
K.R. LAMP2 
c.1114_1116del 
PCH1 YES 
EB/806 LAMP2 1171G>A; 
p.391V>I 
PCH1 YES 
P.1 RBM7                
c.236C > G; 
p.P79R 
SMA-like YES 
P.2 New Gene PCH1 YES 
Table 6. Patients cohort with PCH symptoms and mutations identified. 
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3.3.2 Identification of a novel pathogenic mutation in RBM7  
In an attempt to identify new mutations related to exosomal proteins deficiencies, a 
patient with a SMA-like phenotype was brought to our attention by Prof. O. Elpeleg 
and Dr. S. Edvardson (Hebrew University Medical Center, Jerusalem, Israel). 
The patient was the youngest child of seven siblings of consanguineous parents of 
Palestinian background. Family history was negative for similar symptoms. Muscle 
weakness, both proximal and distal was apparent and required mechanical 
ventilation. During the last episode of respiratory decompensation the patient died at 
age 28 months (Giunta et al., 2016). Pregnancy, delivery and perinatal course were 
uneventfulexcept for breech presentation which necessitated caesarean section. 
Initial concerns were raised around one month of age as hypotonia with poor sucking 
and failure to thrive were observed. No developmental regression or cognitive 
difficulties were noted but gross motor abilities plateaued around 1 year of age when 
unsupported brief sitting was achieved (Giunta et al., 2016). At this time, muscle 
biopsy showed fibre type grouping of small and hypertrophic fibres, compatible with 
SMA (Fig. X). Paraffin embedded sections displayed sheets of foamy macrophages 
(CD68-immunopositive), and only few myofibers, consistent with macrophagic 
myofasciitis. Electromyography/nerve conduction velocity (NCV) was also compatible 
with SMA. SMN1 analysis showed two normal copies. No other significant alterations 
were evident on H&E, GTC, ATPase9.4, ATPase4.3, NADH, SDH/COX, PAS, PAS+ 
D and ORO stains (Giunta et al., 2016). 
Exome sequencing analysis identified homozygous variants that segregate in the 
family in 2 different genes: SNX15 and RBM7. Mutation in SNX15 was discarded 
based on published gene functions. SNX15 published data show its involvement in 
protein trafficking and amyloid beta generation (Feng et al., 2015) (Phillips et al., 
2001). Furthermore, western blot analysis showed a 63% reduction in RBM7 protein 
levels but no reduction of SNX15 (Fig. 3.2).  
RBM7 is a sub-unit of NEXT, a co-factor of the exosome complex (Norbury, 2011) 
which is known to be responsible for binding and carry toward the exosome complex 
non-coding RNAs such as the PROMoter uPstream Transcripts (PROMPTs; Preker 
et al., 2011) and in splicing regulation (Guo et al., 2003).  
The c.236C > G; p.Pro79Arg (Fig. 3.2) mutation is located within the highly 
conserved  RNA Recognition Motif (RRM) Domain (Hrossova et al., 2015) and is 
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predicted to be pathogenic, affecting the structure of the binding domain as well as 
the splice site (according to MutationTaster), decreasing the stability of the protein 
structure (MuPro -http://www.ics.uci.edu/~baldig/mutation.html; Confidence Score: -
0.068480655 and Confidence Score: -0.644794635393117). In silico analysis with 
PROVEAN (http://provean.jcvi.org/index.php) also predicted the mutation to be 
deleterious with a score of -4.49. Align-GVGD (http://agvgd.iarc.fr/agvgd_input.php) 
scored it Class C65 (most likely to interfere with protein functions). All these in silico 
prediction are overall in accord with the western blot analysis (Fig. 3.2) which show 
reduced protein levels in RBM7 mutant cells Given the predominantly neuromuscular 
phenotype and (partially) overlapping symptoms caused by mutations in different 
sub-units or co-factors of the exosome complex, an investigation was carried out in 
order to understand if any common molecular feature that links the pathologies may 
occur. RNA sequencing analysis on EXOSC8 and RBM7 mutant primary fibroblasts 
was then performed and compared to control primary fibroblasts data.   
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(Kelley et al., 2015) (LETTER TYPE) 
Figure 3.2 Muscle biopsies, electropherogram showing the mutation P79G, 
protein structure and WB analysis. Below comparison of the highly conserved 
RBM7 RNA recognition motif. Frozen sections stained with immunohistochemical 
stains for slow- (A) and fast-myosin (B) display striated muscle tissue with large 
group atrophy, includingatrophic myofibers of both types, alongside groups of 
hypertrophic myofibers, most of them type 1.Images showing position of the mutation 
in the highly conserved RNA recognition motif in RBM7 (C, D). 3D image was created 
using Phyre2  (Kelley et al., 2015) according to the structure presented by Hrossova 
et al., 2015; Western blot analysis shows reduced protein levels of RBM7 as well as 
EXOSC8 in RBM7 mutant fibroblasts, compared to controls (E). In yeast, EXOSC3 
mutations cause the impossibility of the protein to assemble to the exosome complex 
and the mutated EXOSC3 is eventually degraded by the proteasome (Fasken et al., 
2017). It may be a similar degradation mechanism happens for RBM7; Comparison of 
the RRM in different species. The mutated P79 is highlighted in red (from Hrossova 
et al., 2015; F). 
C 
D 
C 
E 
F 
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3.3.3 Agilent analysis of RNA sample quality 
In order to proceed with RNA-seq analysis it is essential to have high quality RNA.  
RNA is easily degraded either before extraction from cells or tissues by endogenous 
RNAse or after, by chemical and physical reactions such as ion interaction with the 
single strand (Forconi and Herschlag, 2009). Tissues and cells need to be stored 
properly (ideally snap-frozen in liquid nitrogen and conserved at -80 °C). RNA can 
also be conserved for long times at -80 °C. Numerous freeze-thawing cycles are 
known to have a negative effect on RNA quality and integrity. 
RNA quality can be assessed with an Agilent Bioanalyzer 2100 which is able to 
provide an RNA Integrity Number (RIN; Schroeder et al., 2006). RIN goes from 1 to 
10 and is inversely related to degradation of the sample (higher the number, lower 
the degradation of the sample). 
The machine is based on a microcapillary electrophoretic principle and is able to 
provide an electropherogram which shows the abundance and size of RNA based on 
peaks area and retention time (Fig. 3.3). A good quality RNA should show clearly two 
peaks which correspond to 18S and 28S rRNA, which in normal conditions are 
largely the most abundant. Noise or background in the electropherogram indicates 
degraded RNA. A reduction in the intensity of the 18S and 28S signal and increase in 
the signal toward the left indicates presence of short-fragmented RNA (Fig. 3.3). The 
electropherogram can be recapitulated by the representation of an agarose gel 
analysis on the right hand side of the screen. 
3.3.4 Results of RNA quality control 
Primary fibroblasts from patients and controls were cultured as described in Materials 
& Methods. The cell pellet was collected and frozen in dry ice straight away. Samples 
were then kept at -80 °C. 
A big RIN variation could be noticed when re-analysing the same samples. This was 
probably due to genomic DNA contamination. We were able to obtain a repeatable 
high RIN treating the RNA sample with DNAse before the analysis (as described in 
materials & methods), therefore reducing gDNA contamination.  
Only samples with a RIN >8 were sent for RNA-seq analysis. Three biological 
replicates for each cell line were analysed. 
(Fasken et al., 2017) 
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 3.3.5 RNA-seq analysis results 
Total RNA-seq analysis was performed by AROS Applied Biotechnology A/S 
(Denmark) using the Illumina HiSeq 2500 platform. RNA-seq analysis of RBM7 and 
EXOSC8 cells versus control primary fibroblasts showed several transcripts 
differentially expressed including coding and non-coding RNAs (Table 4). 
Bioinformatic analysis was performed by Dr. Yaobo Xu, Newcastle University.  
Considering an adjusted p-value ≤ 0.05 and Log2-fold change of ±1, RBM7 mutant 
cells showed 312 differentially expressed transcripts compared to controls and 
EXOSC8 mutants showed 193 differentially expressed transcripts, 62 of them being 
shared between the 2 primary fibroblast lines compared to controls (Fig. 3.4). Three 
biological replicates were analysed for each cell line.  
Notably, the two sets of transcripts show a high correlation following the same 
pattern of differential expression (as shown in Fig. 3.4) indicating a shared molecular 
mechanism that drives up or down regulation of a given gene. 13 of the common 
differentially expressed transcripts are involved in neurological functions: CACNA1G, 
HOXC8, PITX1, HOXC11, GNAZ, PCDH10, NTNG1, SOX11, HOXC9, HOXC10, 
HOXC6, HOTAIR, OMD (Fig. 3.5).  
Only 8 of the 62 common differentially expressed genes are AU-rich. Notably, 50% of 
them belong to the group above - involved in neurological functions: OMD, HOXC6, 
NTNG1, SOX11, PDE4B, WNK3, TBX5, KLHL3 (Table 5). 
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Figure 3.3 Representative Agilent Bioanalyzer 2100 electropherograms. Good quality RNA 
shows a graph with 2 higher peaks which represent 18S and 28S rRNA (C). The X-axis show 
the retention time and it is directly proportional to the size of the fragments. The lower peak at 
the left of the graph should be as little as possible, as it represents shorter, digested RNA 
fragments. The small noisy or background peaks in between are also an indication of 
degraded RNA. On the right hand side of each graph there is a representation of an agarose 
gel with the same RNA. Representation of an electropherogram of partially degraded RNA (B). 
The noisy peaks are slightly bigger than in (C). When RNA is heavily degraded, the peaks are 
shifted to the left (A). 
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65 
 
18 of the 62 common differentially expressed transcripts are non-coding RNAs (Table 
4).  
RNA-seq data were confirmed through qRT-PCR (Fig 3.6). Expression levels of the 4 
genes analysed show a high level of correlation either for RBM7 mutant cells or for 
EXOSC8 mutant cells (respectively R2 = 0.98 and R2 = 0.99). 
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Figure 3.4 Summary of RNA-seq data. (A) Venn diagram showing number of 
differentially expressed transcripts for each mutant line. 14% of the total number is 
shared between the two. (B)  The 62 shared transcripts follow same pattern of up or 
downregulation. 
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Gene Gene name RBM7 Log2 
fold change 
EXOSC8 Log2 
fold change 
Gene type 
CACNA1G calcium channel, voltage-dependent, T 
type, alpha 1G subunit 
3.691032007 2.767291607 Protein coding 
HOXC8 homeobox c8, transcription factor 1.396425863 2.419657474 Protein coding 
DGAT2 Diacylglycerol O-Acyltransferase Homolog 
2 
4.410700623 2.622619732 Protein coding 
PEG10 paternally expressed 10, imprinted gene 2.07534546 1.798544111 Protein coding 
PITX1 paired-like homeodomain 1, transcription 
regulation 
4.551147928 4.762613373 Protein coding 
ZNF334 zinc finger protein 2.054463408 2.096171883 Protein coding 
SFRP1 secreted frizzled-related protein 1, Wnt 
pathway  
4.79885953 3.466095963 Protein coding 
TCF21 transcription factor 21 4.364849155 3.415167911 Protein coding 
HOXC6 homeobox c6, transcription factor 1.827229548 2.372816325 Protein coding 
WNK3 lysine deficient protein kinase 3 2.694941819 3.429503882 Protein coding 
HOXC11 homeobox c11, transcription factor 6.116841804 7.594757502 Protein coding 
PTGER2 prostaglandin E receptor 2.795316287 1.692521515 Protein coding 
PDE4B phosphodiesterase 4B, cAMP-specific 1.417020499 1.944871591 Protein coding 
GNAZ guanine nucleotide binding protein 1.58414185 2.050887623 Protein coding 
TCEAL7 transcription elongation factor A (SII)-like 
7  
1.865112273 2.035861836 Protein coding 
HOXC10 homeobox c10, transcription factor 6.105422717 6.79186005 Protein coding 
KCNMB4 potassium channel 3.774588508 3.18771346 Protein coding 
IGF2BP3 (insulin-like growth factor 2 mRNA binding 
protein 3 
3.445626323 2.902385839 Protein coding 
PCDH10 protocadherin 10 3.888768259 2.866653042 Protein coding 
MCTP2 (multiple C2 domains, transmembrane 2) 3.685804339 3.01777966 Protein coding 
SLC14A1 solute carrier 3.835288902 3.786043531 Protein coding 
KLHL3 kelch like family member 3 2.106158547 1.809268059 Protein coding 
UCHL1 ubiquitin carboxyl-terminal esterase L1 
(ubiquitin thiolesterase)  
1.762819833 2.022851498 Protein coding 
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HOXC9 homeobox c9, transcription factor 2.207722452 2.803054114 Protein coding 
NTNG1 netrin G1, axon guidance 2.735818992 3.235429173 Protein coding 
TMEM155 transmembrane protein 155 2.225865777 2.509314216 Protein coding 
RNF180 ring finger protein 180, ubiquitin protein 
ligase 
2.844350479 2.852119379 Protein coding 
ZMAT4 zinc finger matrin type 4 6.074879489 3.591657612 Protein coding 
ZNF804A zinc finger protein 4.62758129 3.37353952 Protein coding 
PLEKHG5 pleckstrin homology domain containing, 
family G 
1.858371049 2.03224899 Protein coding 
SOX11 SRY (sex determining region Y)-box 11, 
transcription factor 
4.234538566 4.107218641 Protein coding 
CLEC12A C-type lectin domain family 12, member A -5.709574946 -4.675362953 Protein coding 
IL20RB interleukin 20 receptor beta  -5.121742683 -2.427950261 Protein coding 
GRIA1 glutamate receptor -3.561025711 -5.068887638 Protein coding 
GSTM1 glutathion S transferase -3.911425405 -3.500338869 Protein coding 
TSPAN2 tetraspanin 2 -3.469786366 -3.8183497 Protein coding 
UBL4B ubiquitin-like protein 4b -6.557094147 -6.640033107 Protein coding 
CLEC2A c-type lectin domain family 2A -6.72183227 -3.21611715 Protein coding 
OMD osteomodulin  -2.66081377 -4.708887346 Protein coding 
PILRB paired immunoglobin-like type 2 
receptors 
-1.390971792 -1.894120381 Protein coding 
TNFSF18 tumor necrosis factor (ligand) superfamily, 
member 18 
-3.81028222 -4.723342904 Protein coding 
L1TD1 LINE-1 type transposase domain 
containing 1 
-3.617196089 -4.022066803 protein_coding 
TBX5 t-box 5, transcription factor -2.878300285 -5.488105064 Protein coding 
KIF26A kinesin family member 26A -3.34455908 -4.127845901 Protein coding 
AL162151.3  -2.21360557 -2.691774485 processed_pseud
ogene 
HTATSF1P2 HIV-1 Tat specific factor 1 pseudogene 2 -2.556743643 -3.466975903 processed_pseud
ogene 
RPL3P2 ribosomal protein L3 pseudogene -2.096968531 -2.684915229 processed_pseud
ogene 
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 RP5-
857K21.11 
unknown sequence, not overlapping with 
any gene 
-5.501265385 -4.521465668 unprocessed_pse
udogene 
VTRNA1-2 vault RNA 1-2 -2.370807682 -2.280895671 misc_RNA 
TARID Homo sapiens TCF21 antisense RNA 
inducing promoter demethylation (TARID), 
long non-coding RNA 
3.669128047 3.584094537 Antisense 
HOTAIR Hox transcript antisense RNA 5.264874941 7.642425264 Antisense 
FLG-AS1  3.495582748 1.516653405 Antisense 
TBX5-AS1  -3.423873961 -5.387431953 Antisense 
LINC01397 long intergenic non-protein coding RNA 
1397 
-5.722161492 -6.540036225 Antisense 
HOXC-AS2  3.48199326 4.271027646 processed_transc
ript 
HOXC-AS3  4.513606333 4.446897002 processed_transc
ript 
AC016757.3 unknown sequence 4.62825053 4.073858065 processed_transc
ript 
AF131215.2 unknown sequence in intron of XKR6 
gene, a bit overlapping with 5.9 
2.797832461 2.7346828 sense_intronic 
AF131215.9 unknown sequence in intron of XKR6 gene 2.887922063 2.363293297 sense_intronic 
FLJ12825  3.009818227 3.660348996 lincRNA 
RP1-15D23.2 unknown sequence, not overlapping with 
any gene 
-3.955064919 -4.750905355 lincRNA 
LINC00869  2.938100879 3.005697201 lincRNA 
Table 7. List of common differentially expressed transcripts in RBM7 and EXOSC8 mutant 
fibroblasts compared to control. 
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  Gene Symbol 
 
RBM7 Log2 Fold 
Change 
EXOSC8 Log2 Fold 
Change 
ARE 
 
Location 
 
TBX5 -2.8783 -5.48811 CTATTTATTTATA 1201-1213 
OMD -2.66081 -4.70889 ATATATTTAGAAT 88-100 
KLHL3 2.106159 1.809268 TAAAATTTATTAT 3741-3753 
NTNG1 2.735819 3.235429 GATTATTTATAAT 2253-2265 
SOX11 4.234539 4.107219 TTTTATTTAAAAA 4497-4509 
PDE4B 1.41702 1.944872 ATTAATTTATATA 1008-1020 
WNK3 2.694942 3.429504 TAATATTTACAAT 2498-2510 
HOXC6 1.82723 2.372816 TTATATTTATGTT 638-650 
Table 8. List of common differentially expressed ARE genes in RBM7 and EXOSC8 mutant 
fibroblasts compared to controls. 
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Figure 3.5 Heatmap showing the pattern of expression of the 62 shared 
transcripts. Red indicates higher counts, white average and blue low counts. 
Highlighted in Blue: genes listed on Pantherdb.org; in green listed on Reactome.org; 
red found function through PubMed. 
71 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
qRT-PCR RNA-seq
Lo
g2
 fo
ld
 c
ha
ng
e 
HOTAIR 
exosc8
rbm7
0
1
2
3
qRT-PCR RNA-seq
Lo
g2
 fo
ld
 c
ha
ng
e 
HOXC6 
exosc8
rbm7
0
1
2
3
4
5
qRT-PCR RNA-seq
Lo
g2
 fo
ld
 c
ha
ng
e 
HOXC8 
exosc8
rbm7
0
1
2
3
4
qRT-PCR RNA-seq
Lo
g2
 fo
ld
 c
ha
ng
e 
HOXC9 
exosc8
rbm7
Figure 3.6 RNA-seq data quality was confirmed by testing 4 transcripts via qRT-PCR 
(HOTAIR, HOXC6, HOXC8 and HOXC9). The two datasets show a high correlation.  
 
72 
 
3.3.6 Alternative splicing analysis  
Analysis of splicing isoforms in mutant cells was also performed. Pre-RNA splicing is 
known to be secondarily regulated by the exosome complex which, in turn, regulates 
the expression of splicing factors (Zhang et al., 2015). 
Analysis was performed on the same RNA-seq data set (by Dr. Yaobo Xu) and 
shown as “sashimi plots” (Katz et al., 2015). 
3.3.7 sashimi_plot 
sashimi_plot is a graphic form for visualization of alternative splicing events in a 
given set of RNA-seq data, based on the MISO (mixture-of-isoforms) model  (Katz et 
al., 2010).  
The MISO model provides a series of parameters to identify alternative splicing 
events and their reliability in our transcriptome data such as the count of alternatively 
spliced isoforms, the type of event (Skipped Exons, Mutually exclusive exons, 
Retained Introns, Alternative 3’ splice sites, Alternative 5’ splice sites), significance of 
the differences (shown as “Bayes Factor” – BF), PSI (or Ψ - Percentage Spliced In). 
The sashimi plot allows direct visualization of alternative events. Alignments in exons 
are represented as read densities, therefore exons result to be thicker and introns 
thinner. Splice junctions are drawn as arcs, connecting the two exons (Katz et al., 
2015). Thickness of the arcs is proportional to the number of reads corresponding to 
a given splicing event (Fig. 3.8). 
Several differential splicing events were identified. Some of them are also common 
between the two cell lines, meaning that they happen in the same locus and it is the 
same type of event (e.g. skipped exon), but in different proportions (Fig. 3.7). 
RNA-seq analysis identified the same differential splicing event in RBM7 and 
EXOSC8 mutant cells in TMEM119, COL6A3, RPL17/C18ORF32 and finally an 
unknown transcript not mapped on ensemble (Fig. 3.8). The other events are 
summarized in Fig. 3.7 
 
3.3.8 Biological function of the mis-spliced genes 
TMEM119/OBIF (Transmembrane Protein 119/ Osteoblast Induction Factor) has 4 
protein coding splicing variants (ENSG00000183160) of 28 aa, 44 aa, 140 aa, 283 aa. 
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OBIF is known to be expressed as a single transmembrane protein, strongly 
expressed in osteoblasts in mouse (Mizuhashi et al., 2012), knock-down of OBIF 
inhibits osteoblastic differentiation of pre-osteoblastic cells in vitro. OBIF-/- mice 
display reduced bone volume in the femur. Subsequently, the same group showed 
OBIF expression (the 283 aa isoform) is also important for bone mineralization and 
spermatogenesis suggesting that OBIF plays a role in differentiation of a number of 
tissues (Mizuhashi et al., 2015). TMEM119 was also shown to induce differentiation 
of myoblasts into osteoblasts and inhibit differentiation of myoblasts into myotubes 
(Tagliaferri et al., 2015). Furthermore, the same 283 aa isoform was found to be a 
stable marker of microglia in human and mouse (Satoh et al., 2016) (Bennett et al., 
2016). 
 
COL6A3 (Collagen Type VI Alpha 3) has 15 splicing variants, 10 of them being 
protein coding (ENSG00000163359). The longest isoform encodes for a 3,177 aa 
protein, the shortest for a 173 aa protein. Differentially spliced isoforms are present in 
pancreatic (Arafat et al., 2011) as well as colon, bladder and prostate cancer 
(Thorsen et al., 2008). COL6A3 in human has 44 exons, mutations in this gene have 
been linked to dystonia. High level of expression in mouse was seen in brainstem 
and midbrain. Suppression of splicing of exon 41in zebrafish resulted in errors of 
motor neuron pathfinding, branching, and extension, suppression of other exons 
resulted in phenotypes more closely resembling other diseases related to COL6A3 
such as Ullrich congenital muscular dystrophy or Bethlem myopathy(Balint and 
Bhatia, 2015). Interestingly, an overexpression of COL6A3 protein was observed in 
plasma, fibroblasts and iPS-derived motor neurons of SMA patients. In a review, 
Fuller and colleagues (Fuller et al., 2016) hypothesize that an overexpression of 
COL6A3 may be seen as an attempt of a protective response, as its overexpression 
protects neurons under cellular stress (Cheng et al., 2011). COL6A3 plays a role in 
neural crest development (Perris et al., 1993).    
The role of RPL17/C18ORF32 is unknown. 
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Figure 3.7 Venn diagram illustrating the differential splicing events identified in 
EXOSC8 and RBM7 mutant cells. RNAseq analysis identified 7 common genes in 
which some sort of differential splicing events occur in both cell lines. Only those which 
are exactly the same type of event and in exactly the same position are shown as 
sashimi_plots below. 
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Figure 3.8 Differential splicing events identified both in RBM7 and EXOSC8 mutant 
fibroblasts versus control. Red: controls; yellow: mutants. Splice event ID refers to the 
genomic coordinates of the splicing event of the upstream (5’) exon, the skipped exon, and the 
downstream (3’) exon of this alternative splicing event, separated by @ symbols; Ψ denotes 
the fraction of mRNAs that represent the inclusion isoform. Overall splicing isoforms analysis 
indicates splicing defects in EXOSC8 and RBM7 cells. These data need to be confirmed by 
RT-PCR. 
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Figure 3.9 Details of the splicing events listed in the sashimi plots above. Sample1: control; 
sample2: mutant. Event type: SE skipped exon; MXE mutually exclusive exons; A3SS alternative 
3’ splice site. Event name same as event ID above. Sample count indicates the raw counts for 
each isoform. In parentheses, 1 and 0 indicate if the reads are consistent (1) or inconsistent (0) 
with the isoform. For example the first line entry is   (0,0):131,(0,1):116,(1,0):388,(1,1):3406 where 
the numbers in brackets correspond to the first (inclusion of the exon) and second splicing event 
(exclusion of the exon). So 131 reads do not support both isoforms, 116 reads do not support the 
inclusion of the exon (first event, 0), but support the exclusion of it (second event, 1), 338 reads 
support the inclusion but not the exclusion, and 3406 reads support both isoforms. The read (0:0) 
are thrown out. Assigned counts: Inferred assignment of reads to isoforms; for example an entry 
like 0:2362, 1:1548 menas 2362 reads were assigned to the first isoform (0) and 1548 to the 
second isoform (1).   
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3.3.9 RT-PCR analysis of human fibroblasts WARS show differential splicing 
events in RBM7 and EXOSC8 cells compared to controls. 
In order to confirm the data obtained through MISO and sashimi_plot I decided to 
perform RT-PCR to check if  actual differential splicing events are taking place upon 
EXOSC8 and RBM7 impaired functions as the exosome complex is thought to 
secondarily affect splicing functions, being primarily involved in splicing factors’ RNA 
processing (Zhang et al., 2015) and RBM7 has been very recently confirmed as 
directly involved in splicing (Guo et al., 2003) (Falk et al., 2016).  
I decided to focus initially on WARS given the known roles of tRNA synthetase 
dysfunction in  neurological disorders although WARS (Tryptophanyl-TRNA 
Synthetase) is not known to be linked to any disease. 
WARS (ENSG00000140105) has 44 splice variants. Covering the whole length of the 
gene required designing of 8 pairs of primers. Results show that differential splicing 
events take place in either EXOSC8 and RBM7 fibroblasts compared to controls (Fig.  
X).   
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Figure 3.10. Results of differential splicing analysis in WARS transcripts. Top figure: 
schematic representation of the primers designed to cover the full length of WARS. Central 
image show differential splicing events identified using fprward primer on exon1 and reverse 
primer on exon3 (1F3R), forward primer on exon8 and reverse primer on exon 11 (8F11R) 
and forward primer on exon11 and reverse primer on exon 13 (11F13R). Arrows show 
[resence of a band which is missing in the control and ellipse show a missing band which is 
present in the control. Bottom image: MFN2 was used a sa control gene to show good quality 
of RNA and cDNA. 
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3.4 Discussion and future directions 
Mutations in exosome related proteins constitute a novel sub-group of severe 
neurological disorders with childhood onset. 
The mutations identified so far provide a very complex spectrum of symptoms (Fig. 
3.10), some of them are unique for a specific gene, others are common features of 
different mutations.  
Exosomal dysfunctions seem to cause a prevalent neurological spectrum of 
symptoms with little involvement of other systems, being the cerebellum and motor 
neurons the most affected tissues, therefore typical features of PCH1. Other features 
may be present too such as hypomyelination (PCH2, PCH4 and PCH5, PCH9 
features), developmental delay (PCH7), or cortical involvement (PCH4, PCH10). One 
Figure 3.11 Graphical representation of the complex pattern of overlapping 
symptoms caused by mutations in EXOSC3, EXOSC8, EXOSC2 and RBM7. 
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patient with EXOSC8 mutation was reported to have cytochrome c negative muscle 
fibres and moderately decreased respiratory chain complexes I and IV activities. 
Mitochondrial disease is a feature of PCH6. The patient with RBM7 mutation did not 
show any cerebellar impairment but clear motor neuron disease and hypotonia. For a 
more comprehensive list of PCH symptoms see Eggens, 2016.  
Considering the fact that the exosome complex is present virtually in all cells of the 
body, the reasons underlying the neural specificity are unclear. In order to clarify this 
and other aspects of this novel subtype of neurological disorders, we extensively 
looked for new pathogenic mutations and identified a new variant in RBM7, a sub-
unit of the NEXT complex which is a co-factor of the exosome complex. The 
identification of a new mutation in RBM7 led us to develop new sets of experiments 
to study the functions of the exosome complex. Based on preliminary data on our 
EXOSC8 deficient cells and zebrafish, we decided to further investigate the roles of 
these genes comparing zebrafish and primary fibroblasts data, which eventually led 
to publication of this work (Giunta et al., 2016). 
We also identified new patients with variants in EXOSC3 and TSEN54 and another 
never reported gene, extending the knowledge of diseases caused by defective RNA 
metabolism.  
RNA sequencing was performed to investigate which coding and non-coding RNAs 
are differentially expressed in EXOSC8 and RBM7 mutant primary fibroblast. Given 
the known role of the exosome complex in degrading/processing RNAs, it may be 
that an overexpression (or better, defective degradation) of some specific RNAs may 
be the underlying cause of the diseases. Indeed we identified 62 transcripts (14% of 
the total) commonly differentially expressed between the two cell lines. Of these 62, 
13 transcripts (19%) are involved in neurodevelopment or neurological functions. It is 
also interesting to notice that all these 62 differentially expressed genes follow the 
same pattern of expression, showing a high level of correlation. A relatively high 
number of differentially expressed HOX genes  was detected in fibroblasts, and given 
their known role in development of peripheral nervous system (Lacombe et al., 2013) 
(Wu et al., 2007) (Vermot, 2005) and in human neurological disorders (Quinonez and 
Innis, 2014), we hypothesize this may be one of the causes of the neurological 
defects observed in patients (Giunta et al., 2016). Expression of these genes in 
knock-down zebrafish models was then investigated, as explained in the next chapter. 
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Overexpression of HOXC genes well matches with overexpression of HOTAIR which 
is known to co-transcribe within the HOXC locus (Clark and Blackshaw, 2014) and 
silences expression of HOXD genes (Clark and Blackshaw, 2014). In support of this, 
HOXD genes were significantly downregulated in our EXOSC8 mutant cells. The 
increase in HOTAIR was associated with a reduction of HOXD10, HOXD11 and 
HOXD13 of respectively -6.67, -5.37 and -4.10 Log2 fold change in expression.  
Several other genes which resulted to be differentially expressed (CACNA1G, PITX1, 
GNAZ, PCDH10, NTNG1, SOX11, OMD) are important for the correct function of 
human neurons. 
In vertebrates, PITX1 induces the expression of HOXC11 (Park et al., 2014), which is 
itself expressed in the posterior neural tube and dorsal root ganglia in mouse during 
development (Hostikka and Capecchi, 1998). Both resulted to be upregulated in our 
data. Interestingly, SOX11 is expressed in the granule layer in the cerebellum (Rex et 
al., 1998), which is in turn essential for cerebellar layer  differentiation (Kani et al., 
2010), which may be important in the clinical presentation of these defects. 
ARE genes analysis identified 8 AU-rich elements differentially expressed. 
Adenylate-Uridylate rich elements (ARE) are found within the 3’ UTR of many 
transcripts and act as signals for rapid mRNA degradation (Barreau, 2005). The AU-
rich RNAs identified here, however, are not the same as the ones we identified 
previously in myoblasts and oligodendroglia cells (Boczonadi et al., 2014), probably 
because of differences in tissue-specific gene expression. The exosome is known to 
degrade AU-rich elements (Mukherjee et al., 2002) but in our data we show that 
TBX5 and OMD are rather downregulated in exosome complex defective cells, while 
the other 6 ARE genes are upregulated as expected. This downregulation could be 
caused by inhibition of expression from some other over-represented transcripts, 
something similar to what HOTAIR transcript exerts on HOXD transcripts, inhibiting 
their expression as discussed above. 
Non-coding RNAs represent an important fraction of the total of transcripts identified 
by our RNA-seq analysis (18 out of 62). Not much is known about the roles of non-
coding RNAs. PubMed search could identify functional studies for only three of non-
coding RNAs present in our data (a part from HOTAIR which is well studied): Tbx5-
as1 (Eckalbar et al., 2016), TARID (Arab et al., 2014) and VTRNA1-3 (Helbo et al., 
2015). Tbx5-as1 function is unknown, it maps close to TBX5 gene. TARID is involved 
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in gene expression regulation, directing demethylation and VTRNA1-3 is associated 
with Myelodysplastic Syndrome, a hematopoietic disorder. 
Non-coding RNAs are known to be related to gene expression regulation (Clark and 
Blackshaw, 2014), embryo development (Ulitsky et al., 2011), neuronal functions 
(Cao et al., 2006) (Qureshi and Mehler, 2013) as well as myelination (Lin et al., 2014). 
HOTAIR functions are well established and it is indeed known to be involved in 
transcriptional regulation of gene expression (Rinn et al., 2007) and post-translational 
regulation (Yoon et al., 2013) of protein functions. HOTAIR is present in all mammals, 
although with poorly conserved sequence as it seems to have evolved very fast 
compared to its flanking genes HOXC11 and HOXC12 (He et al., 2011). It has a 
direct impact on nervous system development, being able to inhibit expression of 
HOXD genes as mentioned before (which are in turn involved in motor neuron 
development (de la Cruz et al., 1999) (Misra et al., 2009). HOTAIR also binds to  
ATXN1 protein (Yoon et al., 2013). Mutations in ATXN1 cause Spinocerebellar ataxia 
1 (OMIM 601556) as it is important for correct cerebellar development (Ebner et al., 
2013).  
Our analysis of alternative splicing confirms involvement of the exosome complex in 
splicing regulation, as previously shown by others (Zhang et al., 2015). RBM7 is also 
known to be involved in splicing (Guo et al., 2003) (Falk et al., 2016), therefore it is of 
particular interest to see some commonly mispliced transcripts in both EXOSC8 and 
RBM7 mutant cells. Some other genes are uniquely differentially spliced in one cell 
line or the other (not shown here) which, similarly to what observed for the differential 
expression analysis, may indicate a partially overlapping mechanism of disease. 
 On this matter it is worth to say that a complex pattern of differential splicing events 
was identified by RNA-seq analysis in WARS (tryptophanyl-tRNA synthetase) in both 
RBM7 and EXOSC8 mutant fibroblasts (not shown in this chapter because they are 
not exactly the same event), but it is of particular interest given the known role of 
aminoacyl-tRNA synthethases mutations in neurological disorders (described in the 
introduction chapter). A reduction in WARS expression (-1.61 Log2fold change) was 
also found only in EXOSC8 mutant fibroblasts. 
RT-PCR analysis seems to confirm differential splicing events in WARS in mutant cell 
lines. The experiments need to be repeated on more control lines and the bands will 
be sequenced to clearly understand which bits of the gene are mispliced.  
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WARS dysfunction may contribute to neurological symptoms triggering toxicity of 
tryptamine, a neurotoxic  decarboxilated tryptophan analog which activates aryl-
hydrocarbon receptors in the brain, causing axonal defects (Paley et al., 2013). 
Tryptamine toxicity is triggered by tryptophanyl tRNA synthetase inhibition or 
downregulation which causes in turn synthesis of aberrant tryptophanyl-tRNA and 
synthesis of abnormal proteins (Paley et al., 2013). 
In conclusion, through RNAseq analysis we could identify several potentially 
interesting patterns which may lead to neurodevelopmental defects: many genes 
which are listed on pathway analysis softwares (Reactome and Panther) as involved 
in neuronal functions (CACNA1G, HOXC8, PITX1, HOXC11, GNAZ, PCDH10, 
NTNG1, SOX11, HOXC9, HOXC10, HOXC6, HOTAIR, OMD) are differentially 
expressed; HOTAIR - a non-coding RNA - is known to be involved in 
neurodevelopmental regulation at transcriptional and post-transcriptional levels; 
splicing defects in several transcripts have also been identified, some of them in 
genes which may cause neurological impairments such as WARS.  
It is difficult at present to speculate which ones of these defects may be relevant for 
the pathology or what are the causes of the neuronal specificity of the disease. 
Considering that we analysed transcriptome in fibroblasts and gene expression in 
this cell type is of course very different from neuronal gene expression, in order to 
clarify which of these transcript are relevant for the pathology,  
Two hypothesis may be worth to mention about the tissue specificity of this 
conditions despite the systemic presence of the mutated proteins: Neurons are most 
affected because of their higher protein synthesis requirements compared to some 
other tissues and/or compensatory mechanism are present in other tissues but not in 
neurons. Anyway, these hypothesis would not explain why only a specific subset of 
neurons is affected (e.g. specifically the cerebellum but not the sensory neurons). 
The following  studies are in preparation to complete this project: 
Our group have recently received from collaborators EXOSC3 and XXXX primary 
fibroblasts mutant lines. Direct conversion of EXOSC3, EXOSC8, XXXX and RBM7 
mutant primary fibroblasts into neural cells will be performed (Meyer et al., 2014). 
Repeating RNA-seq on these cells will help to narrow down the number of non-
specific transcripts and therefore reduce the candidates potentially related to the 
neural pathology. Comparing these human RNA-seq data to RNA-seq from mutant 
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zebrafish’ neurons (described in chapter 5), will help to identify conserved 
mechanisms underlying neurodevelopmental defects caused by the mutations. 
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4 Chapter 4: Results - Zebrafish models of exosomal protein 
deficiency through gene knock-down. 
 
4.1 Gene knock-down in zebrafish 
Zebrafish has been extensively used for investigating the pathomechanism of 
neurodevelopmental and neurodegenerative diseases (Xi et al., 2011) (Sumbre and 
de Polavieja, 2014). By using zebrafish as a model system to study deficiencies of 
RNA metabolism we aim to gain a better understanding of the molecular 
mechanisms underpinning neurodevelopmental defects in exosomal-related diseases.  
To date and for the last 15 years, functional studies in zebrafish have been largely 
performed by gene-knock down in order to transiently down-regulate expression of a 
gene through morpholino technology (Blum et al., 2015; Nasevicius and Ekker, 2000). 
It is a relatively quick and easy way to specifically down-regulate gene expression in 
zebrafish. 
Morpholinos phosphorodiamidate antisense oligonucleotides (MO) are synthetic DNA  
analogue molecules initially developed to overcome the expensive costs associated 
with DNA analogues back in 1989 (1989). MO are very stable within the cell as they 
are resistant to nucleases (Karkare and Bhatnagar, 2006; Hudziak et al., 1996). 
Morpholinos can be designed to bind on the AUG translation start site of the mRNA 
and then act through a translation-blocking mechanism (Kok et al., 2015) or can be 
designed to target a splicing site on the pre-mRNA which can be either an intron-
exon or an exon-intron boundary, therefore causing a splicing defect (Morcos, 2007). 
These two different strategies lead to very different outcomes. For instance, targeting 
the AUG will also impair expression of maternal mRNA, while targeting a splice site 
will only affect zygotic mRNA (Bill et al., 2009). MOs have a narrow timeframe of 
availability and efficacy. It is usually injected in the yolk and this can only be done up 
to 8 cells stage (Bill et al., 2009). Later than that, uptake of morpholino from the yolk 
to the cells will stop or reduce. MOs are considered to work efficiently up to 5 dpf.  
To overcome the fact that MOs need to be injected very early, therefore causing an 
early knock-down of gene isoforms that might not be related to the functions we are 
investigating (Eisen and Smith, 2008), some more advanced MOs have been 
developed. These types of photo-activated molecules can be turned on and off in a 
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spatially and timely restricted manner at need using a specific wavelength (Tallafuss 
et al., 2012).  
4.1.1 Controversies about the use of morpholinos 
MOs, as well as other gene knock-down technologies (Robu et al., 2007) (Jackson et 
al., 2003) (Fedorov, 2006) in zebrafish are known to cause off target effects such as 
activation of p53 - an apoptotic gene - and induce a non-specific p53 dependent cell 
death pathway (Robu et al., 2007). Therefore, co-injection of p53 morpholino 
together with a morpholino for our target sequence, should always be performed to 
reduce unspecific apoptotic effects (Robu et al., 2007). This is, however, a 
controversial topic itself, as some experts in the field do not agree 
MOs have been used for more than 15 years to target genes in zebrafish and other 
animal models (Blum et al., 2015). Recently, the development of a new genome 
editing technique (CRISPR/Cas9) has allowed the easy targeting of genes and 
production of mutants, reviving the discussion about the off-target effects of knock-
down technologies (Kok et al., 2015) (Law and Sargent, 2014) (Schulte-Merker and 
Stainier, 2014). Some authors argued that mutant fish phenotype for a specific gene 
do not recapitulate what observed in morphant fish for the same gene (Kok et al., 
2015). Kok et al., showed that in a screening of more than 20 genes, approximately 
80% of the morphant phenotypes did not match the mutant phenotype indicating that 
off-target effects of morpholino might be much more prevalent than previously 
thought. One possible explanation for these discrepancies could be a genetic 
compensation effect induced by mutations but not by knock-down (Rossi et al., 2015). 
To investigate specificity of MO, Rossi and colleagues first created a mutant line for 
egfl7, which do not show any phenotype. They tested egfl7-MO specificity by 
injecting it in egfl7-null mutants, expecting that, if no off-target effects were caused by 
the morpholino, the morpholino itself should not have any effect on the mutant fish. 
They subsequently genotyped the fish showing a vascular defect and found that 53% 
of them were WT, 37 % were heterozygous and only 9% were homozygous mutant, 
showing that mutant fish were much less sensitive to morpholino implying a 
specificity of the morphant phenotype. They did notice a different phenotype between 
mutant and morphant fish though. To further investigate the reason of these 
differences they performed mass spectrometry and RNA profiling and identified some 
proteins which are upregulated in mutants but not in morphants (namely emilin3a, 
emilin3b and emilin2a) which were able to rescue morphants’ phenotype.  
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Gene knock-down technologies can be very useful to study disease 
pathomechanisms and the function of genes, therefore morpholinos can be the first 
step before moving forward to mutagenesis. The results of MO studies have to be put 
in the right context, considering different aspects and not overestimating them. In this 
chapter we present interesting data we obtained by gene downregulation, where we 
showed for the first time the role played by the exosome complex and its co-factors in 
central and peripheral nervous system development in vertebrates. Nevertheless, 
further studies on mutant zebrafish will be conducted. 
4.2 Results 
4.2.1 Modelling exosomal protein deficiencies in zebrafish 
We decided to investigate the role of the exosome complex-related genes in which 
mutations are known to cause severe neurological disorders such as EXOSC8, 
EXOSC3 and RBM7. EXOSC3 and EXOSC8  protein deficiencies have already been 
modelled in zebrafish by our group (Boczonadi et al., 2014) and others (Wan et al., 
2012) so we used the same translation blocking morpholinos to target exosc8 
(NM_001002865) and exosc3 (NM_001029961) genes in zebrafish. Zebrafish 
exosc3 (NP_001025132) has 247 amino acids while human EXOSC3 has 275 AA 
(NP_057126) and share 55.4% identity and 70.7% similarity. 
Zebrafish exosc8 (NP_001002865) has 277 amino acids while human EXOSC8 
(NP_852480) has 276 AA and share 70% identity and 84 .5% similarity. 
Although the overall homology between the human and zebrafish RBM7 protein is 
relatively low (43% identical and 59% similar protein sequences) and also the 
mutated amino acid is not conserved between the two species (it is substituted with a 
glutamine in zebrafish), if only the highly conserved region of the RRM (the first 94 
amino acids in human, the first 93 in zebrafish) is considered, the degree of 
homology is much higher (14) (69.5% identity and 84% similarity.  RBM7 deficiency  
(described in the previous chapter) have never been modelled in zebrafish before, so 
we designed 2 different new splicing morpholinos against rbm7 - both causing 
skipping of exon 2 - and studied the phenotype of MO downregulated zebrafish (Fig. 
4.1; 4.2). We identified only one rbm7 gene in zebrafish which is on chr:18 
(NM_199925), encoding a 252 amino acids protein. We obtained very similar 
phenotypes targeting 2 different parts of the transcript. MO1 was designed to target 
intron1-exon2 boundary and MO2 was designed to target exon2-intron2 boundary. 
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Efficiency of splicing morpholinos has been confirmed by RT-PCR (Fig. 4.3). Toxicity 
of rbm7-MOs was tested by performing injection of 3 different doses: 10 ng, 5 ng and 
2.2 ng. Analysis of mortality rates between different morphant groups and controls 
indicated that 2.2. ng was the optimal dose for rbm7-MO1 injections, based on the 
evidence of the very high mortality rate of the other 2 doses. rbm7-MO1 is very toxic, 
indeed, already 2.2 ng give a high mortality rate (Fig. 4.4), but it provides a good 
spectrum of different phenotypes, which is essential in order to investigate the 
severity of the defects observed upon gene knock-down.  
The same strategy for choosing the optimal dose was adopted for rbm7-MO2. In this 
case 1.1. ng was chosen as optimal dose. Upon injection of 2.2 ng of rbm7-MO1, 10 
ng of exosc8-MO and 1.5 ng of exosc3 we could observe defects in development and 
movements. exosc8 and exosc3 morphants were previously phenotyped (Wan et al., 
2012; Boczonadi et al., 2014). rbm7 morphants showed defective body morphology 
ranging from mild to severe phenotype (Fig. 4.4). Morphant fish were categorized in 
three phenotypical classes: mild, moderate and severe. Fish with a mild phenotype 
had slightly shorter body length and brain oedema. Mild phenotype fish were not able 
to normally swim away upon touch stimulation, indicating some sort of neuromuscular 
defect. Fish with a moderate phenotype had a curved body shape, smaller head with 
a more prominent brain oedema, and in addition heart oedema was observed. Fish 
with a severe phenotype had a disrupted body morphology with anatomical parts 
barely recognizable. Interestingly, in some severe fish, we could observe a partially 
external development of the spinal cord (Giunta et al., 2016).  
EXOSC8 RBM7 EXOSC3 
Figure 4.1. Homology between human and zebrafish EXOSC3, EXOSC8 and RBM7 
proteins. EXOSC3 and EXOSC8 show an overall high degree of homology between the 2 
species while RBM7 homology is relatively low if the whole protein is considered. 
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Alignment of NM_199925 and chr18:47305773-47311455 
tatataaagc aacatcagag gtcattcatg cattttcttt ttccactagG  47308922 
CTGGGCCATT GATCAAGGTT AAAATCCCTA AAgACAATGA AGGAAAGTCA  47308972 
AAACTGTTTG CATTTGTaAA CTTCAAGCAT GAAGTGTCAG TGCCCTATGC  47309022 
CTTGAACTTG CTGAATGGAA TCCGTCTGCA TGGACGACAG CTCAACATAA  47309072 
AGTTCAAAAC CGgtaggact ttccttattg cgttgattta ttttgtgttt  47309122 
 
Alignment of NM_001002865 and chr10:35058926-35067639 
agcgggcgaa gaaagcgcag attccgccgt gaccaactga aatagcgcca  35058875 
cacaccagag cggaggacgc gaagttctcc gcttttacgt cactgcagtt  35058925 
ATTCACGTGG TGCTTCCAAA CATCATGGCG GCTGGTTTTA Agtgagctac  35058975 
atgtgcaaat tgtttttata atactattaa tgatttatat aggtgtctaa  35059025 
atagtgaggt gatgatttcg ctattttatt tcagctgaat catgttgtgt  35059075 
 
Alignment of NM_001029961 and chr14:51760826-51764911 
tttctgttgt ggacataaag ggttggagag gttttaatga gttaatttgt  51764962 
ataggataag agtccccgtg ccggaagtgc tcagacacgt gtgtttgtgt  51764912 
GTGTTTTCCG CTCCTCCATC ATGGACTCCT CAGTGCACAC TAGTCTGCTG  51764862 
GAGAGGATAG GAGATGTGGT TCTTCCAGGC GAtCTGCTGT TCTCCTTCAG  51764812 
TCCTCCTGAA GCCGGAGACG CGAACCCGAA AGCGGACAGG CTGATCTGCG  51764762 
GCCCGGGGCT GCGGCGGAGC GGAGCGGAGA TCCGTGTGTG TAGAGCaGGA  51764712 
GTCCTGAAAC ACAAACAACC CAACATGTAC TGGGTCAACT GTCAGCAGAG  51764662 
ACGGgtcaga acacacacac acacaacatg tgccagcaca cactattgtt  51764612 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Localization of morpholinos against rbm7 (NM_199925), exosc8 
(NM_001002865) and exosc3 (NM_001029961). Position of morpholinos is 
underlined. Two new morpholinos were designed to target rbm7 exon 2 which 
caused skipping of the same. The other 2 morpholinos were designed against 
the ATG and previously described. 
Figure 4.3 Graphical representation of mode of action of splicing morpholinos and 
position of rbm7-MOs. Morpholinos against intron-exon or exon-intron boundaries are 
predicted to cause exon skipping (top; image from Genetools website). Below, position of 
morpholinos against rbm7 exon 2 and primers used to test efficiency (Giunta et al., 2016). 
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Figure 4.5 Gel electrophoresis of rbm7 RT-PCR of wild type and 
morphant fish. Knock-down efficiency can be easily tested in splicing 
morpholinos. Both MO1 (top) and MO2 (bottom) cause exon 2 skipping 
(Giunta et al., 2016). 
Figure 4.4 Phenotypes (at 48 hpf) and mortality (at 24 hpf) caused by rbm7 knock-down. 
Mild phenotype fish (B) are slightly shorter than WT (A) and a brain oedema could be 
observed. Moderate fish (C) show smaller head and eyes and brain oedema becomes more 
pronounced. In severe fish (D) morphology is completely altered. Scalebar = 200 µm. Mortality 
is much higher compared to ctrl-MO injected fish, indicating that it is caused by rbm7-MO (E). 
Injection of 2.2 ng of rbm7-MO1 caused a range of different phenotypes which allowed an in-
depth downstream analysis (F; images from Giunta et al., 2016). 
A B 
C D 
E 
F 
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4.2.2 Knock-down of rbm7, exosc8 and exosc3 cause defective hindbrain 
development in zebrafish 
Based on the observation of brainstem involvement in pontocerebellar hypoplasia 
type 1 (MedGen 335969) caused by EXOSC3 and EXOSC8 mutations in human, I 
decided to investigate development of brainstem nuclei in zebrafish upon knock-
down of rbm7, exosc8 and exosc3. We compared the phenotypes obtained, taking 
advantage of the islet1:GFP transgenic zebrafish line which expresses GFP in the 
brainstem cranial motorneurons (Lee et al., 2008). Zebrafish cranial motorneurons 
expressing islet1 are divided into 5 nuclei, from rostral to caudal: III (oculomotor), IV 
(trochlear), V (trigeminal), VII (facial) and X (vagal; Higashijima et al., 2000) allowing 
visualization of defects in development of the hindbrain. Fish with a severe 
phenotype were not considered for this experiment, as important morphological 
defects are likely to affect brain structures. rbm7-MO had little effect on this 
anatomical area. At 48 hpf only the slightly shortened nuclei nX (vagal nerve) could 
be observed in mild rbm7-MO fish, compared to control (Fig. 4.5). Similar defects 
were also present in the moderately affected zebrafish. exosc8-MO fish showed 
similar defects of cranial neurons, as observed previously by us (Boczonadi et al., 
2014) with a pattern of disruption which could be observed mostly in moderate fish  
A B C
 
D
 
A’ 
B’ C’ D’ 
Figure 4.6. Knock-down of rbm7, exosc8 and exosc3 affects cranial motor-neurons 
development. In uninjected islet1:GFP fish (A, A’), five cranial motorneurons nuclei are clearly 
distinguishable. rbm7-MO seems to slightly affect nX(B, B’), which results to be shorter than in 
controls, even in mild fish. exosc8-MO fish have several defective structures (moderate 
phenotype; C, C’). exosc3-MO fish lack nVII, while the rest of the hindbrain seems to be 
relatively preserved (D, D’). Scale bar = 200 µm Image from Giunta et al., 2016. 
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(Fig. 4.5). exosc3-MO seem to affect mostly nuclei VII (facial nerve) even in the 
mildly affected embryos (Fig. 4.5). Interestingly, although the role of these three 
different genes in cranial nerve development was never studied before, similar 
disruption of cranial nerves has been observed in a zebrafish SMA model by others 
(Beattie et al., 2007). The authors could observe a defective development of facial 
motor neurons in SMN knock-down zebrafish.  
4.2.3 Knock-Down of exosc8 in zebrafish causes defective myelination 
Based on observation of defective myelination in the central nervous system in 
EXOSC8 patients, I analysed myelination in zebrafish through electron microscopy 
upon knock down of exosc8. In order to confirm what observed we also analysed 
myelin in exosc8-MO zebrafish with a fluorescent dye which specifically stains myelin 
lipids (BrainStain, Thermofisher). Lipid staining was performed by Dr. Veronika 
Boczonadi, Newcastle University. We analysed in both cases myelination in the 
lateral line, as it is one of the first structures that start developing myelin sheaths. 
Analysis of electron microscope images clearly show lack of myelin sheaths 
formation around axons, which appears to be rather well developed in zebrafish at 4 
dpf. Lack of organelles such as mitochondria is also apparent (Fig 4.6. Boczonadi et 
al., 2014). 
99 
 
  
 
 
 
 
Figure 4.7 Defective myelination caused by exosc8 knock down in 4 dpf zebrafish. 
Uninjected fish show normal development of myelin sheats around the axons at 4 dpf in the 
lateral line (arrow, top left) while exosc8 downregulated fish of the same age do not show the 
beginning of the myelination process in the same anatomical area (arrow, top right). Below: in 
order to confirm myelination defects caused by exosc8 knock-down in zebrafish we 
performed myelin staining on transversal section of 4.5 dpf zebrafish uninjected (bottom left) 
and exosc8-MO (bottom right) showing defective myelination.  Images from Boczonadi et al., 
2014. EM Scalebar = 500 nm. 
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4.2.4 Co-downregulation of mbp in exosc8 morphant zebrafish rescues 
hindbrain phenotype 
Previous studies of transcript levels in EXOSC8 mutant fibroblasts and myoblasts, 
showed higher levels of several ARE genes such as SMN1, MOBP and MBP. The  
exosome complex is known to be important for degradation of AU-rich elements, and  
dysfunctions of the same are likely to affect ARE genes levels. MBP level in particular 
was found to be much higher than the other two. In zebrafish, levels of mbp resulted 
to be 4 to 6 times higher upon downregulation of exosc8 at 16 hpf (Boczonadi et al., 
2014). mbp plays a key role in formation of myelin sheaths around the axons. 
Unbalance of its levels is likely to affect the myelination process, causing the 
phenotype observed in the patients. 
To test if this was indeed causative of myelination issues in humans and exosc8-MO 
fish, we performed co-downregulation of exosc8 and mbp in a transgenic zebrafish 
line expressing GFP in cranial motor neurons (islet1:GFP) resulting in a rescue of the 
hindbrain phenotype with better defined structures even in the severe fish (Fig. 4.7) 
and increased survival rate from from 59.3% of survival upon exosc8 knock-down to 
77.7% upon co-downregulation of exosc8 and mbp. Myelin sheaths were not 
analysed after co-downregulation, but it is interesting to notice that mbp is also 
expressed in hindbrain oligodendrocytes at 48 hpf (Kazakova et al., 2006). Therefore 
an overexpression of mbp may affect hindbrain development as well, even before the 
onset of  myelination process. RT-PCR analysis shows that both mbpb and exosc8 
are expressed since very early stages, even maternally in zebrafish (Fig. 4,9). 
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Figure 4.8. Co-downregulation of exosc8 and mbp rescued hindbrain phenotypes. 
Downregulation of exosc8 severely affects development of the hindbrain (left), especially in severe 
fish causing an overexpression of mbp (Boczonadi et al., 2014). Co-downregulation of exosc8 and 
mbp restores development of anatomical structures which are well defined even in severe phenotype 
(right). Images from Boczonadi et al., 2014. 
Figure 4.9. RT-PCR of exosc8 and mbp in zebrafish. Both genes 
present maternal and zygotic expression. Interestingly mbp is expressed 
even before the onset of myelination. 
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4.2.5 Development of motor neurons in zebrafish 
Neurogenesis of motor neurons in zebrafish has been well established. Two main 
classes of peripheral motor neurons that innervate axial muscles can be 
distinguished during development: primary and secondary motor neurons. Each class 
has some anatomical and cellular characteristics that make possible to discriminate 
between the two, although some of these characteristics may overlap in some cases 
(Myers, 1985) (Myers et al., 1986). Each primary motor neuron can be classified 
based on the antero-posterior position within each myotome in Rostral (RoP), Middle 
(MiP) and Caudal (CaP) (Fig. 4.8; Sanes et al., 2012). A fourth type of primary motor 
neuron is present in about half of the hemi-segments (whereas all the others are 
present in all segments, bilaterally). This neuron type is called Variable (VaP) as it is 
not always present (Eisen, 1992). 
Primary motor neurons are larger in size (~ 11 µm somata diameter) and located in a 
dorsolateral position at 48 hpf (Myers et al., 1986). Secondary neurons are located 
more ventrally, they are smaller (~ 6 µm somata diameter) and their axons are thinner. 
Different primary motor neurons can be also recognized based on the direction of the 
axons (Myers et al., 1986) (Issa et al., 2012). At 48 hpf RoP axons direct caudally 
then descend toward the horizontal septum which separates the dorsal and ventral 
part of the somite, continuing elongating at this height in both directions. MiP axons 
extend caudally over the CaP somata and then start growing dorsally turning to the 
opposite hemisegment. Finally, CaP grows quite straight toward the ventral part, 
innervating those ventral muscles, suddenly dividing into two branches. Primary axon 
growth can be  visualized staining axons with antibody against synaptic vesicle 2 
(SV2) (Palaisa and Granato, 2007) (Sainath and Granato, 2013). 
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Figure 4.10 Schematic representation of primary motor neuron development 
in zebrafish. Primary motor neuron development in zebrafish follows a clear 
pattern. RoP (rostral) axons follow the notochord horizontal septum rostrally (solid 
horizontal line) before going ventrally and start branching along the horizontal 
septum (horizontal dotted line). MiP axons (middle) also go ventrally and rostrally  
until notochord and suddenly go up to the most dorsal part of the trunk. CaP 
(caudal) go straight down toward the ventral side and innervate that area where 
they branch. Secondary motor neurons are different in size of soma and axons 
(A). Confocal image of primary motor neurons and graphical representation of the 
same image (B). Images from Myers et al., 1986 (top) and Issa et al., 2012 
(bottom). 
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4.2.6 Knock-down of rbm7, exosc8 and exosc3 causes defective growth of 
motor neuron axons in zebrafish 
In order to understand the role of rbm7, exosc8 and exosc3 in neural development 
we analyzed the growth and pathfinding of motor neuron axons in all three 
morphants at 48 hpf. We stained synapses with SV2 antibody and α-bungarotoxin 
which bind respectively to pre-synaptic vesicles and AChRs.  
In control fish SV2/αBGTX stainings show correct development of primary motor 
neurons. In all three morphants the axon growth was defective,  specifically regarding 
CaP while growth of RoP and MiP seems to be overall correct. Sporadically, in 
exosc8 and exosc3 morphant fish, CaPs seem to branch earlier. In either case CaP 
fail to innervate the ventral trunk (Fig. 4.9). The phenotype resembles what observed 
in morphant zebrafish for sema3a1, a secreted class III of semaphorin (Sato-Maeda, 
2006) and in a smn knock-down zebrafish model (McWhorter et al., 2003). The 
reduced length of the motor neurons resulted to be statistically sgnificant (Fig. 4.9). 
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G H 
Ctrl-MO 48 hpf 
rbm7-MO 48 hpf 
exosc8-MO 48 hpf 
exosc3-MO 48 hpf exosc3-MO 48 hpf 
Ctrl-MO 48 hpf 
rbm7-MO 48 hpf 
exosc8-MO 48 hpf 
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Figure 4.11 Motor neuron axons defects in rbm7, exosc8 and exosc3 morphant fish 
and statistical analysis of axons length. (A-H) Confocal images of  motor neurons stained 
with SV2 (green) and αBGTX (red) in rbm7-MO, exosc8-MO and exosc3-MO. Structures of 
RoP, MiP and CaP can clearly be recognized in ctrl-MO fish. In all three morphants structure 
of CaP seem to be disrupted with premature stopping and defective branching. MiP seem to 
be relatively preserved. RoP seem to be missing in morphant fish. Scale bar = 100 µm. (I) 
axon/somite length ratio in morphant fish is significantly reduced compared to control 
injected fish (axon/somite length ratio = 1). 
Table 9. Axonal defects in different morphant and phenotypical classes. Only 
mild and moderate phenotypes were considered for this analysis. Image from 
Giunta et al., 2016. 
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4.2.7 Imaging of Purkinje cells 
In order to clarify the causes of defective cerebellar development in exosomal protein 
deficiencies, we analyzed differentiation of Purkinje cells (PCs) in zebrafish 
cerebellum. rbm7, exosc8 and exosc3 were downregulated and PCs were stained 
with an antibody against pvalb7, a well known marker of PCs (Bae et al., 2009). 
Knock-down of all three genes caused defective differentiation of PCs even in mild 
fish (Fig. 4.10). The layer of PCs in ctrl-MO fish has a peculiar wing-shaped structure, 
which fails to form in all three morphants. KD of all three genes results in a scattered 
structure which is never observed throughout the differentiating process. pvalb+ cells 
are present since slightly before 3 dpf (Hamling et al., 2015) from progenitor cells 
expressing ptf1a (Kani et al., 2010) and since the beginning of cerebellar 
development the pvalb+ layer has its characteristic shape. 
Figure 4.12 Cerebellar structures in ctrl-MO, rbm7-MO, exosc8-MO and exosc3-MO 
injected fish. Ctrl-MO injected fish show normal differentiation of PCs into the peculiar 
wing-shaped layer (arrowheads, A). Knock-down of all three genes cause defective 
differentiation of pvalb+ cells which result in a scattered layer of PCs (arrowheads, B-D). 
Only mild phenotype fish were considered for this analysis. 47% if rbm7-MO fish showed 
defects, 93% of exosc3-MO and 76% of exosc8-MO. Image from Giunta et al., 2016. 
A B 
C D 
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Table 10. Quantity and respective percentage of fish with cerebellar 
defects.  Only mild and moderate phenotypes were considered for this 
analysis. Image from Giunta et al., 2016. 
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4.2.8 Analysis of gene expression in morphant zebrafish 
In order to understand the molecular pathomechanisms causing the 
neurodevelopmental defects observed in zebrafish after knock down of rbm7, exosc8 
and exosc3, transcript levels of several genes which were up or downregulated in 
mutant human fibroblasts have been analysed. 
We tested the levels of atxn1a, atxn1b, hoxc6a, hoxc6b, hoxc8, hoxc9, hoxc10, 
hoxc11a, and hoxc11b. Gene expression was analysed for all three morphants (rbm7, 
exosc8 and exosc3) in three different phenotypical classes (mild, moderate, severe) 
at four different developmental stages (12 hpf, 16 hpf, 24 hpf and 48 hpf). The 
analysis was repeated on three biological replicates. Because expression of 
reference genes (EF1-α and β-actin) was found to be very variable throughout 
development, expression levels of target genes was compared to expression levels 
of reference genes at the same developmental stage. Although small differences 
could be observed, analyses of hox genes did not show any statistically significant 
difference in transcript levels between morphants and uninjected controls. This may 
be due to tissue and/or species specificity of expression. Instead, atxn1b show a 
great increase in expression after knock down of all three genes (Fig 4.11).  
ATXN1 is present in two paralogs in zebrafish: atxn1a and atxn1b (Carlson et al., 
2009). atxn1a (ENSDARG00000061687) is situated on Chr:19 while atxn1b 
(ENSDARG00000060862) is located on Chr:16. Interestingly, levels of atxn1b but not 
atxn1a were highly increased in morphants compared to controls at 12hpf, 16 hpf 
and 24 hpf. At 48 hpf atxn1b levels returned near to normal.  
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Figure 4.13 Transcript levels of atxn1a and atxn1b after rbm7, exosc8 and exosc3 knock-
down. Gene expression was analysed at 4 different developmental stages in mild phenotype fish 
(from 24 hpf, when a phenotype could be seen). qRT-PCRs were repeated on 3 biological 
replicates. atxn1a did not show any significant change after gene knock-down (left column). 
atxn1b expression shows a dramatic increase after knock-down of all three genes (right column). 
Bars indicate S.D. 
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4.2.9 In silico analysis of AU content of ATXN1, atxn1a and atxn1b 
Human ATXN1 (ENSG00000124788) is located on Chr:6 and it has 2 protein coding 
isoforms of the same length (815 aa). Zebrafish atxn1a has 2 isoforms: which share 
exactly the same identity and similarity with the human gene (43% identity and 55% 
similarity). atxn1b has only one protein coding transcript which shares 36% identity 
and 48% similarity with the human homolog. Analysis of AU-rich element score 
through AREscore (Spasic et al., 2012) showed that human ATXN1 has a similar, 
high AREscore to atxn1b whereas atxn1a has a much lower score (table 6). 
 
Name Score 
Pentamer 
count Sequence length 
H. sapiens ATXN1 ENST00000244769 21.65 17 12967 
D. rerio atxn1a ENSDART00000167664                                                                    3.3 3 3139 
D. rerio atxn1b ENSDART00000149411 19 16 8697 
Table 11. In silico analysis of AU content in ATXN1, atxn1a and atxn1b. Analysis of AU 
content through AREscore (http://arescore.dkfz.de/arescore.pl) show atxn1a and atxn1b 
have a great difference in AU content. Human ATXN1 has a similar score to atxn1b. 
 
4.3 Discussion and future directions 
RNA processing and metabolism is known to be important for efficient development 
of neural system and functions. Mutations in SMN - a splicing factor - cause Spinal 
Muscular Atrophy (SMA) (Seng et al., 2015). Correct levels and structure of non-
coding RNAs are involved in a variety of neurological diseases (Saitsu et al., 2011) 
(Lin et al., 2014) (Qureshi and Mehler, 2013). Incorrect tRNA transcription and 
processing also affects neural system (Breuss et al., 2016) (Simonati et al., 2011) (Li 
et al., 2015) (Antonellis et al., 2006) 
Interestingly, among these neurological disorders, a specific subgroup is caused by 
mutations on sub-units or co-factor of the exosome complex, the main cellular RNA 
degradation machinery. Mutations in genes encoding exosomal subunits EXOSC3 
(Wan et al., 2012), EXOSC8 (Boczonadi et al., 2014), EXOSC2 (Di Donato et al., 
2016a) and exosome co-factor subunit RBM7 (Giunta et al., 2016) cause severe 
childhood-onset neurological symptoms including pontocerebellar hypoplasia, spinal 
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muscular atrophy and central nervous system demyelination, raising many questions 
about the pathomechanisms underlying these disorders. In this thesis I present a 
comparative analysis of functions of rbm7, exosc8 and exosc3 in zebrafish which 
further confirm the role of correct RNA processing in vertebrates neurodevelopment 
and highlights some new aspects of these pathologies. 
These data show for the first time that the exosome complex has a role in axon 
development of motor neurons, specifically affecting the primary motor neurons. 
Knock down of rbm7, exosc8 and exosc3  cause defective axon growth and 
pathfinding of CaP in a very similar way to smn knock down zebrafish (McWhorter et 
al., 2003) suggesting that this early developmental defects may lead to subsequent 
neurodegeneration. The percentage of defective axons with defects at 48 hpf 
suggest that, analysing the level of motor neuron loss at later stages in the same 
morpholino-injected batch may be of interest, although it may be difficult to estimate, 
due to extended axons branching at later stages.  
The molecular causes of these defects are not known. I compared the RNA-seq data 
from patient fibroblasts and identified many HOX genes differentially expressed. HOX 
genes are known to be involved in motor neuron development (Giunta et al., 2016) 
therefore that seemed a logical path to follow. I thorougly analyzed a set of HOX 
genes in zebrafish after gene knock down in order to find the downstream molecular 
events responsible for the defects but could not find any clear indication. Some of the 
HOX genes analyzed were slightly differentially expressed but always <2 fold change 
therefore not statistically significant. This may be due to the fact that analysing the 
whole embryo instead of the single cell introduces a lot of background signal during 
qRT-PCR analysis or, assuming that the human fibroblast data are reflecting the 
causes of neuronal defect, the downstream effects may be different from human to 
zebrafish.  
Many other genes are involved in axonal growth. I tested in zebrafish the expression 
of another gene (CACNA1G), which is differentially expressed in both human 
fibroblasts carrying mutations in EXOSC8 and RBM7 which - according to Reactome 
(Fabregat et al., 2016) - is involved in axonal guidance through NCAM1 interactions 
(Reactome Reaction “NCAM1 interacts with T- and L-type VDCC”). Reactome is a 
pathways analysis software which is able to indicate which cellular  pathways are 
affected by differential expression of genes. It can be very helpful for understanding 
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the meaning of large datasets obtained from analysis such RNA-seq, metabolomics 
and proteomics.  However no differential expression could be found in zebrafish. We 
are confident that taking advantage of the rbm7 (and exosc8) mutants we have 
created (which will be described in detail in the next chapter) we will be able to 
address these questions.  
It will be interesting to analyse in detail the pathfinding of primary motor neuron 
axons using the islet1:GFP fish. This fish expresses GFP in the soma of neurons, 
and co-staining with SV2 will follow the growth of the axon. In future studies on 
mutant fish we will perform qRT-PCR of some genes which are known to be involved 
in axon pathfinding in zebrafish such as semaphorins (Sato-Maeda, 2006).  
In the cerebellum the reduction of Purkinje cells is a clear hallmark of PCH1 (Eggens 
et al., 2014). It was already shown by others that pvalb7 transcript levels were 
reduced in a zebrafish model of PCH1 (Wan et al., 2012). We wanted to test if 
protein expression was also reduced in all three knock-down models we have made: 
rbm7-MO, exosc8-MO and exosc3-MO. As expected we could observe defective 
pvalb+ layer also in exosc8 morphant fish, but rather unexpectedly we observed the 
same also in rbm7-MO, although less frequently.  
The defects observed in downregulated fish at 4.5 dpf cannot be considered just as a 
developmental delay. Indeed, PCs start differentiating just before 3 dpf and 
throughout development not such a scattered structure can be observed (Kani et al., 
2010) (Hamling et al., 2015).  
A molecular explanation of the pathomechanism may be provided by the results of 
the qRT-PCR. Investigation of levels of atxn1a and atxn1b showed that atxn1b is 
present in much higher levels in knock down fish up to 48 hpf when they return close 
to normal levels. In silico analysis of the AU content of the gene shows it has a high 
score, similar to the human ATXN1 gene. Here I note that the exosome complex is 
known to perform degradation of genes which expression is only transiently required, 
such as the AU rich element containing genes (Chen et al., 2001). ATXN1 is 
important for correct cerebellar development, is linked to the pathogenesis of 
spinocerebellar ataxia type 1 (SCA1) (Matilla-Dueñas et al., 2008) causing 
neurodegeneration of PCs and other brainstem structures in human (Ju et al., 2014) 
and mice (Ebner et al., 2013) caused by either a toxic gain of function due to the 
polyQ extension or overexpression of the wild type gene. Overexpression of wild type 
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ATXN1 is toxic for PCs and lead to neural degeneration in mice and D. melanogaster 
(Tsuda et al., 2005) (Fernandez-Funez et al., 2000). A similar pathomechanism may 
occur in our model due to overexpression of atxn1b caused by impaired functionality 
of the exosome complex.  
A similar pathomechanism driven by overexpression of an ARE gene (mbp) was 
found to cause defective myelination in a zebrafish exosc8-MO model. In that case 
also, defective functionality of the exosome complex caused reduced degradation of 
mbp, which supposedly impairs correct formation of myelin sheats around the axons 
(Boczonadi et al., 2014). It is interesting to notice the rescue of hindbrain structures 
caused by co-downregulation of mbp after knock-down of exosc8. Thisse et al., 
showed that mbp RNA is expressed much earlier than the onset of myelination in the 
oligodendrocites in the hindbrain (zfin.org). That may explain why defective mbp 
metabolism due to exosc8 knock down has such a detrimental effect on hindbrain 
structures and also why downregulation of overexpressed mbp rescues the same 
structures.  
A more detailed analysis of the defects observed in cranial motor neurons may 
provide further information. Through confocal microscopy, axon growth can be 
followed throughout de velopment. Live imaging of knocked down (or mutant) 
islet1:GFP fish may allow to understand which neurons are affected and which are 
not, and compare real-time development of cranial motorneurons in mutant and 
control fish. 
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5 Chapter 5: Results - Mutant zebrafish models of exosomal 
proteins deficiency through CRISPR/Cas9 technology 
 
Very recently a new technology for site specific mutagenesis has been developed 
based on the CRISPR/Cas system (Cong et al., 2013) (Mali et al., 2013). Until then, 
previous mutagenesis technologies (zinc finger nucleases – ZFNS -  and 
transcription activator-like effector nucleases - TALENS) had a much lower efficiency 
(Varshney et al., 2015).  
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR 
Associated (Cas) is a natural defense system in prokaryotes (Haft et al., 2005), 
identified for the first time by Ishino and colleagues upstream of the iap gene in E. 
coli (Ishino et al., 1987).  
 Although at that time the biological role of these clustered repeats within the 
prokaryotic genome was unknown, few years later three independent in silico studies 
(Mojica et al., 2005) (Pourcel et al., 2005) (Bolotin et al., 2005) demonstrated 
homology between these repeats and extra-chromosomal elements such as viruses 
and plasmids, leading to the hypothesis that these repeated sequences were a 
defensive mechanism of archaea and bacteria against invading viruses and plasmids 
(Makarova et al., 2006) (Horvath and Barrangou, 2010) (van der Oost et al., 2009).  
In order to build this defence system, microbes take up genetic material from 
invaders and build up these loci (CRISPR) which are able to target specific 
sequences of the intruders’ genome. These CRISPR sequences (usually about 20 nt 
long) co-transcribe with Cas genes which encode for endonucleases. If Cas is co-
transcribed with a specific sequence (CRISPR), able to target the exogenous 
genome, the CRISPR/Cas system will provide adaptive immunity against phages or 
plasmids. There are many types of Cas proteins. Bionformatic analysis has shown 
that there are about 65 different orthologous in different organisms, which can be 
classified in three different systems (Makarova et al., 2011). Cas9 - which contains at 
least 2 nuclease domains - belongs to type II CRISPR/Cas system (Makarova et al., 
2011).  CRISPR/Cas9 system needs a proto-spacer adjacent motif (PAM) sequence 
to work,  which is an “NGG” (being “N” any nucleotide) sequence, downstream of the 
CRISPR target sequence (Fig. 5.1) (Wu et al., 2014). The predicted cut site on the 
target genome is 3 nucleotides upstream of the PAM sequence (Jiang et al., 2013) 
116 
 
(Jinek et al., 2012). Autoimmunity in microbes is prevented thanks to the lack of a 
PAM sequence within the CRISPR arrays.  
 
Figure 5.1 CRISPR/Cas is an acquired immune system of bacteria and archaea. During 
the first infective event, viral or plasmid DNA is cleaved and incorporated into the bacterial 
genome immunizing the cell from further infections (A). When a second infective event 
occurs, the previosuly incorporated exogenous DNA fragments act as guide RNAs, in fact 
“guiding” Cas protein to target regions of the invading genome, causing inactivation through 
cleavage (B). Autoimmunity is prevented due to lack of PAM sequences on the prokaryote 
genome (Image modified from Horvath and Barrangou, 2010). 
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The CRISPR/Cas9 system has been adapted to produce sequence specific double 
strand breaks (DSB) in eukaryote’s genomes. For our purposes, the CRISPR 
sequence is substituted with a single-guide RNA (sgRNA) which is designed to target 
a specific sequence. The sgRNA is co-transcribed with Cas9 RNA, which will be 
subsequently translated, allowing the cleavage of the DNA introducing random 
deletions or insertions via the non-homologous end joining (NHEJ) system 
(Armstrong et al., 2016) (Irion et al., 2014). 
5.1 Overview of the technique 
5.1.1 Designing sgRNA and testing efficiency in the F0: 
In order to perform mutagenesis in zebrafish two sgRNAs against 2 exons of rbm7 
were designed using CRISPRscan (Fig. 5.2; Moreno-Mateos et al., 2015; 
http://www.crisprscan.org/) targeting exon 2 and exon 4.  
CRISPRscan categorizes all potential guide RNAs based on their efficiency. 
Score >70 is highly efficient sgRNA, >55 is efficient sgRNA. In the UCSC interface, 
bright green is for “high activity sgRNAs”, grey-green is for “low CRISPRscan score”, 
grey is for “sgRNA with potential off-target effects” (Fig. 5.2).   
The selected sgRNAs have respectively a score of 56 (bright green) for exon 4 and 
score of 33 (grey-green) for exon 2 (Fig. 5.2). 
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 Synthesis of sgRNA and purification was performed  as described before (Varshney 
et al., 2015). Mutations in the F0 are known to be mosaic and we wanted to avoid 
mixing WT and mutant genomes when sequencing for testing the system, which 
would have resulted in a noisy electropherogram (or it would have caused 
impossibility to read the mutant sequences). Therefore, in order to test the efficiency 
of the sgRNAs and injection method, we injected sgRNA + Cas9 RNA in embryos at 
1 cell stage of development, extracted genomic DNA from 10 injected embryos at 24 
hpf, amplified the exon of interest by PCR and cloned it into a plasmid, which was 
subsequently transfected in E.coli. We then plated the bacteria and performed colony 
PCR in a 96 well plate and sequenced the PCR product. This system allowed having 
only one copy of the gene per colony and therefore a clear electropherogram.  
 
Figure 5.2 Screenshot of the UCSC-based interface of CRISPRscan. CRISPRscan works 
on a UCSCgenome based interface. Selecting the organism and typing the name of the gene 
we need automatically show this page with a graphical representation of the gene (RefSeq 
genes, blue) with exons (asterisks) and introns. All potential sgRNAs are listed above in 
different shades of green(blue bracket) corresponding to the exons. 2 sgRNAs were chosen for 
our experiment based on position on the gene and efficiency score (underlined in red). 
* * * * * 
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5.2 Results: 
5.2.1 Testing mutagenesis efficiency in F0 
Considering that genomic DNA from 10 fish was extracted, we calculated efficiency % 
based on how many mutations were found in a 96 well-plate. An average efficiency 
of 6.5% for Exon 2 and 13% for Exon 4 was observed. 
With sgRNA_56 against exon 4 we identified 3 different types of mutation in F0. Two 
of them were subsequently identified in F1 as well (Fig 5.3): 
• c.440delCA (also found in F1) 
• c.434delCCTCCACAG (also found in F1) 
• c.442delGCACA (not found in F1) 
 
 
 
 
 
 
Figure 5.3 Sequencing of E. coli colonies with insertion of Ex4. Genomic DNA 
extraction and insertion into bacterial cells followed by Sanger sequencing allowed to clearly 
identify “homozygous” deletions within the exon. Red orizontal bars at the bottom show 
deletions. 
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Analysis of the predicted effect of the mutation on the protein structure with EMBOSS 
Transeq (http://www.ebi.ac.uk/Tools/st/emboss_transeq/) provided the following 
results: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutations c.440delCA and c.442delGCACA are frameshift deletions and predicted to 
create stop codons at different points within the amino acid sequence. 
c.434delCCTCCACAG is an in-frame deletion and predicted to remove three amino 
acids (P-P-Q) from the protein but does not cause a downstream stop codon (Fig. 
5.4). 
 
With sgRNA 33 for Exon2 we found 2 different types of mutation in the F0 (Fig. 5.5, 
Fig. 5.6): 
• c.156delCA 
• c.156delC 
 
 
 
Figure 5.4 In silico prediction of exon 4 mutations effects on amino acid sequence. Top 
left: Wild type zebrafish rbm7 sequence. Top right: the identified frameshift mutation 
4228_4229delCA is just after the P highlighted by the red square. It is predicted to cause 
different downstream stop codons. In-frame  deletion  c.434delCCTCCACAG cause deletion of 
P-P-Q (underlined in red, bottom left). Frameshift deletion c.442delGCACA also creates several 
downstream stop codons, possibly causing a C-terminal truncated protein (bottom right). 
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Figure 5.5 Representative image of a deletion in exon 2. Representative 
image of sequencing of E. coli colonies with insertion of rbm7 exon2. 
Efficacy of the system could be easily checked thanks to the clarity of the 
electropherogram. Red orizontal bars show a deletion. 
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Figure 5.6 In silico prediction of exon 2 mutations effects on amino acid sequence. Either 
c.156delCA and c.156delC are frame-shift mutations (red square top right and bottom left) and 
predicted to create stop codons soon after the mutation itself, Because the stop codon is >50-55 
nt before the next exon-exon boundary, these mutations are likely causing a non-sense 
mediated decay of RNA (Popp and Maquat, 2016). 
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5.3 Breeding strategy – overview. 
F0 injected fish were left to grow up to 3 months of age, until sexual maturity was 
reached.  
About fifteen F1 fish were screened for mutation transmission pairing two F0 injected 
fish. If at least one fish of the progeny was positive for the mutation, the two F0 fish 
were out-crossed with a WT golden fish to understand which one was the carrier of 
the mutation (male or female). Progenitors which resulted to have progeny negative 
for the mutation were discarded. From the outcrossing of positive F0 fish, some of the 
F1 were sequenced in order to discriminate the carrier of the mutation, and the rest 
was left to grow up to 3 months of age. Adult F1 fish were later screened by fin-
clipping in order to separate them by mutation type (Fig. 5.7). 
124 
 
5.4 Genotyping of F1 zebrafish  
Germline transmission resulted to be very variable. For some of the injected batches 
was 0%, for some others it was positive. 
In the positive ones, a high germline transmission rate (Fig 5.8) could be observed. In 
order to better understand which one was the actual carrier of the mutation (male or 
female) F0 fish were outcrossed with a wild-type golden fish. In many cases both fish 
Figure 5.7 Breeding strategy in order to obtain a stable mutant strain. About 200 
eggs from different batches were injected with sgRNA+Cas9 RNA in order to have 
enough F0 adults. F0 are known to be mosaic mutants so they may not carry the 
mutation into the germline and they may not be able to transmit it to their progeny. 
Therefore, a screening of the F1 embryos was carried out in order to identify those F0 
adults able to transmit the mutation. Some batches resulted to be negative (0% 
transmission), some others resulted to be positive. From the positive batches, F0 fish 
were outcrossed with a wild type fish in order to understand which fish was the carrier 
(male or female). This heterozygous F1 has been left to grow and sequenced in order to 
separate the fish based on different types of mutations. 
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were carrying mutation(s) in the germline. Furthermore, different types of mutations 
were identified in the germline from the same fish (Fig. 5.8).  
For sgRNA_56_Ex4, 92 F1 embryos were screened from 8 outcrossed pairs, we 
found an overall germline transmission rate of 32.60% (n=30).  
90% of the mutations were deletions and 10% insertions. 9 different types of 
deletions and 2 different types of insertions were found in all mutants. Up to 5 
different types of mutations were found in the progeny of a single F0 fish 
(summarized in Fig. 5.8). F1 fish were let to grow and screened for mutations when 
adults by fin clipping. Different types of mutants will be grown and bred separately to 
study the role of different mutations on embryo development.  
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Regarding rbm7 exon 2 mutagenesis,  the same number of eggs was injected with 
sgRNA for exon2 + Cas9 RNA. After three months, screening for germline 
transmission showed again that for some batches the injection and mutagenesis 
worked fine, for some others did not work. For those batches that contained 
mutations, germline transmission was about 20%. Types of mutations were different 
than for exon 4. Indeed in exon 2, other than insertions and deletions (accounting 
together for about 76% of total mutations), 23% were duplications (n=17). None of 
the mutations previously found in the F0 was identified in the F1.  
8 different types of mutations were identified (4 deletions, 2 insertions and 2 
duplications). Up to 3 different types of mutations were found in the progeny from a 
single F0 fish (Fig. 5.9).  
For both sgRNAs, no clear differences in the types of mutation or % of germline 
transmission was seen between males and females. 
Figure 5.8 Analysis of germline transmission for sgRNA_Ex4. Total germline 
transmission in the F1 was similar to what previously reported by others (A); Several types 
of mutation were find for a single sgRNA, either insertions and/or deletions (B, C); Even 
within a single fish, the same sgRNA caused different types of mutations (E-L), fish #6 was 
not included in the analysis as it had 0% germline transmission. Overall the most frequent 
seems to be a frameshift deletion of CA. 
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Figure 5.9 Analysis of germline transmission for sgRNA_Ex2. Overall transmission was 
lower than sgRNA_ex4. This may be due to lower predicted efficiency (A); ~23% of mutations 
were duplications, which were not present in mutants for exon 4 (B). The total number of 
different types of mutation was also lower than in exon 4 mutants (C), maybe again because 
of lower efficiency of sgRNA_Ex2 compared to sgRNA_Ex4. Also analysing mutation types 
per single fish, number of mutations is lower (E-I). 
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5.5 Selection of F1 adults mutation carriers and phenotype analysis in F2 
embryos 
Adult F1 fish were selected for genotyping through fin-clipping. 30 random fish from 
the pairs who carried the highest rate of mutation (#4 and #5) were selected for 
sequencing. The mutations identified and selected resulted to be a deletion of 3 
nucleotides and a c.162DelATC_InsGTTA (Del3_Ins4) nucleotides. Sanger 
sequencing was performed with the help of summer student  Alba Vilella. 
The mutation c.164delCAA (Del3) is an inframe deletion resulting in a deletion of 2 
amino acids (IK) and insertion of 1 (M) as follows: 
 
 
 
 
 
 
 
The second selected mutation c.162DelATC_InsGTTA results in a frameshift 
mutation which is predicted to introduce stop codons downstream of the InDel as 
shown below.  
 
 
 
 
Both mutations are located within the RNA Recognition Motif of RBM7, a highly 
conserved and catalytically active region of the protein (Hrossova et al., 2015). 
 
 
 
 
 
>EMBOSS_WT 
MGIADEADRTLFVGNLDPQVTEEVIFELFLQAGPLIKVKIPKNNEGKSKLFAFVNFKHEV 
SVPYALNLLNGIRLHGRQLNIKFKTGSSHINQEGKSPANSQNPSPANTPGHRGGRTPEQM 
GSPSYSPPQHMQRPFSSPDTLQRQAMMNNMWQVQMQQLQMLSGTFQQGMQQPRGNADGGW 
SGHRGQRHSPQDNNNHQGRDQRHGNGANNYERNRRDGQRGDFYHHDDRSGGHNRNYPPDR 
RRDSREGRWRHF* 
 
>EMBOSS_Del3_Ex2 
MGIADEADRTLFVGNLDPQVTEEVIFELFLQAGPLMVKIPKNNEGKSKLFAFVNFKHEVS 
VPYALNLLNGIRLHGRQLNIKFKTGSSHINQEGKSPANSQNPSPANTPGHRGGRTPEQMG 
SPSYSPPQHMQRPFSSPDTLQRQAMMNNMWQVQMQQLQMLSGTFQQGMQQPRGNADGGWS 
GHRGQRHSPQDNNNHQGRDQRHGNGANNYERNRRDGQRGDFYHHDDRSGGHNRNYPPDRR 
RDSREGRWRHF* 
 
>EMBOSS_Del3_Ins4_Ex2  
MGIADEADRTLFVGNLDPQVTEEVIFELFLQAGPLVKG*NP*KQ*RKVKTVCICELQA*S 
VSALCLELAEWNPSAWTTAQHKVQNRQQSY*SRRQKSSKLSKPQSSKYTGSPWRKNPRAD 
GLSVLLSSTAHAEAFLFTRHSAETGHDEQHVAGSDAAVANAQRNLPAGHAAA*GERRRRL 
VWAPRAAPLAPGQQQPSGQRSAARKRSK*L*AESARWAAGRFLSP**PQWRTQQKLPPRQ 
TERLQRGTMETLLX  
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5.6 Analysis of phenotype in F2 mutant embryos 
In order to characterize a possible effect of the identified mutations on embryo 
development in zebrafish, a morphological analysis was carried out of both mutants 
throughout development up to 5 dpf. No clear morphological defect could be 
observed for the Del3 mutants, although it seemed that, starting from 2 dpf, 
swimming movements of some fish was not as effective as in wild type fish. Altough 
they were able to swim away upon touch stimulation, the number of movement 
events if not stimulated, efficacy of the movement and speed was decreased 
compared to control fish. The exact percentage of fish with behavioural defects is not 
known though, due to difficulties in identify a clear phenotype 
Progenitor fish carrying the c.162DelATC_InsGTTA mutation on exon 2 were paired 
and a clear phenotype could be seen starting from 24 hpf. Embryos showed a variety 
of different phenotypes from milder to severe. Mild and moderate fish had shorter 
body length, heart oedema and smaller head. The most severe fish had completely 
altered body morphology with barely recognizable anatomical structures. ~50% of the 
fish showed a phenotype (Fig. 5.10). The experiment was repeated three times (with 
the same pair of F1 fish). Genotyping of fish these was not performed.  
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 5.6.1 Immunostaining of F2 mutant embryos 
Immunostaining on F2 embryos was performed in order to identify possible defects in 
motor neurons and/or cerebellum. Immunostaining of PCs was performed with an 
anti-parvalbumin7 antibody and immunostaining of neuromuscular junctions was 
performed with SV2 antibody which allows to visualize motor neurons, as previously 
described. 
Analysis of PCs and motor neurons in the c.164delCAA mutants did not show any 
defect in cerebellar structures. pvalb7 is also expressed in muscle fibers, resembling 
expression of PARVALBUMIN in mammals muscle fibers (Hazama et al., 2002) 
(Racay et al., 2006). Incidentally, an analysis of muscular structure in mutant fish 
A B 
C
 
E
D
F
G
Figure 5.10 F2 Zebrafish with the rbm7 c.162DelATC_InsGTTA mutation display 
different phenotypes at 48 hpf. Fish with a normal phenotype (A) were ~50% of the 
total. The other phenotypes look very different from each others (B-G). Head is generally 
smaller but overall the external morphology is preserved. Trunk and tail seem to be more 
affected by the mutation. 
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could be performed on the same batch of samples showing a rather slightly disrupted 
structure of the fibers which display empty spaces between single fibers and do not 
look perfectly parallel and packed as they do in WT fish (Fig. 5.11).  
 
The loose apperance of muscle fibers in mutant fish becomes more pronounced in 
larvae carrying a c.162DelATC_InsGTTA mutation (Fig. 5.11). 
Analysis of c.162DelATC_InsGTTA mutants show also defective structure of the PCs 
layer at 5 dpf which seems to be thinner on the sides when observed from above in 
some cases and completely scattered in others. Analysis of motor neurons in 
c.162DelATC_InsGTTA fish showed defective growth and pathfinding of the axon of 
CaP neurons which seem to wrongly grow rostrally first and then suddenly move 
caudally. Also a branching defect of the neuron at midline level was observed, which 
may be due to defective branching of a RoP neuron (Fig. 5.11). These, however, are 
preliminary data and need further investigation in order to be confirmed. 
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Figure 5.11. Immunostaining of mutant zebrafish. Muscle fibers show different degrees of 
disruption depending on the type of mutation (A-C). In WT fish, muscle fibers appear packed 
and parallel (A) while in fish with the inframe mutations are slightly looser (B, arrows). Muscle 
structure appears to be completely disrupted in mutants with the frameshift mutation (C. 
arrows). Purkinje Cells Layer has a defective structure in mutant fish (D-F). The external side 
of PCs layer appears thinner (E) compared to control (D). In other cases it is not well 
differentiated appearing scattered (F). No defects of PCs was observed in the in frame  Del3 
mutants. Motor neuron axons in frameshift mutants have growth and pathfinding defects (G, 
arrow-heads).  
pvalb7 – 5 dpf pvalb7 – 5 dpf  pvalb7 – 5 dpf 
WT Ex2_Del3 Ex2_ Del3_Ins4 
pvalb7 – 5 dpf pvalb7 – 5 dpf pvalb7 – 5 dpf 
WT Ex2_Del3_Ins4 Ex2_ Del3_Ins4 
SV2 – 48 hpf 
Ex2_Del3_Ins4 
A B C 
D E F 
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5.6.2 Update with most recent CRISPR-Cas9 data 
Despite many efforts to identify a morphological or behavioural defect which could 
correlate with the mutation, genotyping of F2 fish carrying the 
c.162DelATC_InsGTTA which were displaying developmental disruption did not 
show any genotype-phenotype correlation. Upon identification of a restriction enzyme 
(BclI) which digests only the wild type sequence,  it was possible to screen a larger 
number of adult fish in a much faster way (Fig. 5.12). Therefore I was able to identify 
other 2 fish with the  same c.162DelATC_InsGTTA mutation. 
Crossing of different pairs of fish with the same mutation did not show any severe 
phenotype anymore. Immunostaining for α-bungarotoxin/SV2 for neuromuscular 
junctions and phalloidin staining for slow and fast muscle fibers were comparable to 
controls. 
In silico analysis of cryptic splice site within exon2 excluded the possibility that the 
mutation could have been somehow skipped. 
Meanwhile some F2 fish I did breed from heterozygous fish had become adults and I 
was able to identify 2 adult fish homozygous for the c.162DelATC_InsGTTA.  
This allowed me to have a progeny without any WT maternal contribution. 
Unfortunately, even pairing the 2 homozygous fish did not provide any clear 
phenotype. 
RNA extraction from F3 rbm7-/- embryos allowed to sequence the transcript and 
check if the mutation is still present in the RNA. As expected I was able to see a clear 
electropherogram showing the mutation on an RNA level. 
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Het. 
Mut. 
WT 
zRBM7_Ex2 
Figure 5.12. BcII restriction enzyme digestion site and digested product on an agarose 
gel. BcII works on a TGATCA sequence which - in this case - is right across the predicted 
CRISPR/Cas9 cut site, therefore it can be used for any kind of mutation identified so far. 
Highlighted in red the PAM sequence; underlined in red the enzyme digestion site; green: 
sgRNA complementary sequence;  yellow: PCR primers (left). On the right: agarose gel of a 
digestion reaction of a heterozygous, homozygous mutant and homozygous WT fish. 
Mutant DNA 
Mutant RNA 
WT DNA Cut site 
DelATC 
InsGTTA 
Figure 5.13. Comparison of WT rbm7_Ex2 DNA sequence, mutant DNA and mutant RNA. 
The delATC_Ins GTTA mutation is still present in the RNA  
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5.7 Discussion and future directions 
With the advent of the CRISPR/Cas9 technology, mutagenesis has become easier to 
perform on-site than ever before. The critical step for an efficient CRISPR/Cas9 
mutagenesis is to design a good quality guide RNA which needs to have specific 
characteristics such as a certain length (between 18 and 21 nucleotides, the shortest 
being more specific), it has to be near a PAM sequence on the target genome and to 
have a certain number of guanines, in specific positions within the sequence. This 
critical step has been overcome with the use of bioinformatic tools such as 
CRISPRscan (Moreno-Mateos et al., 2015). 
Given the increasing number of controversies that are addressed over knock-down 
technologies (especially in zebrafish) and the opportunity of performing mutagenesis 
relatively easily, nowadays it is necessary to perform gene inactivation through 
mutagenesis if functions of a given gene are investigated. 
Therefore, as we wanted to further delineate exosome complex functions in disease, 
we decided to create a mutant zebrafish strain. I decided to target exon 2 and exon 4 
of RBM7 for two different reasons: the active domain of rbm7 is predicted to be only 
within the first ~94 amino acids (Hrossova et al., 2015) so targeting exon 2 is most 
likely going to affect protein functions, even with an in-frame mutation. The guide 
RNA on exon 4 was predicted by CRISPRscan to be the most efficient (with a score 
of 56). Targeting the first exon is not advised, due to potentially alternative AUGs 
downstream to the canonical start codon. 
Targeting exons downstream of the active domain of the protein should cause a loss-
of-function effect anyways, if a stop codon is introduced (due to frame-shift 
mutations) >50-55 nt before an exon-exon junction, due to non-sense mediated 
decay (Popp and Maquat, 2016). In the case of mutations in exon 4, they are 
predicted to introduce a stop too close to the exon-exon junction. It may rather be 
that if a phenotype will be observed in exon 4 targeted fish this may be due to the 
synthesis of a C-terminal truncated protein (Barrangou et al., 2015). 
Because this was the first time we tried such approach, we wanted to test the 
efficacy of our technique in creating a DSB in our target, therefore we decided to use 
the colony PCR approach followed by Sanger sequencing as previously described in 
 
139 
 
this chapter. This approach resulted probably in a lower estimation of the efficiency 
(between 6.5% and 13%) in the F0 but we confirmed the effectiveness of our system.  
The reason for the lower efficiency is probably because of the mosaicism of the 
mutants. Amplification of genomic DNA extracted from 10 fish and insertion of single 
copies of the exons into E. coli may not give a proportional ratio of mutagenesis 
efficiency. It is anyway an efficient qualitative method to establish the presence or 
absence of the mutation, although it cannot be used as a quantitative assay. 
The reason of mosaicism and presence of different types of mutations in the germline 
of a single fish is not completely clear. It could be that, although sgRNA+Cas9 RNA 
are all injected at one cell stage, the Cas9 RNA does not get translated and start 
working on the target genome straight away. Instead, it is moved between cells 
during cell division and gets translated at different time points in different cells, 
therefore causing different types of mutations (Tu et al., 2015). It is an issue that 
needs to be taken into account or chances are to have a mixed population of mutant 
and WT genomes therefore a lot of background when Sanger sequencing the F0. 
Analysis of germline transmission in our experiments (~32% for exon4 and ~20% for 
exon2) is overall in accord with previous studies which reported an average  
transmission of 28% (Varshney et al., 2015).  
A very high difference in mutagenesis efficiency was found between different batches 
of fish, which may be due to experimental set-up differences. For some batches 
efficiency was 0%, although on the batches where mutagenesis worked, efficiency 
was nearly 100%.    
The initial observation of a phenotype in the rbm7 mutant fish was proven to be 
wrong by further genotype-phenotype analysis. I may conclude the phenotype 
observed was probably due to some inbreeding issues. Indeed pairing those 2 fish 
carriers of the unknown mutation and raising the F2 generation (and of course getting 
rid of the most severe ones which could not survive until adult age) have washed 
away the defect-causing mutation and even pairing 2 homozygous mutants do not 
show any clear external phenotype. Neverthless, having managed to obtain 2 
homozygous mutants is a useful step forward because it allows to get rid of the 
maternal WT contribution and allow to perform analysis without caring about 
selecting the actual 25% of homozygous mutants which raise from 2 heterozygous. 
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For example now I can extract RNA from 20 homozygous mutant embryos and 
perform qRT-PCR to check expression levels of those genes which were differentially 
expressed in the morphant fish (e.g. atxn1) or other genes which expression I may 
expect to be misregulated such as genes involved in muscle development or neuron 
development. 
It is striking to observe such a strong difference between the effect of morpholino 
against rbm7 – which appears to be very toxic - and a frameshift mutation on the 
same gene.  
It is especially interesting because rbm7 seems to be a key protein for RNA 
metabolism. It may be that some other proteins take over its functions in presence of 
a deleterious mutation in similar way to what observed by Rossi and colleagues 
(Rossi et al., 2015).  
It could also be that the defects are there, just not as clear as with morpholino 
injections. Maybe the differences are more subtle, therefore the mutants need to be 
analysed more carefully – e.g. higher microscopy magnification. 
Next step will be to perform qRT-PCR on the homozygous mutant embryos. It will be 
an relatively quick and easy way to screen differential expression of tens of genes 
involved in different pathways (muscle development, motor neuron development, etc.) 
and levels of rbm7 itself. If some of these genes will result to be differentially 
expressed, then I will keep investigating in that direction via immunofluorescence 
imaging, in situ hybridization, histology analysis. In order to increase the chances to 
see a phenotype I may try to trigger a physiological reaction injecting a low dose of 
morpholino which would not cause any effect in WT embryos but may help to reduce 
the levels of mRNA.   
Then I will analyse the phenotype in Ex4 mutant fish to understand the role of this 
part of the protein which is not known. Given that the first ~90 amino acid are all 
within the highly conserved RNA Recognition Motif and has a catalityc role, it may be 
that the rest of the protein could be involved in binding to MTR4 and ZCCHC8 
forming the NEXT complex or perhaps binding to the other RBM7 molecules forming 
the ring-shaped pentameric structure presented in a recent publication (Sofos et al., 
2016).  
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qRT-PCR analysis on the homozygous mutant fish will be a quick way to check the 
expression of a number of genes involved in different pathways (muscle development, 
motor neuron development, etc.) in order to identify a disruption in any of those and 
then investigate deeper the defects caused by a up or downregulation.  
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6 Chapter 6 - Summary, conclusions and future directions 
 
Pontocerebellar hypoplasias (PCHs) are a rare and heterogeneous subtype of 
neurological disorders which share symptoms of hypoplasia of the cerebellum and 
pons and motor neuron disease. Common symptoms are severe psychomotor 
retardation and muscle weakness which often lead to premature death of the patients. 
Ten different subtypes of PCHs have been classified to date. Many different genes 
have been linked to the pathogenesis which seems to be related somehow to 
incorrect RNA metabolism and processing, suggesting that these mechanisms are 
specifically important in cerebellar Purkinje cells. 
One of the issues investigators have to face when studying rare diseases is the lack 
of satisfactory number of samples, which makes the development of experimental 
models particularly important in this field. In this thesis I show the identification of a 
new human disease gene involved in RNA metabolism (RBM7) and investigated the 
pathomechanisms in both in vitro (primary fibroblasts) and in vivo (zebrafish) models.  
I showed that RBM7 mutation results in a similar defect of RNA metabolism as 
mutations in EXOSC8, another exosomal defect. To further understand disease 
mechanisms I developed a zebrafish model of RBM7 deficiency and then compared 
phenotypical and molecular findings to previously published zebrafish PCH models. 
Furthermore here I present the creation of CRISPR/Cas9 induced zebrafish rbm7 
mutant lines , which may further help to understand this subset of disease. The 
results of this thesis show that a common pathomechanism exists in exosomal 
protein deficiency, indicated by common molecular and phenotypical findings 
between different disease models.     
6.1 Identification and characterization of a novel pathogenic mutation in 
RBM7 
RBM7 is known to be involved in RNA metabolism and splicing. Our collaborators in 
Jerusalem identified a patient from a consanguineous Palestinian family with 
symptoms of motor neuron disease. Exome sequencing identified a homozygous 
pathogenic mutation in RBM7, however even after intensive search, we could not 
confirm the clinical phenotype in a second patient. The pathogenic role of this RBM7 
mutation was supported by lower protein level in fibroblasts, suggesting a loss-of-
function effect of the mutation. The mutation in RBM7 also caused a reduction of 
EXOSC8 protein, further supporting the hypothesis of RBM7 mutation’s role in the 
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disease. The c.236C>G; p.Pro79Arg mutation is located in a highly conserved RNA 
binding domain (RRM) and is predicted to alter protein stability (Giunta et al., 2016). 
RBM7 is known to be involved in RNA splicing and degradation of ncRNAs such as 
tRNA, rRNA, snRNA and PROMPTs, which are transcribed upstream of the 
promoters of many protein coding genes, competing with canonical downstream 
transcription for RNA polymerase II and other transcription factors. RNA-seq analysis 
showed defective metabolism of many coding and non-coding RNAs in both RBM7 
and EXOSC8 mutant cells. We strongly believe that the identification of so many 
shared differentially expressed transcripts and alternative spliced RNAs between 
EXOSC8 and RBM7 mutant fibroblasts, also strengthens this hypothesis. 
In the next months a deeper bionformatic analysis of differential splicing events will 
be performed on EXOSC3 and EXOSC9 fibroblasts and neuronal cells and data will 
be confirmed by standard RT-PCR. The identified bands will also be Sanger 
sequenced in order to clarifiy which part of the gene is mispliced and try to identify 
potential loss or gain of functions. 
6.2 Zebrafish models of PCH  
Zebrafish is an ideal model for studying disorders of the motor neurons and 
cerebellar Purkinje cells (Bae et al., 2009) (Babin et al., 2014). The development and 
comparison of three zebrafish models of exosomal protein deficiencies (rbm7-MO, 
exosc8-MO and exosc3-MO) seems to further confirm a common pathomechanism 
underlying the phenotype observed in all three models. The similar defects in motor 
neuron axons and in Purkinje cells, confirm an involvement of the exosome, 
specifically in these types of neuronal cells, which is a key aspect of the clinical 
presentation of exosomal protein defects. The defects observed in motor neurons of 
our morphant fish (defective growth and branching) are very similar to those 
observed in previous zebrafish models of SMA (McWhorter et al., 2003) as well as 
fish with deficiencies for proteins known to be involved in axon pathfinding (Sato-
Maeda, 2006). It is interesting to notice that brainstem nuclei were severely affected 
upon gene knock down in zebrafish exosc3-MO and exosc8-MO models, but very 
mildly affected in rbm7 knocked down fish. This resembles what observed in patients: 
EXOSC3 and EXOSC8 mutations cause PCH1 with severe involvement of the 
brainstem, while RBM7 mutation caused motor neuron disease, with no apparent 
defects of the brainstem. Also, a smaller percentage of rbm7-MO fish show a 
cerebellar defect as indicated by our experiments. 
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It may be that the subset of genes differentially expressed only in EXOSC8 mutant 
cells could be specific for the onset of PCH1 and hypomyelination while the shared 
genes differentially expressed both in RBM7 and EXOSC8 may underlie the cause of 
common symptoms of motor neuron disease. Performing RNA-seq on EXOSC3 
fibroblasts and coverted neurons will hopefully help to clarify this aspect. 
The creation of the mutant line(s) is a step forward toward the understanding of such 
molecular mechanisms. It is well known that morphants may display a different 
phenotype than mutants due to off target effects or compensatory effects observed in 
mutants but not in morphants.  
At present it is unclear why rbm7 mutants do not show any phenotype at all or a 
much milder one. It may be because compensatory factors are induced by 
mutagenesis but not by gene knock down. It may be that the phenotype is milder 
therefore fish need to be analysed better. 
A more detailed analysis of different structures at different developmental stages may 
show defects: investigation of motor neurons at 48 hpf, 3 dpf and 4 dpf with a higher 
magnification may indicate some smaller defects which may have been 
underestimated before.  
A high throughput quantitative analysis of gene expression of genes involved in 
motor neuron development such as olig2 (Park et al., 2002) will be performed in 
order to identify possible anatomical structures to look at.  
I have already crossed mutant fish with islet1:GFP transgenic. This will allow to show 
possible defects during development of motor neurons under control of islet1 
promoter. 
Analysis of mutants instead of morphants will abolish variability due to unavoidable 
quantitative differences during the morpholino injection. As we introduced different 
mutations into our new CRISPR/Cas9 zebrafish models, mutants will be sorted by 
mutation type, in order to investigate different roles of different mutations.  
Trying to inject a very low dose of morpholino in the mutants or a stress test may also 
help to amplify defects which may be too small to be identified at the moment. 
Having induced mutations on exon 2 and exon 4, likely able to cause stop codons 
and/or in-frame mutations, we may be able to understand different roles of the 
protein through the synthesis of proteins truncated at different levels.  
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High throughput behavioural studies of zebrafish larvae can be performed in a 
standardized manner using software which are able to track movements of a single 
larvae over a given amount of time and directly compare speed, number of events 
and length of the event between mutant and WT fish (Ingebretson and Masino, 2013)  
Using technologies such as single cell laser micro dissection and/or magnetic 
activate cell sorting (MACS) or flow cytometry it will be possible to extract high quality 
RNA for whole transcriptomic analysis from specific cell types, without contamination 
from neighbouring cells (Bandyopadhyay et al., 2014) (Welzel et al., 2015).  
One issue with laser microdissection may be the degradation of RNA due to 
processing time and high temperature. The creation of mutant zebrafish strain will 
further help to investigate the in vivo molecular mechanism underlying the disease.  
On the other hand, if no phenotype or defects is actually identified, RNAseq analysis 
of rbm7 mutant fish may help to understand which are – if any – the compensatory 
mechanism that allow the fish to do not develop a motor neuron phenotype. 
Moreover, direct conversion of patients’ fibroblasts into neuronal cells (Meyer et al., 
2014) and subsequent RNA-seq (and possibly proteomic) analysis will also narrow 
down the number of candidates transcripts and enable validating our previous data in 
better cellular models.  
Comparing the two sets of data is likely going to give some insights on the RNA 
species which are commonly differentially expressed and regulated in human 
patient’s neurons and mutant fish.     
Furthermore, the development of a stable, closely resembling model of RNA 
processing related disease (and specifically, exosome complex related disease) like 
our rbm7 mutant zebrafish models is fundamental in order to perform drug discovery, 
whenever a therapeutic approach will be possible to be tested on animal models or to 
do large high-throughput screening of chemical compounds (Gibert et al., 2013) 
(MacRae and Peterson, 2015). If a specific gene will result to be upregulated in 
exosome complex deficiency, it would be a suitable target for downregulation or 
pharmacological inhibition of related pathways. As we showed in chapter 3, co-
downregulation of exosc8 and mbp – which was overexpressed upon knock down of 
exosc8 – resulted in better preserved brain structure and increased survival. ATXN1 
levels are regulated by the RAS–MAPK–MSK1 pathway, which can itself be 
regulated pharmacologically (Park et al., 2013). On a pure speculative basis this 
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could be a possible approach to test RAS-MAPK-MSK1 as a potential target to 
rescue cerebellar phenotype in PCH in our zebrafish model.The opposite could be 
performed in those cases where there is an over-degradation of certain RNAs. 
Reducing physiological functions of the exosome complex may have a positive effect 
on the symptoms. This obviously has to be finely regulated in order to do not interfere 
with other functions of the exosome complex. 
Zebrafish mutants could be used for testing a new possible therapeutic approach 
which was recently published by Fasken and colleagues: they modelled different 
mutations in Rrp40/EXOSC3 in yeast and show that, upon impossibility of the 
mutated sub-unit to join the exosome complex, the mutated protein it is degraded by 
the proteasome. This well matches with our previous finding of reduced protein levels 
in EXOSC8 and RBM7 mutants cells. Even more importantly though, they show that 
if the WT protein is provided together with the mutant protein, this is even more 
unstable and gets targeted by the exosome complex even more. Therefore the WT 
protein is successfully able to replace the mutant one and get assembled within the 
exsome complex either in yeast and mouse cells (Fasken et al., 2017). 
Overall, this thesis expands the knowledge about mechanisms underlying 
neurological disorders caused by defective RNA metabolism. Furthermore it forms 
the basis for further studies using new experimental models such as rbm7 mutant 
fish and - ideally – neuronal cells directly converted from patients fibroblasts. 
Understanding the roles of different exosome specific factors may potentially be 
useful to take advantage of the exosome complex as a therapeutic strategy in RNA 
processing deficiency diseases.  
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